Histamine H3-receptors in the central nervous systems of rats and mice by Jansen, F.P.

Histamine H3-receptors· in the
central nervous system of
rats and mice
Characteristics, distribution and function
studied with [l25I]iodophenpropit
Ph.D.-thesis
Most of the research described in this thesis was performed at the Division of Molecular
Pharmacology of the Leiden/Amsterdarn Center for Drug Research (LACDR), Department
ofPharmacochernistry, Vrije Universiteit, De Boelelaan 1083, 1081HV, Amsterdam, The
Netherlands.
Some of the investigations were carried out in close collaboration with other institutes.
The work described in Chapter 6 was done in cooperation with the European Graduate
School of Neuroscience, EURON, Department of Psychiatry and Neuropsychology,
Maastricht University, Maastricht, The Netherlands. Part of the experiments presented in
Chapter 7 were performed at the Division of Toxicology, Department of Pharmaceutical
Biosciences, Uppsala Biomedical Center, Uppsala University, Uppsala, Sweden, and
research described in Chapter 8 was performed at the Department of Medical Physics,
School of Allied Health Sciences, Faculty of Medicine, Osaka University, Osaka, Japan.
The author gratefully acknowledges Solvay Duphar (Weesp, The Netherlands) for
financing the major part of the work described in this thesis.
The publication of this thesis was financially supported by Solvay Duphar, by Harlan
CPB (Zeist, The Netherlands) and by Rephartox (Maarssen, The Netherlands).
ISBN: 90-74538-21-5
© Frank P. Jansen, 1997. All rights reserved. No part of this book may be reproduced,
restored in a retrieval system or transmitted in any form or by any means, mechanical,
photocopying, or otherwise, without the prior written permission of the holder of the
copyright.
VRIJE UNIVERSITEIT
HISTAMINE H3-RECEPTORS IN THE
CENTRAL NERVOUS SYSTEM OF
RATS AND MICE
Characteristics, distribution and function
studied with [125I]iodophenpropit
ACADEMISCH PROEFSCHRIFf
ter verkrijging van de graad van doctor aan
de Vrije Universiteit te Amsterdam,
op gezag van de rector magnificus
prof.dr. E. Boeker,
in het openbaar te verdedigen
ten overstaan van de promotiecommissie
van de faculteit der scheikunde
op woensdag 18 juni 1997 om 15.45 uur
in het hoofdgebouw van de universiteit,
De Boelelaan 1105
door
Frank Pieter Jansen
geboren te Amsterdam
Promotor:
Copromotoren:
prof.dr. H. Timmerman
prof.dr. A. Bast
dr. B. Rademaker
Dr J.-M. Arrang of the Unite de Neurobiologie et Pharrnacologie (U. 109) de l'INSERM
(Paris) is gratefully acknowledged for reviewing this thesis.
Contents
Chapter 1. Introduction 7
Chapter 2. The first radiolabelled histamine H3-receptor antagonist
[125I]iodophenpropit: saturable and reversible binding to rat
cortex membranes - preliminary characterization 51
(based on Eur. J. Pharmacol. 217, 203-205).
Chapter 3. Characterization of the binding of the histamine H3-receptor
antagonist [125I]-iodophenpropit to rat brain 57
(based on Br. J. Pharmacol. 113, 355-362).
Chapter 4. Characterization of histamine H3-receptors in mouse brain using
the H3-antagonist [l25I]-iodophenpropit; an in vitro study 75
Chapter 5. The distribution of binding sites of the histamine H3-receptor
antagonist [l25I]iodophenpropit in rat brain studied by storage
phosphor autoradiography; chemically unrelated H3-antagonists
reveal a homogenous population of binding sites 93
Chapter 6. Unilateral 6-hydroxydopamine denervation of the nigrostriatal
pathway in the rat differentially affects histamine H3-receptors in
the striatum and in nuclei of striatal efferents 113
Chapter 7. A quantitative and whole-body autoradiographic study of the
radio-iodinated histamine H3-receptor antagonist iodophen-
propit, after intravenous administration to rats 131
Chapter 8. The histamine H3-receptor agonist immepip and the H3-receptor
antagonist clobenpropit modulate rat hypothalamic histamine
release in vivo. Effects of intrahypothalamic and peripheral
application 145
Chapter 9. Summary and discussion 159
Samenvatting en discussie 164
List of publications
About the author
Nawoord
171
173
175

· Chapter 1 .
Introduction
Contents
1. General introduction
1.1. Histaminergic neurons in the CNS: distribution and function
1.2. The histamine H3-receptor: the autoreceptor of histaminergic neurons
1.3. Regulation of histaminergic neuronal activity by heteroreceptors
1.4. H3-Heteroreceptors
1.5. Postsynaptic H3-receptors
1.6. The H3-receptor as a regulatory entity of histaminergic signal transduction
1.7. The second messenger system of the H3-receptor
2. H3-Receptor ligands
2.1. H3-Agonists
2.2. H3-Antagonists
3. H3-Receptor binding studies
3. 1. Prelude: selection criteria for radioligands
3.2. Radiolabelled H3-agonists
3.3. Radiolabelled H3-antagonists
3.4. Distribution of H3-receptor binding sites in the CNS
3.5. H3-Receptor binding studies in peripheral tissues
3.6. Heterogeneity of binding sites
3.6.1. Radiolabelled H3-agonist binding sites
3.6.2. Radiolabelled H3-antagonist binding sites
3.6.3. Evidence for receptor heterogeneity from functional studies
3.7. Resumption and concluding remarks
4. Aim and outline of this thesis
- 7 -
Chapter 1
1. General introdnction
The visualization in the early eighties of the histaminergic neuron system has provided
new perspectives in histamine research. Histaminergic neurons are widely spread in the
vertebrate and the invertebrate central nervous system (CNS), and constitute an important
regulatory entity of brain activity (Wada et at., 1991; Schwartz et al., 1991; Schwartz et
al., 1995). Soon after the identification of the histaminergic system, the histamine H3-
receptor was discovered, mediating the feedback inhibition of neuronal histamine release
and synthesis (Arrang et al., 1983; Arrang et al., 1987b). H3-Receptors were
additionally found to regulate the release of other neurotransmitters via presynaptic and
postsynaptic mechanisms, both in the central nervous system and in peripheral tissues
(Schwartz et al., 1990; Timmerman, 1990; Schlicker et at., 1994c). Hence, the H3-
receptor plays an essential role in the integration of histaminergic signal transmission in
the CNS and in the peripheral nervous system (PNS). The understanding of the
physiological and pathophysiological role of the H3-receptor is considered to yield new
therapeutic opportunities in CNS and PNS diseases (Arrang et at., 1989; Schwartz et
at., 1990; Onodera et at., 1994; Leurs et at., 1995b; Alves-Rodrigues, 1996).
Progress in receptor pharmacology is largely dependent on the availability of potent and
selective drugs. During the last ten years various H3-receptor ligands belonging to distinct
chemical classes have been found, including valuable tools for in vitro and in vivo
studies (recent review: Leurs et al., 1995b). Moreover, eight different H3-receptor
radioligands were developed. H3-Receptor binding studies have substantially contributed
to the current knowledge of characteristics, distribution and function of H3-receptors.
The present chapter starts with a brief introduction on the functional role of H3-receptors
in the CNS and in peripheral tissues. Thereupon, H3-receptor ligands will be reviewed,
with emphasis on the different H3-receptor radioligands and their application in H3-
receptor research.
1.1. Histaminergic neurons in the CNS: distribution and function
The role of histamine as a member of the monoaminergic transmitters in the invertebrate
and mammalian CNS is now well established. The first evidence for the existence of
histamine in nervous tissue was obtained at the end of the 1960s (Carlini & Green, 1963;
Kataoka & De Robertis, 1967). After the development of a radioisotopic assay for the
histamine synthesizing enzyme L-histidine decarboxylase it was shown that histamine is
synthesized in histaminergic neurons (Taylor & Snyder, 1971; Baudry et al., 1973).
Also it was demonstrated that histamine is released from nervous tissue in a depolarization
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and calcium dependent way (Atack & Carlsson, 1972; Taylor & Snyder, 1973; Verdiere
et aI., 1975). Lesion studies provided preliminary information on the distribution of
histaminergic neurons in rat brain (Garbarg et aI., 1974). Disruption of the medial
forebrain bundle at the level of the lateral hypothalamic area resulted in a reduction of L-
histidine decarboxylase activity and of histamine content in different forebrain areas
indicating an ascending histaminergic pathway passing through the hypothalamus
(Garbarg et at., 1974). In the 1980s, the distribution of the histaminergic system in the
rat brain was visualized immunocytochemically with antibodies against histamine
conjugates (Wilcox & Seybold, 1982; Panula et at., 1984; Panula & Airaksinen, 1991)
and histidine decarboxylase (Watanabe et aI., 1983; Watanabe et aI., 1984; Tohyama et
aI., 1991; Wouterlood & Steinbusch, 1991).
brain stem
spinal cord
-------------
* tuberomammillary nucleus
Figure 1. Schematic presentation of the histaminergic system in rat brain. (Modified from Wada et ai.,
1991).
Histaminergic neurons originate from five distinct cell groups (E1-E5) located in the
tuberomammillary neuron complex of the posterior hypothalamus (see Figure 1). With
respect to their efferents, the histaminergic perikarya can be regarded as a single neuronal
group, projecting diffusely throughout the CNS in ascending and descending pathways
(Wada et at., 1991). The hypothalamus itself belongs to the most densely innervated
areas, especially the suprachiasmatic, the supraoptic, the arcuate and the paraventricu1ar
nuclei. Ascending pathways project through the medial forebrain bundle and
periventricu1ar1y to the olfactory bulb, most subcortical structures and the cerebral cortex.
Of these areas a high innervation is found in the olfactory tubercle and various thalamic
nuclei. Some histaminergic fibers also enter the median eminence terminating in the
- 9 -
Chapter J
pituitary (Steinbusch & Mulder, 1984; Inagaki et at., 1988). Descending pathways
project to various mesencephalic structures and to the spinal cord. Apart from neuronal
elements, some histaminergic varicosities make contact with glial cells, small blood
vessels and capillaries (Tohyama et at., 1991). Also, long dendrites penetrate into the
ependyma and make contact with the cerebrospinal fluid (Ericson et at., 1987; Wada et
at., 199 I). Electrophysiological studies indicated that histaminergic neurons fire
spontaneously and regularly (Haas & Reiner, 1988). Most of the histaminergic fibers are
unmyelinated and make relatively few synaptic contacts (Tohyama et at., 1991).
Besides the rat brain, the histaminergic system has also been studied
immunohistochemically in the CNS of other vertebrates (Onodera et ai., 1994) including
the human brain (Panula et al., 1990; Airaksinen et at., 1991). In human brain,
histaminergic neurons occupy a larger area of the hypothalamus and are about thirty times
more abundant as compared to the rat (Airaksinen et al., 1991). Despite species
differences of the localization of the histaminergic perikarya, the tuberomammillary
neuron complex can be regarded as one functional entity in all species examined
(Airaksinen et ai., 1991; Panula & Airaksinen, 1991).
From studies with local and intracerebroventricular injections of histamine, ligands
selective for histamine receptor subtypes (i.e. HI, H2, and H3), and studies with the
histidine decarboxylase inhibitor a-fluoromethylhistidine, several functions of the
histaminergic system have been identified. Histamine has been assigned a 'wake amine'.
Activation of the histaminergic system decreases sleep and increases wakefulness (for
review see: Schwartz et al., 1991; Onodera et al., 1994) and locomotor activity
(reviewed by Onodera et al., 1994). Correlating to the 'wake' effects of histamine, the
activity of histaminergic neurons in the brain displays a circadian rhythm, histamine levels
being elevated during the active phase and decreased during the nonactive phase
(Mochizuki et al., 1992).
Several functions of the histaminergic system may originate from the hypothalamus
which, as already mentioned, contains the histaminergic perikarya and has one of the
highest densities of histaminergic terminals. A role of the hypothalamic histaminergic
system in feeding, drinking, autonomic regulation (cardiovascular, respiratory and
gastrointestinal modulation, thermoregulation), and pituitary hormone secretion has been
indicated (reviewed by Onodera et al., 1994). Histaminergic mechanisms may also be
involved in learning and memory processes (Kamei et al., 1993; Smith et at., 1994;
Meguro et al., 1995; Miyazaki et al., 1995; Blandina et al., 1996; Sziklas et al., 1996)
and may playa modulatory role in epileptic seizures (Yokoyama et at., 1992; Yokoyama
& Iinuma, 1996). Moreover, the histaminergic system has been suggested to be affected
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in schizophrenia (Prell et at., 1995) and in neurodegenerative diseases like Alzheimer's
disease (Airaksinen et at., 1991; Nakamura et at., 1993) and multiple system atrophy
(Nakamura et at., 1996).
1.2. The histamine H3-receptor: the autoreceptor of histaminergic neurons
Differently from other monoaminergic neurotransmitters, for histamine and for its
precursor histidine, no uptake mechanism selective for histaminergic neurons could be
demonstrated (Arrang et at., 1983; Smits et at., 1988). Histamine is selectively
synthesized in histaminergic neurons, due to the exclusive presence of L-histidine
decarboxylase in these neurons. Consequently, histaminergic neurons can be selectively
labelled with [3H]-histamine in vitro by incubation of brain slices with [3H]-histidine.
Using this procedure, Arrang and coworkers (Arrang et at., 1983) demonstrated that
histamine is able to inhibit its own potassium-induced release (up to 60% of control) from
rat cerebral cortex slices by activation of a histaminergic autoreceptor. Based on the
deviating potencies of selective H1- and H2-receptor ligands in this assay, the effect of
histamine was proposed to be mediated by a novel class of histamine receptors, the
histamine H3-receptor (Arrang et at., 1983). A few years later, the existence of the
histamine H3-autoreceptor was further documented by the introduction of the first
selective ligands to study histamine H3-receptors i.e. the agonist (R)a-methylhistamine
and the antagonist thioperamide (Arrang et at., 1987a). Using an in vitro superfusion
technique, H3-receptor activation was also shown to inhibit neuronal histamine release
induced by electrical stimulation (Van der Werf et at., 1987). More recently, modulation
of rat hypothalamic histamine release by activation of the Hrautoreceptor has been
evidenced in vivo, using cerebral microdialysis (Mochizuki et at., 1991; Hoh et at.,
1992; Prast et at., 1994; Chapter 8 of this thesis). H3-Receptor mediated inhibition of
histamine release was also observed in human cerebral cortex slices (Arrang et at.,
1988). As an autoreceptor, activation ofhistarnine H3-receptors was also shown to inhibit
the synthesis of histamine (Arrang et at., 1987b).
1.3. Regulation of histaminergic neuronal activity by heteroreceptors
Neuronal histamine release and synthesis were shown to be affected by different
heteroreceptors. Depolarization induced [3H]histamine release from rat cerebral cortex or
hypothalamic slices in vitro was inhibited by activation of a2-adrenoceptors (Hill &
Straw, 1988; Gulat-Marnay et at., 1989), M I-muscarinic (Gulat-Marnay et at., 1989;
Ono et at., 1992), K-opioid (Gulat-Marnay et at., 1990) and galanin receptors (Arrang
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et ai., 1991). Histamine release was increased by activation of Il-opioid receptors (striatal
tissue, Hoh et ai., 1988) and of nicotinergic receptors (Ono et ai., 1992). Using
microdialysis, neuronal histamine release was shown to be modulated in vivo by
stimulation of a2-adrenoceptors (Prast et ai., 1991; Laitinen et ai., 1995), NMDA
receptors (Okakura et ai., 1992), IL-1 p-receptors (Niimi et ai., 1994), Il-opioid
receptors (Chikai et ai., 1994; Chikai & Saeki, 1995), GABAKreceptors (Okakura-
Mochizuki et ai., 1996) and GABAB-receptors (Okakura-Mochizuki et ai., 1996).
Histamine turnover was found to be affected by Il-receptors (Hoh et ai., 1988),
muscarinic receptors (Oishi et ai., 1990), nicotinergic receptors (Oishi et ai., 1990) and
5-HT1A-receptors (Oishi et ai., 1992).
1.4. H3-Heteroreceptors
H3-Receptors are widely distributed in the CNS and their localization is not confined to
histaminergic neurons. With the use of the H3-receptor agonist (R)a-methylhistamine and
the H3-antagonist thioperamide it was shown that Hrheteroreceptors are able to modulate
the release of different neurotransmitters Le. noradrenaline (Schlicker et ai., 1989),
serotonin (Fink et ai., 1990; Rodrigues et ai., 1995) and dopamine (Schlicker et ai.,
1993) in rodent brain. Recently, activation of Hrreceptors was shown to inhibit
[3H]noradrenaline release from the human cerebral cortex (Schlicker, 1996).
H3-Receptors are also present in several peripheral tissues like the airways (Ichinose &
Barnes, 1989; Ichinose et ai., 1989; Burgaud & Oudart, 1993; Danko et ai., 1994;
De1aunois et ai., 1995), the cardiovascular system (Ea-Kim & Oudart, 1988; Heyet
ai., 1992; Ea-Kim et ai., 1993; Gothert et ai., 1995), the stomach (Bertaccini et ai.,
1991; Coruzzi et ai., 1991; Hollande et ai., 1993; Bertaccini & Coruzzi, 1995) the
intestine (Trzeciakowski, 1987; Hew et ai., 1990; Coruzzi et ai., 1991; Leurs et ai.,
1991; Schworer et ai., 1992; Vollinga et ai., 1992) and the retina (Schlicker et ai.,
1990). Also in the periphery, modulation of release of the previously mentioned
neurotransmitters (Schlicker et ai., 1994c), of acetylcholine (Tamura et ai., 1988; Poli
et ai., 1991) and of neuropeptides (Matsubara et ai., 1992; Imamura et ai., 1996)
seems to be an important mechanism underlying H3-receptor mediated effects. H3-
Heteroreceptors were demonstrated on nerve terminals of postganglionic parasympathetic
and sympathetic nerves and on NANC neurons (C-fibers). Additionally, H3-receptors
appeared also to be located on non-neuronal cells, e.g. intestinal enterochromaffin cells
(Schworer et ai., 1992; Schworer et ai., 1994) and enterochromaffin-like (ECL) cells in
the stomach (Bertaccini & Coruzzi, 1995).
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1.5. Postsynaptic H3-receptors
More recently, receptor autoradiographic studies in rat brain provided evidence for the
existence of postsynaptic H3-receptors (Cumming et aI., 1991; Pollard et aI., 1993; Ryu
et at., 1994). Destruction of postsynaptic structures of the striatum with the neurotoxins
quinolinic acid or kainic acid resulted in a marked reduction of striatal H3-receptor
binding. As the majority of the striatal efferents use y-aminobutyric acid (GABA) as their
neurotransmitter H3-receptors in the striatum may be largely located on GABA neurons,
projecting to other parts of the basal ganglia. Postsynaptic H3-receptors might also exist
in other components of the basal ganglia. Lesions of the dopaminergic system increased
H3-receptor binding in the substantia nigra (Ryu et aI., 1994; this thesis, Chapter 6). In
addition, altered H3-receptor binding was found in the globus pallidus (decreased
binding) and the entopeduncular nucleus (increased binding), following neurochemical
destruction of the dopaminergic system (see Chapter 6). The changed H3-receptor binding
in the basal ganglia after destruction of dopaminergic neurons with 6-hydroxydopamine
showed a pattern similar to the changed binding of GABAA -receptors, which are
predominantly of postsynaptic origin. Hence, H3-receptors in the basal ganglia might in
part be co-localized with GABAA -receptors. Postsynaptic H3-receptors may also be
present in other brain areas. Electrocoagulation of the lateral hypothalamus resulted in an
increased [3H](R)a-methylhistamine binding in the rat cerebral cortex (Pollard et aI.,
1993). Its must be noted though that evidence for the existence of postsynaptic H3-
receptors is mainly based on receptor binding studies. The functional role of postsynaptic
H3-receptor is yet to be explored.
1.6. The H3 -receptor as a regulatory entity in histaminergic signal
transduction
The discovery of the histamine H3-receptor has provided new perspectives in histamine
research. As the autoreceptor of histaminergic neurons, the histamine H3-receptor may
playa pivotal role in the modulation of processes related to histaminergic neuronal activity
in the brain. Both, H3-heteroreceptors and postsynaptic H3-receptors may play an
important role in the cross-talk of the histaminergic system with other neurotransmitter
systems in the brain. Especially in peripheral tissues, histamine H3-receptors are also a
putative target for histamine released from non-neuronal stores such as mast cells,
basophils, enterochromaffin cells and adrenal chromaffin cells (Tuominen et ai., 1993;
Dimitriadou et at., 1994; Ohkubo et at., 1994; Bertaccini & Coruzzi, 1995). The
affinity of histamine for H3-receptors is about 1DO-fold higher than its affinity for H1- and
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H2-receptors. This makes the histamine H3-receptor a primary target in tissues where all
three subtypes of histamine receptors co-exist.
1.7. The second messenger system of the H3-receptor
Up till now, attempts to identify the HTreceptor gene have not been successful. Hence,
information on the transductional mechanism of HTreceptors obtained so far is based on
pharmacological studies performed in membrane fractions and from functional receptor
assays.
The H3-receptor has been partly purified from bovine brain. Digitonin-solubilization from
bovine brain homogenates yielded a molecular mass of 220kDa, probably representing the
receptor coupled to a co-solubilized G-protein (Zweig et al., 1992). A more accurate
estimation of the H3-receptor protein mass has been obtained in the human gastric tumor
cell line HGT-l (Cherifi et al:, 1992). The H3-receptor has been purified to a degree of
84% from these cells. SDS-PAGE revealed a molecular mass of 70kDa (Cherifi et al.,
1992).
Several lines of evidence have been obtained for the involvement of G-proteins in H3-
receptor mediated signal transduction. H3-Receptor binding studies performed in rat and
bovine brain revealed the sensitivity of agonist binding to guanine nucleotides (West et
al., 1990b; Arrang et al., 1990; Zweig et al., 1992; Jansen et al., 1994; Ligneau et
al., 1994). Also, H3-agonists were shown to stimulate the binding of GTPyS to rat
cerebral cortical membranes (Clark & Hill, 1996). Moreover, the H3-receptor mediated
stimulation of GTPyS binding was abolished by pertussis toxin (Clark & Hill, 1996). In
the mouse pituitary cell line AtT-20, pertussis toxin pretreatment decreased H3-receptor
binding, which was associated with the ADP ribosylation of a 41kDa protein (Clark et
al., 1993; West et al., 1994).
The involvement of G-proteins in H3-receptor mediated signal transduction has also been
indicated from functional studies. Pertussis toxin attenuated the H3-receptor mediated
inhibition of the adrenergic responses of the guinea-pig atrium (Endou et al., 1994),
[3H]noradrenaline release from rat spinal cord slices (Celuch, 1995), sympathetic
neurotransmission in guinea-pig perivascular mesenteric arteries (Ishikawa & Sperelakis,
1987) and cholinergic transmission in the guinea-pig duodenum (Poli et al., 1993). In
HGT-l cells, H3-receptor mediated inhibition of inositol phosphates formation was
sensitive to both cholera toxin and pertussis toxin treatment (Cherifi et al., 1992). A
pertussis toxin insensitive GTP binding protein was suggested to be involved in H3-
receptor mediated augmentation of Ca2+ currents in the rabbit saphenous artery (Oike et
al., 1992). Hence, different G-protein subfamilies might be involved in H3-receptor
- 14-
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mediated signal transduction. Most of the studies cited indicate the coupling of H3-
receptors to Gilo-proteins however.
Yet, the second messenger of the Hrreceptor is not well understood. It seems unlikely
that H3-receptors are directly coupled to adenylate cyclases (Garbarg et at., 1989; Clark
et at., 1993; Poli et at., 1993; Schlicker et at., 1994a). In AtT-20 cells, attempts to
show an H3-receptor mediated modulation of phospholipase A2, C or D and efforts to
modulate Ca2+ or cyclic nucleotide levels were reported not to be successful (Clark et al.,
1993). Cherifi et al. provided evidence for a negative coupling of H3-receptors to
phospholipase C in HGT-l cells (Cherifi et at., 1992). The Hragonists (R)a-
methylhistamine and NlX-methylhistamine inhibited the basal release of inositol
triphosphate from the gastric tumor cells (Cherifi et at., 1992). The inhibition by (R)a-
methylhistamine was antagonized by thioperamide. In addition, (R)a-methylhistamine
counteracted the carbachol stimulated inositol triphosphate formation. Thus, H3-receptors
in HGT-l cells might be directly coupled to phospholipase C (Cherifi et al., 1992).
Several reports have described an effect of ion channel modulators on H3-receptor
mediated effects. Inhibition by H3-agonists of [3H]noradrenaline release from mouse
cerebral cortex slices was attenuated by the K+-channel blocker tetraethylammonium
(TEA), but was unaffected by the ATP-sensitive K+-channel blocker glibenclamide
(Schlicker et at., 1994a). The effect of TEA was dependent on the calcium concentration
in the superfusion medium. It was suggested that Hrreceptor stimulation modulated ion
channels via indirect mechanisms (Schlicker et al., 1994a). Differently from the study
described by Schlicker and coworkers, H3-receptors in the rat hindpaw were proposed to
be coupled to ATP-sensitive K+-channels, based on the attenuation by glibenclamide of
the H3-receptor mediated inhibition of substance P released from sensory nerve endings
(Ohkubo & Shibata, 1995). Involvement of N-type Ca2+-channels in H3-receptor
activation has been suggested in the guinea-pig heart (Endou et at., 1994), in the guinea-
pig intestine (Poli et at., 1994), in the rabbit saphenous artery (Oike et at., 1992) and in
the rat brain (Takemura et al., 1989). At present it is however not clear whether the
described effects of cation channel modulators on H3-receptor responses result from a
direct coupling of the receptors to these channels or from secondary mechanisms.
H3-Receptor activation has also been indicated to stimulate the release of nitric oxide in
the rabbit cerebral artery (Kim et al., 1992), in the guinea-pig cardiovascular system (Ea-
Kim et at., 1993; Ea-Kim et at., 1996) and in guinea-pig bronchioles (Burgaud &
Oudart, 1994). The H3-receptor response in the tissues mentioned was attenuated by
inhibitors of nitric oxide synthase. The effects of H3-receptor ligands on the nitric oxide
pathway are likely to be secondary to activation of the H3-receptor second messenger
system.
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Table 2. Structures and potencies ofpotent histamine HTreceptor antagonists.
compound
thioperamide
GRI68320
clobenpropit
structure potency
pA2 =8.4a
EDso = 2 mglkgb
pA2 =9.9c
EDso = II mglkg; rat
d
EDso = -I mglkg; mouse
e
reference
Schwartz, 1990
Garbarg, 1989
Brown, 1996
Vander Goot, 1992
Barnes, 1993
Yokoyama, 1994
iodophenpropit Jansen, 1994
Schlicker, 1994
Stark, 1994
alnhibition of neuronal histamine release from rat cerebral cortex; bhistarnine turnover, rat brain, Lp.
administration; cinhibition of the neurogenic contraction of the guinea-pig intestine; dex vivo
displacement of [3H]N<X-methylhistamine from rat brain, s.c. administration; einhibition of electrically
induced convulsions in mice, Lp. administration; finhibition of [3H]noradrenaline release from mouse
cerebral cortex.
methylhistamine was reported to be substantially improved by the application of
azomethine prodrugs of (R)a:-methylhistamine (Krause et ai., 1995; Krause et ai.,
1996). These compounds may become valuable tools, both pharmacologically and
clinically (Krause et ai., 1995).
[3H](R)a:-Methylhistamine, [3H]N<X-methylhistamine and [3H]histamine have been used
as radioligands to characterize histamine H3-receptors in the eNS and in peripheral
tissues (see section 3.2).
- 18 -
Introduction
Table 2. (continued).
compound structure potency reference
iodoproxyfan
GT-2016
impentamine
(VUF4702)
GR175737
clozapine
~o~ pA2 =9.0g Ligneau et at., 1994HNVN I # EDso > 10 mglkgh Stark et at., 1996
0
r=P~ pKi =7.4i Tedford et at.. 1995
HNVN EDso - 5 mglkgj Tedford et at.. 1995
~NH2 pA2 =8Ag Vollinga et at.. 1995
HNVN .
O-N~N~C1 pA2 =8.1g Clitherow et at., 1996HNVN
EDso = 1.4 mglkgj Clitherow et at., 1996
2-1\ NH
""-".,.f '~ pA2 =7.lk Rodrigues et at., 1995N ~
CI
gInhibition of the neurogenic contraction of the guinea-pig intestine; hhistarnine turnover, mouse brain,
p.o. administration; iinhibition of [3H]Nu-methylhistamine binding to rat cerebral cortex membranes;
jex vivo displacement of [3H]Nu-methylhistamine from rat brain, GT-2016: Lp. administration,
GR175737: s.c. administration; kinhibition of [3H]serotonin release from rat cerebral cortex. Note:
impentamine is a partial agonist on the HTreceptor mediated inhibition of [3H]noradrenaline release from
mouse cerebral cortex slices ([Leurs, 1996 #123], pDz=8.1, La.=0.6) Iodoproxyfan has been reported to be
a partial agonist on the guinea-pig ileum (Schlicker et at., 1996, neurogenic contraction, pDz and
intrinsic activity not described) and on the H3-receptor mediated inhibition of [3H]noradrenaline release
from mouse cerebral cortex slices (Schlicker et ai., 1996, La.=0.3, at 10 nM).
2.2. H3"Antagonists
Analogous to H3-agonists, the most potent H3-antagonists currently known share an
imidazole group. The side chain of compounds with Hrantagonistic activity display an
even larger heterogeneity than the side chain of H3-agonists (see Table 2). In addition to
the compounds mentioned in Table 2 other potent antagonists have been found, including
carbamates (Stark et at., 1996a; Stark et at., 1996b), esters (Stark et ai., 1996a), ethers
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(Huls et at., 1996) and amidines (Aslanian et at., 1995).
Most of the mentioned compounds show pAz-values between 8 and 10 and, as far as
described, in vivo ED50-values in the range of 1 to 10 mg/kg (Table 2). The classical
H3-receptor antagonist thioperamide is a potent and valuable tool, being widely used for
in vitro and in vivo studies (Arrang et at., 1987a; Leurs & Timmerman, 1992;
Onodera et at., 1994). One of the most potent antagonists in vitro presently known is
clobenpropit (pAz-value of 9.9), a derivative of the agonist imetit (Van der Goot et at.,
1992). Clobenpropit displays a relatively low potency with respect to in vivo CNS
effects in rats (Barnes et at., 1993; Mochizuki et at., 1996, Chapter 8 of this thesis). In
mice however, the compound potently inhibited electrically induced convulsions
(Yokoyama et at., 1994). Another highly potent H3-antagonist in vitro is GR168320, in
which the thiourea-moiety of thioperamide is replaced by a guanidine group (Brown et
at., 1996). Some histamine Hz-receptor ligands possess a moderate antagonistic activity
towards histamine H3-receptors, such as burimamide (pAz-value of 7.5, Arrang et at.,
1983), various burimamide dedvatives (Vollinga et at., 1995b) and impromidine (pAz-
value of 7.5, Arrang et at., 1983).
The imidazole moiety is not prerequisite for H3-antagonistic activity, although the
currently known non-imidazole compounds show rather low to moderate potencies.
Examples of non-imidazole containing H3-antagonists are the atypical neuroleptic
clozapine (pAz-value of 7.1, Rodrigues et at., 1995; pAz-value of 6.3, Kathmann et at.,
1994), the Hz-agonist dimaprit (pAz-value of 5.5, Schwartz et at., 1990) and betahistine
(pAz-value of 5.2, Arrang et at., 1985).
Another interesting compound with a moderate antagonistic activity is verongamine
(lC50-value of 0.5 11M) which was isolated from a marine sponge (Mierzwa et at.,
1994). Verongamine has been used as a starting compound for the synthesis of the first
chiral H3-antagonists (Tedford et at., 1996). These compounds may become powerful
tools in H3-receptor research, especially with respect to SAR studies.
Although clear H3-receptor related CNS effects are observed with various H3-antagonists
(see Table 2), only a minor fraction of peripherally injected antagonists penetrates into the
brain (Sakurai et at., 1994; Windhorst et at., 1996, Chapter 7 of this thesis).
Consequently, also for H3-antagonists undesired peripheral effects may occur at the doses
needed to occupy central H3-receptors. Hence, the development of H3-antagonists
exhibiting a higher brain penetration is desirable.
The structural diversity of the side chain of compounds with H3-antagonistic activity
provides opportunities for the development of radioligands. In 1992, our research group
introduced [lZ5I]iodophenpropit as the first radiolabelled histamine H3-receptor antagonist
(Menge et at., 1992; Jansen et at., 1992). In addition, four other radiolabelled H3-
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antagonists have been described i.e. [3H]S-methylthioperamide (Yanai et at., 1994),
[125I]-iodoproxyfan (Ligneau et at., 1994), [3H]thioperamide (Alves-Rodrigues et al.,
1996) and [3H]GR168320 (Brown et at., 1996). The binding characteristics of these
radioligands will be discussed in section 3.3.
3. H3-Receptor binding studies
3.1. Prelude: selection criteria for radioligands
Receptor radioligands playa crucial role in receptor research, covering many aspects of
receptor pharmacology. From in vitro receptor binding studies information is obtained on
receptor-ligand interactions, tissue distribution of the receptor, G-protein coupling, ion
dependence, receptor heterogeneity and isolation and structural identification of the
receptor protein. In addition, in vivo receptor binding techniques such as single photon
emission computed tomography (SPECT) and positron emission tomography (PET)
contribute to the unraveling of receptor physiology and pathophysiology.
The main criteria for the selection of a radioligand are summarized in Table 3.
Development of a ligand binding assay starts with a ligand (agonist or antagonist) meeting
the following basic requirements: a high binding affinity, reversibility, selectivity and an
appropriate radiosynthesis route yielding a sufficiently high specific activity (an important
determinant in the sensitivity of the assay). Furthermore, the ligand must bind to the
tissue preparations in a saturable way. The nonspecific binding, defined as binding of the
radioligand to 'non-target-receptor components' should be sufficiently low, yielding a
high 'signal-to-noise-ratio'. The two last criteria (saturability and signal-to-noise-ratio) are
difficult to predict in advance, as they largely depend on the tissue and on the
pharmacodynamical characteristics of the ligand. The fulfilment of these criteria is
determined by the relative affinity of the radioligand for the target receptor as compared to
the non-target-receptors and by the ratio between the target and the non-target receptor
densities in the tissue. Another criterion is that binding of the radioligand must be region
or tissue specific and display a heterogeneous subcellular distribution. Finally, binding to
the target receptor has to be validated by the correlation of the receptor binding affinities
of a preferably heterogeneous group of ligands with their potencies determined in
functional studies. Enantiomers exhibiting a clear stereoselectivity for the receptor are also
valuable tools in this respect (see also: Laduron, 1988).
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Table 3. Selection criteria for a radioligand for in vitro receptor binding studies.
basic criteria:
-high affinity
-reversibility
-high selectivity
-high specific activity
additional criteria:
-validation of the 'basic criteria'
-saturability
-proper 'signal to noise ratio', preferably higher than 50%
-heterogeneous tissue distribution
-heterogeneous subcellular distribution
-correlation of binding data with functional data
using a heterogeneous group of ligands
using stereoselective binding tools, if available
From the discovery of the histamine H3-receptor in 1983 until now, eight different
radioligands have been used in H3-receptor binding studies. The first three ligands
described are tritiated agonists. More recently, the availability of different selective H3-
antagonists led to the introduction of three tritiated and of two radioiodinated antagonists.
The radiolabelled agonists and antagonists will be successively reviewed in the next
sections.
3.2. Radiolabelled H3-agonists
The tritiated agonists [3H](R)a.-methylhistamine, [3H]N<X-methylhistamine and
[3H]histarnine were the first radioligands used to characterize histamine H3-receptors in
different species. In Table 4 the main characteristics of these ligands are summarized. All
three ligands were shown to bind reversibly, saturably and with high affinity to H3-
receptors in rat brain membrane preparations. [3H](R)a.-Methylhistamine was the first
radioligand available (Arrang et ai., 1987a). The compound has been used at different
laboratories to study H3-receptor characteristics and distribution from rodents to primates
(Arrang et ai., 1987a; Martinez-Mir et ai., 1990; West et ai., 1990a; Fujimoto et ai.,
1991; Yanai et ai., 1992; Pollard et ai., 1993).
As mentioned before, N<X-methylhistamine has a lower H3-receptor selectivity as
compared to (R)a.-methylhistamine (Schwartz et ai., 1990; Oishi et ai., 1993).
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Nevertheless, [3H]Na.-methylhistamine has proven to be a very suitable radioligand for
H3-receptor binding studies and it has widely been used (Korte et at., 1990; Cumming
et at., 1991; Cherifi et at., 1992; Clark et at., 1993; Kathmann et at., 1993; West et
at., 1994). [3H]Na.-Methylhistamine has the advantage of a higher specific activity and a
lower nonspecific binding as compared to [3H](R)a.-methylhistamine (Table 4).
[3H]Histamine has a relatively low selectivity towards H3-receptors and would not be the
first choice for H3-receptor binding studies. A few reports have described its use as a
radioligand to study histamine H3-receptors however (Cumming et at., 1991; Zweig et
at., 1992). [3H]Histamine has been successfully used to partially purify the H3-receptor
protein from bovine brain (Zweig et at., 1992). In 1980, Barbin et at. found that the
binding profile of tritiated histamine to rat brain membranes did not correspond to H1- and
Table 4. Characteristics of radiolabelled agonists used to study histamine H;-receptors.
[3H](R)o.-MeHA [3H]Nll-MeHA [3H]histamine
Dissociation constant (KD• nM)a 0.4 - 2.5 0.4 - 2 5-8
Receptor density (Bmax' fmollmg)a 30 - 190 40 - 150 20 - 80
Specific binding (% of total binding)a 60 - 90 > 90
- 75
Specific activity (Ci/mmol) 20 - 40 80 6 - 43
Sensitivity to guanine nucleotides
Functional potency (ECso-value, nM) 4 IS 62
Species characterized rat rat rat
guinea-pig guinea-pig bovine
primate mouse
References used [1-5] [6-14] [8,9]
[11 Arrang et al., 1987a, [2] Arrang et aI., 1990, [3] West et aI., 1990a, [4] Kilpatrick & Michel,
1991, [5] Yanai et al., 1994, [6] Korte et al.• 1990, [7] West et al., 1990b, [8] Cumming et aI.,
1991, [9] Zweig et aI., 1992, [10] Clark et aI., 1993, [11] Kathmann et al., 1993, [12] West et al.,
1994, [13] Clark & Hill, 1995, [14] Brown et al., 1996. Data are derived from receptor binding studies
in the species indicated, using brain membranes preparations (except for Cumming, 1991;
autoradiographic study). aValues correspond to experiments using rat whole brain or rat cerebral cortex.
The specific binding is related to radioligand concentrations around or below the KD-value. ECso-Values
correspond to the inhibition of the potassium induced [3H]histamine release from rat cerebral cortex slices,
as taken from Leurs et al. (1992). Abbreviations: [3H](R)a.-MeHA, [3H](R)a.-methylhistamine; [3H]NCI._
MeHA, [3H]NCI.-methylhistamine.
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H2-receptors known at that time (Barbin et at., 1980). Hence, [3H]histamine may be the
first radioligand used to 'unintentionally' label H3-receptors at the time the H3-receptor
had not yet been identified. Nevertheless, [3H]histamine cannot be regarded as a very
selective radioligand. At nanomolar concentrations [3H]histamine binds to multiple sites
in guinea-pig cerebral cortex membranes (Sinkins et at., 1993; Sinkins & Wells, 1993).
Binding of the three tritiated agonists to brain tissue is sensitive to guanine nucleotides
(Table 4) and to pertussis toxin ([3H]Nll-methylhistamine; Clark et at., 1993), indicating
that histamine H3-receptors, like histamine H1- and H2-receptors, belong to the G-protein
coupled receptors. Guanine nucleotides were generally shown to inhibit agonist receptor
binding (Arrang et at., 1990; West et at., 1990b; Cumming et at., 1991; Kilpatrick &
Michel, 1991; Zweig et at., 1992; Clark et at., 1993; Clark & Hill, 1995). The
underlying mechanism(s) for the reduction of radiolabelled agonist binding has not been
investigated in most studies and is currently not well understood. The reduction of agonist
binding may result from both a reduced Bmax or from a reduced affinity (Clark et at.,
1993). It has also been suggested that guanine nucleotides affect a subpopulation of the
binding sites (West et at., 1990b). In one report, the guanine nucleotide induced
reduction of agonist binding has been described to be dependent on the presence of
calcium in the incubation buffer (Arrang et at., 1990). It is obvious that the radiolabelled
H3-agonists do not display a straightforward binding profile with respect to the G-protein
coupling and this may partly explain the inconsistencies found in literature.
There is a clear discrepancy between the receptor binding affinities and the functional
potencies of H3-agonists (Table 4). In general, the affinity of agonists observed in
binding studies exceeds their functional potency by about lO-fold (Arrang et at., 1990;
Schwartz et at., 1990; Leurs et at., 1995b). In contrast, for H3-antagonists, a good
correlation between receptor binding affinity and functional potencies is generally
obtained (Kathmann et at., 1993; Schlicker et at., 1994b; Leurs et at., 1995b; see next
section). The discrepancy between binding affinities and functional potencies as observed
with agonists is likely to result from the involvement of G-protein coupling in agonist
binding, i.e. the radiolabelled agonists may bind to the high affinity receptor state
predominantly. This phenomenon might also explain the relatively low H3-receptor
densities observed using tritiated agonists (30 to 190 fmoUmg of protein; Table 4) as
compared to the densities observed for most radiolabelled antagonists (70 to 400 fmoUmg
of protein; Table 5). The involvement of G-protein coupling in agonist binding can be
regarded as a general drawback of the use of radiolabelled agonists as tools for receptor
binding, complicating the interpretation of the binding data.
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3.3. Radiolabelled H3-antagonists
The complexity of the binding profile of the radiolabelled agonists stressed the need for
radiolabelled antagonists for H3-receptor binding studies. In the last five years two radio-
iodinated and thr~e tritiated antagonists have been reported. The main characteristics of
these ligands are summarized in Table 5. Binding of the antagonists to rat brain show a
high affinity, and is saturable and reversible. Like for the agonists, also the radiolabelled
antagonists described so far are irnidazoles, differing in their side chain (for the chemical
structures see section 2.2).
The introduction of [l25I]-labelled antagonists has led to probes with a high specific
activity, yielding a higher sensitivity as compared to tritiated compounds. The high
sensitivity ofthe radioiodinated probes has been especially beneficial with respect to the
exposure time required to obtain receptor binding autoradiograms (Le. several hours
versus several months, using conventional Hyperfilm). It may be noted though that the
exposure times of tritiated radioligands could be significantly reduced to several days
using the recently developed storage phosphor imaging method, which has been applied
to study the autoradiographic distribution of [3H](R)a-methylhistarnine and of [3H]S-
methylthioperamide (Yanai et al., 1992; Yanai et al., 1994; see also Chapter 5 and
Chapter 6 of this thesis).
As shown in Table 5, considerable differences are found between the receptor densities
described with the radiolabelled antagonists. Although it may be noted that the values
given in Table 5 are not all derived from the same tissue preparation, the tissue variation
does not adequately explain the differences in Bmax-values.
The nonspecific binding of the radiolabelled antagonists appeared to be comparatively
high, except for [3H]GRI68320. The definition of the nonspecific binding of the
radiolabelled antagonists needs critical consideration. For some antagonists, radioligand
binding displaced by antagonists was found to exceed radioligand binding displaced by
agonists, depending on the brain area and species used. An obvious interpretation of these
observations is that the radiolabelled antagonists bind to 'non-H3-receptor components'
from which they are readily displaced by H3-antagonists, and not by H3-agonists. The
phenomenon has been observed for [l25I]iodophenpropit, [l25I]iodoproxyfan and for
[3H]thioperarnide (see Chapter 5; Ligneau et ai., 1994; Alves-Rodrigues et al., 1996).
For [125I]iodophenpropit, the magnitude of the difference between agonist and antagonist
displacement largely varied between different rat brain regions. In most brain areas a
difference of 10 to 20% was found between [l25I]iodophenpropit binding displaced by
the Hrreceptor agonist (R)a-methylhistamine and by the H3-receptor antagonist
thioperarnide (Chapter 5). A difference of about 40% between binding displaced between
agonists and antagonists has been observed for [l25I]iodoproxyfan, in striatal tissue
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(Ligneau et at., 1994). Comparable differences were found for [3H]thioperarnide binding
to rat cerebral cortex membranes (Alves-Rodrigues et at., 1996). From these results it
has been concluded that Hragonists can generally be regarded as more reliable tools to
define the nonspecific binding of the radiolabelled antagonists.
At present, the origin of the non-H3-receptor binding component(s) of H3-antagonists is
largely unknown. For [3H]thioperarnide, binding to cytochrome P450 isoenzymes may be
involved (Alves-Rodrigues et at., 1996). The same has been suggested for [3H]S-
methylthioperamide (Yanai et at., 1994). The origin of the nonspecific binding may of
course differ between the radiolabelled antagonists however. Illustrative for this rationale,
the thioperamide related compound [3H]GR168320 seems not to exhibit the phenomenon
of a differential displacement by agonists and antagonists, at least in rat cerebral cortex
membranes (Brown et at., 1996). Recently, iodophenpropit and thioperarnide have been
screened on a about forty different receptor assays (Leurs et at., 1995a). The screening
Table 5. Characteristics ofradioiabelled antagonists used to study histamine Hrreceptors.
[125[][ppa [125[][PFb [3H]SM'fC [3H]thioperamidea [3H]GR[68320a
Dissociation constant (KD• nM) 0.3 - 0.6 0.[ 2. [ 0.8 0.[
Receptor density (Bmax' fmollmg) 250 - 350 78 550 73 4[2
Specific binding (% of total binding) 45 - 55d 50 - 60 70 - 80 50 - 60 >90
Specific activity (Ci/mmol) 2000 2000 50 6 5
Sensitivity to guanine nucleotides N.D. N.D. N.D.
Functional potency (KB-value. nM) 0.3 I - 5 N.D. 0.2
Species characterized rat rat rat rat rat
mouse
References used [1,2] [3] [4] [5] [6]
[1] Jansen et ai., 1992, [2] Jansen et ai., 1994, [3] Ligneau et ai., 1994, [4] Yanai et ai., 1994, [5]
Alves-Rodrigues et ai., 1996, [6] Brown et ai., 1996. Data are derived from receptor binding studies
using brain membranes preparations, and values correspond to experiments using arat cerebral cortex, brat
striatum or Crat forebrain. d -75% as determined in mouse whole brain. The specific binding is related to
radioligand concentrations around or below the Ko-value. Functional potencies correspond to the
inhibition of the potassium induced [3H]histamine release from rat cerebral cortex slices or to H3-receptor
mediated inhibition of the electrically contracted guinea-pig jejunum. Abbreviations: [125I]IPP,
[125I]iodophenpropit; [125I]IPF, [125I]iodoproxyfan; [3H]SMT, [3H]S-methylthioperamide; N.D., not
described.
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did not yield a possible candidate for the nonspecific binding of both radioligands. Both
iodophenpropit and thioperamide display a relatively high affinity for 5HTrreceptors
(Kj-values of 11 nM and 120 oM, respectively). At the experimental conditions used,
5HT3-receptor binding does not interfere with the the assay for both radioligands
however. The relatively high nonspecific binding of most radiolabelled antagonists can be
regarded as a drawback. In this respect, [3H]GR168320 may be the most appropriate
radioligand. However, its low specific activity of 4.8 Ci/mmol seems to be inadequate for
the generation of autoradiographic images.
Consistent with conventional models of antagonist receptor binding, saturation binding
curves of [lZSI]iodophenpropit were not affected by guanine nucleotides. Displacement of
[lZSI]iodophenpropit by H3-agonists was usually biphasic in nature and displacement
curves were shifted to the right (towards a monophasic curve) after inclusion of GTPyS in
the incubation medium, consistent with an involvement of G-proteins in the binding of the
agonists (Jansen et al., 1994; Leurs et at., 1996; Chapter 3 and 4). In contrast to
[l2SI]iodophenpropit, binding of [l2SI]iodoproxyfan to rat striatal membranes was shown
to be partly sensitive to guanine nucleotides (Ligneau et al., 1994). This observation
might be related to the partial agonistic nature of iodoproxyfan recently described
(Schlicker et al., 1996). Also for [lZSI]iodoproxyfan biphasic agonist displacement
binding curves were reported. Histamine competition binding curves were shifted to the
right by guanine nucleotides (Ligneau et at., 1994). The effect of guanine nucleotides on
the binding curves of the tritiated antagonists has not been investigated so far. Tritiated
antagonists yielded biphasic agonist competition binding curves. Competition binding
curves of (R)a-methylhistamine were shown not to be affected by GTPyS, using
[3H]thioperamide as a radioligand (Alves-Rodrigues et al., 1996). This rather
unexpected finding might result from a changed G-protein coupling at the relatively low
temperature (Le. 4°C) used in the study (Alves-Rodrigues et at., 1996). Altogether, the
radiolabelled antagonists provided further evidence for an involvement of G-proteins in
H3-receptor mediated signal transduction. However, not all the antagonists display a
'classical' behaviour regarding the sensitivity towards guanine nucleotides.
Using radiolabelled antagonists, the affinities of different unlabelled antagonists generally
correlated well with their functional potencies (pAz-values). For [3H] S-
methylthioperamide a detailed binding analysis including competition binding curves of
different ligands has not been presented however. Considering competition binding
curves of agonists, with [lZSI]iodophenpropit, [3H]thioperamide and [3H]GR168320, a
good correlation of the high affinity binding site of agonists with the ECso-values found
in functional studies has been described (Jansen et al., 1994; Alves-Rodrigues et at.,
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1996; Brown et at., 1996). For [l25I]iodoproxyfan, agonist affinities obtained from
competition binding experiments were 3 to 10-fold higher as compared to their functional
potencies. In this respect, [l25I]iodoproxyfan displays characteristics comparable to
radiolabelled agonists (see previous section).
To resume, the introduction of radiolabelled antagonists has provided useful new tools for
H3-receptor binding studies. A good correlation has generally been obtained between
binding of unlabelled H3-antagonists and their functional potencies. For most of the
radiolabelled antagonists, the same holds true with respect to agonist competition binding
curves, implicating a lack of involvement of G-protein coupling in the binding of the
radioligands themselves. However, the guanine sensitivity of binding of tritiated
antagonists has largely to be explored. Further studies are also required to elucidate the
origin of the nonspecific binding observed for most radiolabelled antagonists.
3.4. Distribution of H3-receptor binding sites in the eNS
H3-Receptor radioligands have provided important information on the localization of H3-
receptors in the brain. The autoradiographic distribution of H3-receptor binding sites has
been studied in rat brain using [3H](R)a-methylhistamine (Arrang et at., 1987a; Yanai
et at., 1992; Pollard et at., 1993; Ryu et at., 1995), [3H]Nu-methylhistamine
(Cumming et at., 1991; Cumming et at., 1994a) and more recently with
[125I]iodophenpropit (Jansen et at., 1994), [l25I]-iodoproxyfan (Ligneau et at., 1994)
and [3H]S-methylthioperamide (Yanai et at., 1994). In contrast to the differences in
binding characteristics between the H3-receptor radioligands found using brain membrane
preparations, a consistent overlap is observed with respect to the autoradiographic
distribution of the radioligand binding sites.
A comprehensive study on the distribution of Hrreceptors in the rat CNS has been
described by Pollard et at., using [3H](R)a-methylhistamine (Pollard et at., 1993). H3-
Receptor binding sites in rat brain are heterogeneously distributed. Highest densities are
observed in the cerebral cortex, the olfactory tubercles, the caudate putamen, the nucleus
accumbens and the substantia nigra. Moderate densities are found in the hippocampus, the
globus pallidus, the thalamus and the hypothalamus, including the histaminergic perikarya
in the posterior area. Densities are low in the cerebellum and in the brain stem. In some
brain areas a laminar distribution of H3-receptor binding sites is found. For example, in
the cortex highest densities are observed in the deeper layers (IV-VI). The hippocampus
displays a relatively dense labelling in the dentate gyrus and the subiculum (pollard et at.,
1993).
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Yet no substantial species differences have been found for the H3-receptor distribution, in
contrast to marked species differences previously described for H1- and H2-receptors
(Garbarg et ai., 1992). Beside the rat, the distribution of H3-receptors has been
examined in guinea-pig, mouse and primate brain. In guinea-pig (Cumming et ai.,
1994b) and mouse forebrain (Cumming et at., 1994b; see also Chapter 4), a distribution
is found similar to the distribution described in the rat. The guinea-pig shows relatively
low densities in the striatum as compared to the cerebral cortex. In mouse brain, relatively
high densities were observed in the globus pallidus, as compared to the rat globus
pallidus (see Chapter 4). Receptor autoradiographic studies have also been performed in
monkey and in human brain (Martinez-Mir et ai., 1990). These two species showed a
distribution comparable to rodents. However, in primates, the highest H3-receptor
densities were found in the basal ganglia, especially in the medial and lateral segments of
the globus pallidus.
H3-Receptor binding sites in the CNS display a distribution pattern distinct from the
localization of the histaminergic varicosities. Considering the existence of H3-
heteroreceptors, this finding is not unexpected. Functional studies have indicated the
presynaptic localization of Hrreceptors on noradrenergic (Schlicker et ai., 1989), and on
serotonergic (Fink et at., 1990; Rodrigues et at., 1995) nerve terminals in the cerebral
cortex. In addition, H3-receptor activation also inhibited the release of acetylcholine from
the entorhinal cortex (Clapham & Kilpatrick, 1992; Arrang et ai., 1995). The inhibition
of acetylcholine release was not found in synaptosomes and may therefore occur either via
presynaptic regulation of non-cholinergic neurotransmitter release or via postsynaptic
mechanisms (Arrang et at., 1995). Receptor binding studies provided evidence for a
presynaptic localization of H3-receptors on GABA neurons in the substantia nigra
(Cumming et ai., 1991; Ryu et ai., 1994). Chemical destruction of striatal GABA
neurons terminating in the substantia nigra, resulted in a decrease of H3-receptor binding
sites in the substantia nigra (Cumming et ai., 1991; Ryu et at., 1994). The presynaptic
localization of H3-receptors in the substantia nigra has recently been confirmed in
superfused rat brain slices, demonstrating an inhibition by H3-agonists of dopamine D1-
receptor stimulated GABA release (Garcia et at., 1997).
Receptor binding studies have also indicated a postsynaptic localization of H3-receptors.
Chemical destruction of postsynaptic structures in the striatum using quinolinic and kainic
acid resulted in a marked decrease of striatal H3-receptor binding sites (Cumming et ai.,
1991; Pollard et at., 1993; Ryu et ai., 1994). A major part of the striatal H3-receptors
may be located on striatal GABA neurons, representing more than 85% of the striatal
efferents (Kita & Kitai, 1988). H3-Receptors in the striatum may be functionally linked
to doparninergic neurons. Lesion of doparninergic neurons originating from the substantia
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nigra increased H3-receptor densities in the striatum, especially in the dorsal aspects (Ryu
et al., 1994; see also Chapter 6). These observations indicated that striatal H3-receptors
are not predominantly located on dopaminergic neurons, in line with an indicated
postsynaptic localization. An interaction between H3-receptors and the dopaminergic
system has also been indicated in other components of the basal ganglia. Lesion of
nigrostriatal dopaminergic neurons also increased Hrreceptor densities in the substantia
nigra (Ryu et at., 1994; Ryu et al., 1996). The increased binding in the substantia nigra
was reversed by striatal application of the Dl-receptor agonist SKF38393 indicating a
functional role of dopamine and of striatonigral GABA neurons in H3-receptor regulation
in the substantia nigra (Ryu et at., 1996). Additionally, lesions of the rat dopaminergic
system changed H3-receptor binding in the globus pallidus and in the entopeduncular
nucleus (see Chapter 6). The H3-receptors in the different basal ganglial areas mentioned
may be in part of postsynaptic origin.
Increased H3-receptor binding in the striatum and in the cerebral cortex after lesions of the
medial forebrain bundle at the level of the hypothalamus has also indicated a possible link
between H3-receptors and other aminergic transmitters, including histamine (Pollard et
at., 1993). Accordingly, selective depletion of neuronal histamine with the histidine
decarboxylase inhibitor a-fluoromethylhistarnine increased H3-receptor binding in the
striatum and in the substantia nigra (Ryu et al., 1995; Ryu et at., 1996). Treatment of
rats with reserpine resulted in a marked reduction of H3-receptor binding in the nucleus
accumbens and the striatum (Cumming & Vincent, 1993). In contrast, H3-receptor
binding in the surrounding cortical areas remained unchanged. The authors suggested that
the decreased H3-receptor binding in the striatal areas may result from an increased
histamine synthesis and consequent increase of histamine release, induced by reserpine
treatment (Cumming & Vincent, 1993). Visual deprivation by enucleation of the rat eye,
resulted in a marked increase (50 - 100%) of H3-receptor binding in the superior
colliculus, the area receiving the major part of the retinal efferents (Nakagawa et at.,
1994). Increased H3-receptor binding was also observed in the visual cortex following
visual deprivation (Nakagawa et at., 1994). Resuming, several autoradiographic studies
have reported an increase of H3-receptor binding following a loss of neuronal input (Ryu
et at., 1996).
3.5. H3-Receptor binding studies in peripheral tissues
The densities of H3-receptors in the periphery appeared to be much lower as compared to
densities in the CNS. This makes peripheral H3-receptors less accessible for receptor
binding studies, and consequently explains that only a limited number of studies on H3-
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receptor binding in peripheral tissues has been described so far. H3-Receptors in the
periphery of the guinea-pig have been characterized with [3H]NlX-methylhistamine (Korte
et aI., 1990). In most tissues H3-receptor densities were below 1 fmol/mg of protein.
Highest densities (between 4 and 8 fmol/mg protein) were found in the large intestine, the
ileum, the pancreas and the pituitary. A full pharmacological characterization of the
[3H]NlX-methylhistamine binding sites in the peripheral tissues was not presented (Korte
et al., 1990).
H3-Receptors were also detected in the human gastric mucosa (Courillonmallet et aI.,
1995). [3H]NlX-Methylhistamine saturation binding to mucosal H3-receptors yielded a
receptor density of 10 fmol/mg of protein. H3-Receptor binding was reduced in
Heliobacter pylori infected patients (Courillonmallet et al., 1995). Gastric H3-receptors
have also been characterized using a human fundic tumor cell line (HGT-l). Binding of
[3H]NlX-methylhistamine to these cells was sensitive to GTPyS and to both cholera and
pertussis toxin, again indicating the coupling of the gastric H3-receptors to G-proteins
(Cherifi et aI., 1992). Similar results have been obtained in the murine pituitary tumor
cell line AtT-20 (Clark et aI., 1993; West et al., 1994). [3H]N lX-Methylhistamine
binding was sensitive to GTPyS and to pertussis toxin, indicating the coupling to G-
proteins of the Gi/o subfamily (Clark et aI., 1993). In guinea-pig lung the distribution of
H3-receptors has been visualized by receptor autoradiography (Schwartz et al., 1990).
[3H](R)a-Methylhistamine binding was scattered in the parenchyma. A more dense
labelling was observed in the bronchioles (Schwartz et al., 1990).
Except for [3H]S-methylthioperamide, receptor binding studies to peripheral tissues have
not been described for radiolabelled antagonists. [3H]S-Methylthioperamide showed a
considerably high amount of nonspecific binding, which interfered with the accurate
determination of H3-receptors in peripheral tissues (Yanai et aI., 1994). Based on the
relatively high amount of nonspecific binding observed with most radiolabelled H3-
antagonists, similar limitations may evolve for other radiolabelled antagonists.
3.6. Heterogeneity of binding sites
3.6.1. Radiolabelled H3-agonist binding sites
In 1990, West et ai. reported that thioperamide and burimamide discriminated [3H]NlX_
methylhistamine binding to rat brain membranes into high and low affinity binding sites
(West et al., 1990b). [3H]NlX-Methylhistamine binding was partly decreased by the GTP
analogue GTPyS. In the presence of GTPyS, thioperamide and burimamide yielded
monophasic competition binding curves, with affinities corresponding to their high
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affinity binding sites. From these results the existence of subtypes of H3-receptors Le.
H3K and H3B-receptors was proposed, the latter being sensitive towards guanine
nucleotides (West et ai., 1990b). [3H]Nll-Methylhistamine itself did not discriminate
between the proposed H3A- and H3B-receptors.
In a study by Arrang and co-workers, using the agonist [3H](R)a-methylhistamine as the
radioligand, biphasic competition binding curves in rat cerebral cortex membranes were
obtained for burimamide, but not for thioperamide (Arrang et al., 1990). A guanine
nucleotide sensitivity of the burimamide binding sites was not reported in this study. In
contrast to [3H]Nll-methylhistamine (West et al., 1990b), in the standard incubation
medium, binding of [3H](R)a-methylhistamine was not sensitive to the GTP analogue
Gpp(NH)p. However, when calcium was added to the incubation buffer, two binding
sites were found for [3H](R)a-methylhistamine, the low affinity site being abolished by
Gpp(NH)p (Arrang et al., 1990). From these observations it may be suggested that the
possible heterogeneity of burimamide binding sites and of [3H](R)a-methylhistamine
binding sites are unrelated phenomena. The heterogeneity of [3H](R)a-methylhistamine
binding sites was suggested to result from the conversion of a subpopulation of the
receptors into low-affinity binding sites, triggered by calcium (Arrang et al., 1990).
A heterogeneity of [3H](R)a-methylhistamine binding sites has also been found in kinetic
studies, using buffer without calcium (West et ai., 1990a). In this study a homogeneous
population of [3H](R)a-methylhistamine binding sites was observed at equilibrium
conditions (Le. saturation binding analysis) however. Thioperamide and burimamide
yielded monophasic competition binding curves in this report (West et al., 1990a).
The three reports cited illustrate the complexity of the receptor binding data obtained with
the radiolabelled agonists and the controversies in literature with respect to a heterogeneity
of H3-receptor binding sites. Biphasic competition binding curves for burimamide have
been described in several reports using [3H](R)a-methylhistamine (Arrang et al., 1990)
and [3H]Nll-methylhistamine (West et ai., 1990b; Kathmann et al., 1993; Cumming &
Gjedde, 1994; Brown et al., 1996). Accordingly, different studies reported a
heterogeneous displacement of [3H]Nll-methylhistamine by thioperamide (West et al.,
1990b; Cumming & Gjedde, 1994; Clark & Hill, 1995; Brown et ai., 1996).
Controversially, other studies did not confirm the presence of two distinct binding sites
for burimamide (West et al., 1990a; Kilpatrick & Michel, 1991; Clark & Hill, 1995)
and for thioperamide (Arrang et al., 1990; West et al., 1990a; Kilpatrick & Michel,
1991; Kathmann et al., 1993).
One explanation for the different observations concerning heterogeneity of thioperamide
and burimamide binding sites is the relatively small difference in affinity between the two
separate binding sites, making it difficult to discriminate them statistically. In addition, the
controversies concerning the heterogeneity of binding sites may arise from different
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experimental conditions used, like the choice of buffer (Tris-HCI, phosphate, HEPES),
the ionic composition of the buffer (mono- and divalent cations) and the tissue preparation
used (cerebral cortex versus whole brain). For example, it has been reported that the
affinity of thioperarnide for [3H](R)a.-methylhistamine binding sites was to-fold higher
in phosphate buffer as compared to Tris-HCI buffer (West et al., 1990a). In contrast the
affinity of the agonists histamine, (R)a.-methylhistarnine and NCCmethylhistarnine were
not substantially different when phosphate and Tris-HCI buffer are compared (Arrang et
al., 1987a; West etal., 1990a).
Also, the ionic composition of the buffer has been indicated to differentially affect binding
characteristics of ligands. As previously cited, guanine nucleotide sensitivity of
[3H](R)a.-methylhistarnine (but not of [3H]Nll-methylhistamine; West et al., 1990b) was
dependent on the presence of calcium in the buffer (Arrang et al., 1990). Sodium ions
were shown to abolish the low affinity binding site of thioperarnide, whereas the binding
affinities of clobenpropit and Nll-methylhistarnine were not affected (Clark & Hill,
1995). From these results, it was suggested that the H3-receptor exists in different
conformations, for each of which thioperarnide has a different affinity (Clark & Hill,
1995).
Hence, contribution of differential allosteric effects dependent of the buffer composition
may relate to the observed heterogeneity of binding sites and to the controversy in
literature in this respect. A differential allosteric action of sodium has also been reported
for other receptor systems including the binding of HI-receptor antagonists (Treherne et
al., 1991; Gibson et al., 1994). The allosteric effect may also be related to the
involvement of G-proteins in the binding of agonists to the receptor, further complicating
the interpretation of the binding data. Altogether, the complexity of the binding profile of
radiolabelled agonists does not provide a sound basis for the definition of H3-receptor
subtypes. The necessity for the validation of the possible heterogeneity of H3-receptors
by functional pharmacological studies clearly emerges.
3.6.2. Radiolabelled H3-antagonist binding sites
From a theoretical viewpoint, radiolabelled antagonists are expected to display a more
straightforward binding profile lacking effects of receptor - G-protein interaction on
binding of the radioligands themselves. In section 3.3 it has already been indicated that
not all antagonists currently known fit into the conventional receptor model however.
For all radiolabelled antagonists, biphasic competition binding curves were reported for
H3-agonists (Jansen et al., 1994; Yanai et al., 1994; Ligneau et al., 1994; Alves-
Rodrigues et al., 1996; Brown et al., 1996). In the [1 251]iodophenpropit and [1 251]-
iodoproxyfan binding assays, agonist competition binding curves were sensitive to
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guanine nucleotides (Jansen et al., 1994; Ligneau et al., 1994). The apparent
heterogeneity of agonist binding may therefore be attributed to the involvement of G-
proteins in the agonist receptor binding rather than to a receptor heterogeneity. (Jansen et
at., 1994; Chapter 3). For the tritiated antagonists, the sensitivity to guanine nucleotides
was not studied or could not be demonstrated at the experimental conditions used (Alves-
Rodrigues et at., 1996).
[l25I]Iodophenpropit was biphasically displaced from rat cortex membranes by the
antagonists burimamide and dimaprit (Jansen et at., 1994; Chapter 3). In contrast to
agonist binding, antagonist binding was not affected by GTPyS. Hence, biphasic
competition binding curves of burimamide and dimaprit were likely not related to the G-
protein coupling of the [l25I]iodophenpropit binding sites. So far, a heterogeneous
distribution of putative H3-receptor subtypes has not been demonstrated. Using a receptor
autoradiographic approach, [l25I]iodophenpropit binding to ten different rat brain areas
was not discriminated by a chemically heterogeneous group of H3-receptor antagonists
(see Chapter 5). For the other radiolabelled antagonists, biphasic competition binding
curves of antagonists have so far not been demonstrated. Remarkably, thioperamide and
burimamide yielded steep competition binding curves (Hill-coefficients of 1.7 and 1.9,
respectively) in rat striatal membranes using the [l25I]-iodoproxyfan assay (Ligneau et
at., 1994).
Yet, it can be concluded that receptor binding studies with radiolabelled antagonists did
not reveal clear evidence for H3-receptor heterogeneity. In general, the exploration of H3-
receptor subtypes requires the availability of ligands with a higher selectivity towards one
of these putative subtypes.
3.6.3. Evidence for receptor heterogeneity from functional studies
A few reports described the putative existence of H3-receptor heterogeneity based on
functional studies. H3-Receptors inhibiting acetylcholine release from rat entorhinal cortex
slices were proposed to be pharmacologically distinct from the 'classical H3-receptors'
mediating the inhibition of neuronal histamine release (Clapham & Kilpatrick, 1992).
Phenylbutanoylhistamine and betahistine, exhibiting a rather week antagonistic potency
for the H3-receptors mediating the inhibition by (R)a.-methylhistamine of neuronal
histamine release (Arrang et at., 1985; Clapham & Kilpatrick, 1992), failed to
antagonize the inhibition of acetylcholine release from the entorhinal cortex (Clapham &
Kilpatrick, 1992). The lack of antagonism by phenylbutanoylhistamine and betahistine
was also reported in the periphery, Le. on the H3-receptor mediated inhibition of the
NANC contractions of the guinea-pig intestine (Taylor & Kilpatrick, 1992) and the
inhibition of serotonin release from the porcine enterochromaffin cells (Schworer et al.,
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1994). In addition, also impromidine and burimamide failed to antagonize the H3-receptor
mediated inhibition of serotonin release from the pig intestine (Schworer et ai., 1994).
The involvement of an H3-receptor subtype in the deviating potency of
phenylbutanoylhistarnine has recently been questioned. Arrang et ai. showed that
micromolar concentrations of phenylbutanoy1histamine inhibited acetylcholine release, by
a non-histaminergic mechanism (Arrang et ai., 1995). It was therefore suggested that the
deviating potency of phenylbutanoylhistamine on the acetylcholine release from the
entorhinal cortex may be attributed to the limited selectivity of the compound, rather than
the existence of H3-receptor subtypes (Arrang et ai., 1995). The same could account for
betahistine which is not a histamine H3-receptor selective compound. Additional results
on the deviating potencies of impromidine and burimamide have not been presented so
far.
A series of histamine homologues was recently shown to display a discriminative
pharmacological behaviour between the functional assay in the jejunum and in the eNS
(Leurs et ai., 1996). The propylene, butylene and pentylene (impentamine) homologues
of histamine were full antagonists on the guinea-pig ileum, but displayed partial agonism
in the mouse brain cortex (Leurs et ai., 1996). Similar phenomena were recently
described for iodoproxyfan and its deiodo analogue (Schlicker et ai., 1996). Moreover, a
homologue of the H3-agonist immepip was found to discriminate between H3-receptors in
the guinea-pig jejunum and the rat cerebral cortex (Alves-Rodrigues, 1996). At present, a
straightforward interpretation of these data in terms of receptor subtypes, species
differences or signal transductional mechanisms is not possible. In this respect, additional
potent compounds are desired with an exclusive antagonistic behaviour in different
functional models.
The functional studies mentioned above obviously do not provide evidence for the
putative existence of H3A- and H3B-receptors as suggested from the biphasic
displacement by thioperamide and burimamide of radiolabelled agonists from rat brain
(West et ai., 1990b). Based on the functional potencies of thioperamide and of tiotidine,
H3A- and H3B-receptors were suggested to be linked to H3-receptor mediated inhibition
of histamine release and synthesis, respectively (West et ai., 1990b). So far, the
existence of putative receptor subtypes has not clearly been further documented. Hence,
the existence of H3A- and H3B-receptor subtypes is yet not certain.
3.7. Resumption and concluding remarks
Studies performed with H3-receptor radioligands have substantially contributed to the
current knowledge of the characteristics, distribution and function of the histamine H3-
receptor. Tritiated agonists were successfully used to study H3-receptors in rodent and
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primate CNS. Binding studies with radiolabelled agonists provided evidence for a role of
G-proteins in H3-receptor mediated signal transduction. The apparent involvement of G-
protein coupling in the binding of the radiolabelled agonists may underlay two less
favourable features of the radioligands however. At first, an overestimation of H3-
agonists potencies is obtained in competition binding studies. Secondly, the complexity of
the radiolabelled agonists binding dynamics makes it difficult to distinguish binding
phenomena related to G-protein coupling, allosteric interactions, and receptor
heterogeneity in terms of H3-receptor subtypes. Radiolabelled agonists are advantageous
with respect to their low nonspecific binding in the rat CNS. [3H](R)a.-Methylhistamine
and [3H]NlX-methylhistamine were both shown to be very useful studying the distribution
ofH3-receptors by autoradiography.
The introduction of radiolabelled H3-receptor antagonists yielded improved tools for H3-
receptor binding studies. With the use of these ligands additional evidence was provided
for the interaction of H3-receptors with G-proteins. As compared to radiolabelled
agonists, [125I]iodophenpropit, [3H]GRI68320 and [3H]thioperamide exhibit the
advantage of a good correlation between agonist binding affinities and their functional
potencies.
So far, studies with radiolabelled H3-antagonists did not provide much progress in the
search for H3-receptor heterogeneity. Ligands which more clearly discriminate between
putative subtypes are still awaited, and a link between binding heterogeneity and
functional receptor responses will be indispensable. Not all radiolabelled antagonists
display a straightforward binding profile, which may in part be due to the relatively high
amount of nonspecific binding of most antagonists, to be considered as a drawback. In
this respect [3H]GRI68320 is a promising ligand, displaying a negligible amount of
nonspecific binding, allowing a unambiguous interpretation of receptor binding data.
4. Aim and outline of this thesis
When this PhD-project was initiated in 1992, only tritiated agonists Le. [3H](R)a.-
methylhistamine, [3H]NlX-methylhistamine and [3H]histamine were available for
histamine H3-receptor binding studies. In the same year our group introduced
[l25I]iodophenpropit, the first radiolabelled H3-receptor antagonist. Iodophenpropit is a
member of a series of highly potent isothiourea containing H3-antagonists, developed at
our laboratory. The major part of this thesis deals with the validation of
[l25I]iodophenpropit as a radioligand for in vitro receptor binding experiments studying
characteristics, distribution and function of Hrreceptors in the brain.
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Chapter 2 describes a preliminary characterization of [l25I]iodophenpropit binding to rat
cerebral cortex membranes. A comprehensive analysis of [l25I]iodophenpropit binding to
rat brain is presented in Chapter 3. [l25I]Iodophenpropit meets the criteria for a suitable
radioligand to study the histamine H3-receptor in rat cortex membranes. Receptor binding
studies with [l25I]iodophenpropit provided additional evidence for the interaction of H3-
receptors with G-proteins and also for a heterogeneity of H3-receptor binding sites. In
Chapter 3, the autoradiographic distribution of [l25I]iodophenpropit binding sites in rat
brain is briefly described.
The mouse has been routinely used for in vivo H3-receptor models. Using these models,
a species difference between rat and mouse has emerged for clobenpropit, a close
analogue of iodophenpropit. Almost no data were available on H3-receptor ligand binding
dynamics in mouse brain. In Chapter 4 we therefore describe the characterization of H3-
receptors in mouse brain using [l25I]iodophenpropit, in view of a possible species
difference between H3-receptors in rat and mouse.
In Chapter 5 the distribution of [l25I]iodophenpropit binding sites in rat brain has been
visualized in more detail by receptor autoradiography. Receptor binding densities were
quantified using storage phosphor autoradiography, a new method in which digitized
images are obtained by exposure of radiolabelled brain sections to storage phosphor
plates, instead of exposure to conventional films. In the search for H3-receptor subtypes,
a possible heterogeneity of [l25I]iodophenpropit binding sites was studied in different
brain regions, performing competition binding experiments with a chemically
heterogeneous group of H3-antagonists.
In chapter 6 we investigated the functional link between central H3-receptors and the
nigrostriatal dopaminergic pathway. 6-Hydroxydopamine denervation of rat dopaminergic
neurons altered [125I]iodophenpropit binding in different components of the basal ganglia
indicating an involvement of H3-receptors in basal ganglial neurotransmission.
In order to investigate the potential of iodophenpropit and of its derivatives for in vivo
imaging studies (e.g. PET and SPECT), radioiodinated iodophenpropit was injected into
rats (Chapter 7). The distribution of radiolabelled iodophenpropit and of its radioactive
metabolites in different rat tissues is quantified and visualized using whole-body
autoradiography.
In Chapter 8 the dynamics of in vivo neuronal histamine relea,se from the anterior
hypothalamic area is studied, using microdialysis. The effect of the novel H3-agonist
immepip and of the antagonist clobenpropit, chemically related to iodophenpropit, on
histamine release has been investigated both after local and systemical administration of
the drugs.
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The first radiolabelled histamine H3-receptor antagonist
[125I]iodophenpropit: saturable and reversible binding to
rat cortex membranes - preliminary characterization
Frank P. Jansen, Ben Rademaker*, Aalt Bast, and Hendrik Timmerman
Abstract
We describe the binding of [125I]iodophenpropit, the first radiolabelled histamine H3-antagonist, to rat
cortex membranes. The binding of [125I]iodophenpropit was selective, saturable, readily reversible, and of
high affinity (Ko-value of 0.32 nM; Bmax-value of 209 fmoVmg of protein). Specific binding at a
concentration of 0.3 nM accounted for 45 to 55% of total binding. [125I]Iodophenpropit is a promising
ligand for H3-receptor binding studies.
*Rephartox B.V., Maarssen, The Netherlands.
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Introduction
Both release and synthesis of neuronal histamine in the central nervous system are
modulated by a histaminergic autoreceptor characterized as the H3-receptor (Arrang et
ai., 1983). Moreover, the H3-receptor acts as a heteroreceptor on both central and
peripheral nerve tissue (Schwartz et ai., 1990; Timmerman, 1990).
A number of H3-selective ligands have meanwhile been developed, including the agonist
(R)a-methylhistamine and the antagonist thioperamide (for review see: Schwartz et ai.,
1990; Timmerman, 1990; Leurs et ai., 1995). For H3-receptor binding studies the
tritium-labelled agonists [3H](R)a-methylhistamine (Arrang et ai., 1987), [3H]NlX-
methylhistamine (Korte et ai., 1990) and [3H]histamine (Zweig et ai., 1992) have been
initially used. Although these radioligands proved to be valuable tools to study histamine
Hrreceptors, their binding profiles are rather complex, which may partly arise from the
involvement of the interaction of the agonist-receptor complex with G-proteins (review
see: Leurs et at., 1995). Hence, radiolabelled H3-antagonists may constitute improved
pharmacological tools for H3-receptor binding studies.
In our laboratory, a new class of H3-antagonists exhibiting a high affinity and selectivity
towards the H3-receptor has previously been developed (Van der Goot et ai., 1992).
Among these H3-antagonists are halogenated compounds which are potential tools for
H3-receptor binding studies. An iodinated member of this series is iodophenpropit which
exhibits a high antagonistic activity (pA2-value of 9.6) and a high selectivity towards the
histamine H3-receptor, its affinity for H1- and H2-receptors being more than 1000-fold
lower. In this chapter we describe the binding characteristics of [l25I]-labelIed
iodophenpropit, the first radiolabelled H3-receptor antagonist (Menge et ai., 1992)
(Figure 1).
Figure 1. The chemical structure of[125/]iodophenpropit
Note: In addition to [125Ijiodophenpropit, other radiolabelled histamine Hrantagonists have more
recently been described i.e. [125Ijiodoproxyfan, [3HjS-methylthioperamide, [3Hjthioperamide and
[3HjGRI68320. These radioligands are discussed in Chapter 1,4,5 and 7.
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Materials and Methods
Fresh cerebral cortex membranes from male Wistar rats (200-250 g, Harlan C.P.B.,
Zeist, The Netherlands) were prepared for each experiment in 50 mM Tris-HCl buffer
(pH 7.4 at 4°C) containing 145 mM NaCl and 5 mM MgClz, by a method essentially
according to Leurs et at. (1986). [l25I]Iodophenpropit (S-[3-(4(5)-imidazolyl)propyl]-
N-[2-(4-iodophenyl)ethyl] isothiouronium hydrogen sulfate; specific activity =1900
Ci/mmol) was synthesized as described by Menge et al. (1992).
Binding experiments were performed at 37°C in Tris-HCl buffer (pH 7.4) with a total
incubation volume of 0.5 mI, using polyethylene tubes. In saturation and displacement
studies, membranes were incubated for 60 minutes. The incubation was started by the
addition of 100 III membranes (20-60 Ilgltube) and was terminated by rapid filtration
through polyethyleneimine (0.3% w/v) pretreated Whatman GF/C filters, using a Brandel
filtration apparatus. The filters were washed twice with 3 mI of ice-cold Tris-HCl buffer
(pH 7.4 at 4°C). Subsequently, the radioactivity bound to the filters was measured by an
LKB gamma counter. (For a more detailed description of the method see Chapter 3)
Results and discussion
At 37°C [l25I]iodophenpropit (0.5 nM) rapidly bound to rat cerebral cortex membranes
reaching half maximal binding within 1 minute and equilibrium at approximately 30
minutes, which remained stable for at least one additional hour (Figure 2). Specific
binding, defined as the difference between total binding and binding in the presence of
0.1 !!M thioperarnide, was readily reversed by the addition of 1 !!M thioperarnide (Figure
2). The association and dissociation constants calculated from the kinetic data were 0.75
nM-l.min-1 and 0.35 min-1respectively, yielding a KD-value of 0.47 nM.
Incubation of rat cortex membranes with increasing concentrations [125I]iodophenpropit
(0.025 - 5 nM) showed that the specific binding of [l25I]iodophenpropit was saturable
(Figure 3) and yielded linear Scatchard plots (Figure 4). Computer analysis (Munson &
Rodbard, 1980) of the saturation binding curves revealed binding of
[l25I]iodophenpropit to a single class of sites with a KD of 0.32 ± 0.06 nM and a Bmax of
209 ± 53 fmol/mg of protein (nH = 0.97 ± 0.02, n = 5). Specific binding at a
concentration of 0.3 nM accounted for 45 to 55% of total binding. The dissociation
constant of [125I]iodophenpropit calculated from the saturation experiments is in
agreement with its pA2-value of 9.6 ± 0.2 as determined on the H3-receptor mediated
relaxation of the electrically contracted guinea-pig jejunum. Displacement of
[125I]iodophenpropit (0.25 nM) by the antagonists thioperarnide and iodophenpropit was
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Figure 2. Kinetics of[125Ijiodophenpropit binding to rat cerebral cortex membranes. The association of
[ 125Ijiodophenpropit (0.5 nM) was started by addition ofthe membranes and was measured in the absence
(e) and in the presence (0) ofthioperamide (0.1 J1M), to discriminate between specific and nonspecific
binding. Dissociation of[125Ijiodophenpropit (t» was initiated by the addition of thioperamide (1 J1M),
after 60 minutes. Data displayed are obtained from a single experiment (of three separate experiments)
with triplicate determinations.
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Figure 3. Saturation binding of [125ljiodophenpropit binding to rat cerebral cortex membranes.
Symbols: (e), total binding; (0), nonspecific binding; (~), specific binding. Nonspecific binding was
defined as [125Ijiodophenpropit binding in the presence ofthioperamide (0.1 J1M). Data are obtainedfrom
a representative experiment. Each assay was performed with duplicate determinations.
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Figure 4. Scatchard transformation ofthe [125I]iodophenpropit saturation binding curve.
best fit by a one site model with KD- and Bmax-values of 5.1 ± 1.9 nM and 326 ± 104
fmol/mg of protein for thioperamide (n =9) and 1.2 ±0.4 nM and 357 ± 51 fmol/mg of
protein for iodophenpropit (n =6), respectively. In contrast, displacement curves for the
agonists histamine and (R)a-methylhistamine were shallow and revealed two binding
sites. For histamine the KH and KL were 24 ± 16 nM and 1.6 ± 1.21lM, with a density
of 126 ± 59 and 150 ± 46 fmol/mg of protein, respectively (n = 8). (R)a-
Methylhistamine showed a KH and KL of 4.3 ± 3.4 nM and 0.22 ± 0.15 IlM, with
corresponding densities of 157 ± 57 and 157 ± 54 fmol/mg of protein, respectively (n =
5). The biphasic displacement of [125I]iodophenpropit by the two agonists may arise from
the involvement of G-proteins in agonist binding (see next chapter).
In conclusion, the H3-antagonist [l25I]iodophenpropit seems to fulfill the basic criteria for
a suitable ligand for H3-receptor binding studies, exhibiting a high affinity, saturability,
reversibility, selectivity and a high specific activity.
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Characterization of the binding of the histamine H3-receptor
antagonist [125I]iodophenpropit to rat brain
Frank P. Jansen, Tin-Seng Wu, Hans-Peter Voss, Harry W.M. Steinbusch1,
Roeland C. Vollinga, Ben Rademaker2, Aalt Bast,
and Hendrik Timmerman
Abstract
We characterized the binding of the selective radiolabelled histamine Hrreceptor antagonist
[125Iliodophenpropit to rat cerebral cortex membranes. [125IjIodophenpropit, radiolabelled to a high
specific activity of 1900 Ci'mmol-1, saturably bound to a single class of sites with a KD of 0.57 ± 0.16
nM (n=4) and a Bmax of 268 ± 119 fmol'mg-1 protein. Specific binding at a concentration below 1 nM
represented 50 to 60 % of total binding. Binding of [125Ijiodophenpropit to rat cerebral cortex membranes
was readily displaced by histamine H3-agonists and antagonists. In contrast, the inhibitory potencies of
selective histamine Hr and H2-receptor ligands were very low.
[125IjIodophenpropit was biphasically displaced by the histamine H3-receptor antagonists burimamide and
dimaprit, which may indicate the existence of histamine H3-receptor subtypes. Other histamine Hr
receptor antagonists showed a monophasic displacement.
Competition binding curves of H3-agonists were biphasic and showed a rightward shift upon the addition
of the nonhydrolysable GTP analog guanosine 5' -O-(3-thio)triphosphate (GTPyS; 100 J,lM), implicating
the interaction of histamine H3-receptors with G-proteins. The affinities of the Hrreceptor antagonists
iodophenpropit, thioperamide and burimamide were not altered by GTPyS. Histamine competition
binding curves were shifted to the right by different nucleotides (100 J.lM) with a rank order of potency
GTPyS > Gpp(NH)p, GTP.
In vitro autoradiographic studies revealed a heterogeneous distribution of [125Ijiodophenpropit binding
sites in ratbrain, with high densities observed in the cerebral cortex, the striatum, the olfactory tubercles,
and the substantia nigra.
It is concluded that the histamine H3-receptor antagonist [125Ijiodophenpropit meets the criteria for a
suitable radioligand to study histamine Hrreceptors in rat brain.
lEuropean Graduate School of Neuroscience, EURON, Maastricht University, Department of Psychiatry
and Neuropsychology, Maastricht, The Netherlands. 2Rephartox B.Y., Maarssen, The Netherlands.
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Introduction
The histamine H3-receptor has been characterized as an autoreceptor inhibiting neuronal
histamine release in the CNS, and as a heteroreceptor inhibiting the release of various
neurotransmitters both in CNS and PNS (Leurs & Timmerman, 1992; Schlicker et al.,
1994). Initially, in receptor binding experiments the agonists [3H]histamine, [3H](R)a-
methylhistamine and [3H]NlX-methylhistamine have been used to study the molecular
pharmacology and distribution of histamine H3-receptors (Arrang et al., 1990; Korte et
al., 1990; West et aI., 1990a; West et aI., 1990b; Kilpatrick & Michel, 1991; Zweig
et al., 1992; Clark et aI., 1993). These studies suggested the interaction of histamine
H3-receptors with G-proteins (West et al., 1990b; Arrang et al., 1990; Zweig et aI.,
1992; Clark et al., 1993). Moreover, from studies with [3H]NlX-methylhistamine the
presence of subtypes has been suggested (West et aI., 1990b). However, the binding
profile of the radiolabelled agonists appeared to be rather complex. Therefore, the
development of radiolabelled histamine H3-receptor antagonists is of great importance.
In 1992, a new class of highly potent histamine H3-receptor antagonists has been
described (Van der Goot et al., 1992). Its most potent member is clobenpropit
(VUF9153) showing a pA2-value of 9.9 as determined on the electrically contracted
guinea-pig intestine. The series allowed the development of the first radiolabelled
histamine H3-receptor antagonist [125I]iodophenpropit (Menge et al., 1992). Preliminary
results indicated that [l25I]iodophenpropit is a promising tool for histamine H3-receptor
binding experiments (Jansen et al., 1992; Chapter 2). In this chapter we describe the full
characterization of [l25I]iodophenpropit as a radioligand to study histamine H3-receptors.
Methods
Preparation ofrat cerebral cortex membranes
Male Wistar rats (200-250 g, Harlan C.P.B., Zeist, The Netherlands) were killed by
decapitation and the brains were rapidly removed. The cerebral cortices were dissected
and homogenized in 15 volumes (v/w) of ice-cold Tris-HCl buffer (50 mM Tris-HCl; 5
mM MgCI2, 145 mM NaCl; pH 7.4 at 4°C) using an Ultra-Turrax homogenizer (8
seconds) and a glass-teflon homogenizer (four up and down strokes) subsequently. All
Note: In addition to [125Iliodophenpropit, other radiolabelled histamine H3-antagonists have more
recently been described Le. [125I]iodoproxyfan, [3H]S-methylthioperamide, [3H]thioperamide, and
[3H]GR168320. These radioligands are discussed in Chapter 1,4,5 and 7.
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subsequent steps preceding incubation were performed at a temperature of 0 to 4°C. The
homogenate was centrifuged at 800 g for ten minutes. The pellet was discarded and the
supernatant was centrifuged for 20 minutes at 40,000 g. The resulting pellet was
resuspended and the last centrifugation step was repeated. The pellet was resuspended in
1.5 volumes (v/w) Tris-HCl buffer and stored at -80°C. Before each receptor binding
experiment the membranes were resuspended in Tris-HCl buffer and were centrifuged for
20 minutes at 40,000 g. Finally, the pellet was resuspended in 7 volumes (v/w) of
incubation buffer (50 roM Tris-HCl containing 5 roM MgClz, 145 roM NaCl ; pH 7.4 at
37°C. In some experiments NaCl was omitted).
Receptor binding experiments
Binding experiments were performed at 37°C in the Tris-HCl incubation buffer (pH 7.4)
with a total incubation volume of 0.5 ml, using polyethylene tubes. Determinations were
performed in triplicate. Drugs (except for thioperamide, see "drugs and chemicals") were
prepared in incubation buffer. Rat cerebral cortex membranes were incubated for 60
minutes to reach equilibrium (Jansen et at., 1992; Chapter 2). In saturation experiments
membranes were incubated with [lZ5I]iodophenpropit in final concentrations ranging
from 0.025 to 3 nM. In competition binding experiments a concentration of 0.25 nM
[lZ5I]iodophenpropit was used. Specific binding was defined as the difference between
total binding and binding in the presence of 0.3 IlM thioperamide and represented more
than 50 to 60 % of total binding, at [lZ5I]iodophenpropit concentrations below 1 nM.
[lZ5I]Iodophenpropit was displaced to about the same level by all of the histamine H3-
receptor ligands tested. Moreover, at this level [lZ5I]iodophenpropit binding was not
further displaced upon the addition of 0.1 IJ.M thioperamide.
Incubations were started by the addition of 100 III membranes (20 - 60 Ilg of protein per
tube) and were terminated after 60 minutes by adding 2 ml of ice-cold Tris-HCl buffer
(pH 7.4 at 4°C) immediately followed by filtration through Whatrnan GF/C filters using a
Brandel filtration apparatus. Filters were pretreated (for two hours) with 0.3%
polyethyleneimine, reducing filter binding to less than 1 % of the total radioactivity added.
After filtration of the membranes, the filters were washed twice with 2 ml of ice-cold
Tris-HCl buffer. The amount of radioactivity bound to the membranes was not reduced
by repetition of the washing procedure up to five times. The radioactivity bound to the
filters was measured by an LKB gamma counter.
Data analysis
Saturation and competition binding experiments were evaluated using the non-linear curve
fitting program LIGAND (Munson & Rodbard, 1980) on a Macintosh computer. With
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the aid of this program binding curves were fit (unweighed) to a one and a two site model
respectively, and statistically tested on the increasing goodness of the fit for a model with
additional parameters, based on the 'extra sum of squares' principle (Draper & Smith,
1966), using a probability level of 5%.
Protein assays
Protein concentrations were determined using the Bio-Rad Protein Assay (Bradford,
1976). Bovine serum albumin (BSA) was used as a standard.
Receptor autoradiography
Male Wistar rats (200-250 g, Harlan c.P.B., Zeist, The Netherlands) were killed by
decapitation and the brains were removed. Brains were frozen using liquid carbon
dioxide. Cryostate sections (14 !lm) were mounted on gelatine/chromalum-coated glass
slides and stored at -80°C until use. The brain sections were thawed and subsequently
incubated with 0.3 oM [125I]iodophenpropit for 60 minutes at 37°C in 50 mM Tris-HCI
buffer containing 145 mM NaCI, 5 mM MgCl2 and 0.25% BSA (pH 7.4 at 37°C). Non-
specific binding was determined by incubation of adjacent sections in the presence of 0.3
J.lM thioperamide. To stop the incubation, the slices were washed twice for 15 minutes in
ice-cold Tris-HCI buffer (50 mM Tris-HCI; 5 mM MgCI2, 145 mM NaCl; pH 7.4 at 4°C)
and 15 seconds in ice-cold distilled water. Sections were dried by a stream of cold air and
were exposed to Hyperfilm, (Amersham International, U.K.) for 20 hours.
Drugs and chemicals
[125I]Iodophenpropit was labelled to a specific activity of 1900 Ci mmol-1as described by
Menge et al. (1992). The radiolabelled compound was stored at 4°C in a 1 mM H2S04
solution in ethanol. H2S04 did not affect the pH of the Tris-HCI buffer at the final
concentrations of the radioligand used. HPLC-Analysis of the stock solution of
[125I]iodophenpropit two months after preparation revealed that the radioactivity was
almost quantitatively present in one peak with a retention time corresponding to the
radioligand.
The following drugs and chemicals were used: thioperamide (Schering Corporation),
iodophenpropit dihydrobromide (laboratory stock), clobenpropit dihydrobromide
(VUF9153, laboratory stock), impromidine trihydrochloride (SK&F Laboratories, UK),
burimamide (SK&F Laboratories), dimaprit dihydrochloride (SK&F Laboratories),
histamine dihydrochloride (Sigma, St. Louis, USA), (R)a-methylhistamine maleate (gift
from Prof.Dr. J-C. Schwartz, Paris), (S)a-methylhistamine dihydrobromide (Cookson
Chemicals, St. Louis, USA), imetit dihydrobromide (VUF8325, laboratory stock),
immepip dihydrobromide (VUF4708, laboratory stock), 5' -guanylylimidodiphosphate
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(Gpp(NH)p, Sigma), guanosine 5'-O-(3-thio)triphosphate (GTPyS, Sigma), guanosine
5' -triphosphate (GTP, Sigma), betahistine dihydrochloride (Solvay Duphar, Weesp,
Netherlands), mepyramine hydrochloride (Sigma), triprolidine hydrochloride (Sigma),
amthamine dihydrobromide (laboratory stock), tiotidine (ICI, Macclesfield, U.K.),
imidazole (Merck) and polyethylenimine (Aldrich, Zwijndrecht, Netherlands). Drugs
were dissolved in distilled water or in Tris-HCI buffer except for thioperarnide which was
diluted in buffer from 1 mM stock solutions prepared in DMSO. At the final
concentrations used, DMSO did not affect [l25I]iodophenpropit receptor binding.
Statistical analysis
Dissociation constants for agonists determined in the absence and presence of guanine
nucleotides were compared using a one tailed unpaired Student's t-test. The effect of
NaCI on dissociation constants of antagonists was analyzed by a two tailed unpaired
Student's Hest. Differences were considered using a probability level of 5%.
Results
[125I]Iodophenpropit saturation binding experiments
Specific binding of [l25I]iodophenpropit (0.025 - 3 oM) to rat cerebral cortex membranes
was saturable (Figure lA) and yielded linear Scatchard plots (not shown). Computer
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Figure 1. (A) Saturation binding of [l251jiodophenpropit (0.025 - 3 nM) to rat cerebral cortex
membranes. (0) Total binding; (II) non-specific binding; (e) specific binding, determined by the addition
of0.3 J.lM thioperamide. (B) Specific binding of[125ljiodophenpropit to rat cerebral cortex membranes in
the absence (0) andpresence (e) of 100 J.lM Gpp(NH)p. The dissociation constant and receptor density in
the absence of Gpp(NH)p were 0.57 ± 0.16 nM and 268 ± 119 fmol'mg-l protein, and in the presence of
presence Gpp(NH)p 0.55 ± 0.19 nM and 272 ± 101 fmol'mg- l protein, respectively (n=4). Results
displayed are from one representative experiment with triplicate determinations.
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analysis of the saturation binding curves revealed that [l25I]iodophenpropit bound to a
single class of sites with a Ko of 0.57 ± 0.16 nM and a Bmax of 268 ± 119 fmol'mg-1 of
protein (n =4). Hill coefficients were not significantly different from unity (l.00 ± 0.02).
Non-specific binding determined in the presence of 0.3~ thioperamide was linear with
the [l25I]iodophenpropit concentration up to 3 nM. Specific binding at concentrations
below 1 nM accounted for more than 50 to 60% of total binding.
Both, dissociation constant and receptor density of the [125I]iodophenpropit binding sites
were not affected by the non-hydrolysible GTP analog 5'-guanylylirnidodiphosphate
(Gpp(NH)p) at a concentration of 100 flM (Ko = 0.55 ± 0.19 nM; Bmax = 272 ± 101
fmol'mg-1 protein; n =4) (Figure lB).
Competition binding curves ofH3-antagonists
[125I]Iodophenpropit was displaced from rat cerebral cortex membranes by histamine H3-
receptor antagonists (Figure 2). The selective histamine H3-receptor antagonists
clobenpropit (VUF9153) and iodophenpropit showed the highest potency with Ko-values
of 0.9 ± 0.4 nM and 1.0 ± 0.1 nM respectively (Table 1). Omitting sodium chloride from
the buffer significantly reduced the affinity of iodophenpropit and thioperamide for
[125I]iodophenpropit binding sites (Table 1). Competition binding curves of clobenpropit,
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Figure 2. (A) Inhibition of [125IJiodophenpropit binding (0.25 nM) by histamine Hrreceptor
antagonists. (B) Competition binding curves for burimamide and dimaprit compared with the
corresponding theoretical one site competition binding curves (dashed curves). Data are expressed as % of
the specific binding. Specific binding was determined using 0.3 J1M thioperamide and represented 50 to
60% of the total binding. Each curve represents a single representative experiment with triplicate
determinations. Symbols used: (e) clobenpropit, (6.) iodophenpropit, (II) thioperamide, (0)
impromidine, (A) burimamide, (Cl) dimaprit, (x) betahistine.
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iodophenpropit, thioperamide (KD =4.3 ± 1.6 nM) and impromidine (KD =51 ± 9 nM)
were best fit according to a one site model (P > 0.05). In contrast, competition binding
curves of the histamine H3-receptor antagonists burimamide and dimaprit were
significantly better described by a two site model (P < 0.05; Figure 2B). The dissociation
constants for the two different sites were 18 ± 9 nM and 725 ± 392 nM for burimamide
and 0.42 ± 0.11 IlM and 38 ± 37 IlM for dimaprit (Table 2). The histamine H3-receptor
antagonist betahistine had a KD-value of 131 ±371lM (Figure 2A).
Table 1. Affinities ofdifferent ligands towards [125I]iodophenpropit binding sites on rat cerebral cortex
membranes and the effect ofNaCI on histamine H3"receptor antagonist affinity.
ligand
H3"antagonists:
clobenpropit
iodophenpropit
thioperamide
irnprornidine
Tris-buffer
+ MgClz (5 mM)
KD(nM)
N.D.
1.7 ± 0.3 (3)
11 ± 2.3 (7)
107 ± 68 (3)
Tris-buffer
+ MgClz (5 mM)
+ NaCI (145 mM)
KD(nM)
0.9 ± 0.4 (3)
1.0 ± 0.1* (3)
4.3 ± 1.6* (7)
51 ± 9 (3)
other ligands:
mepyramine
triprolidine
tiotidine
amthamine
imidazole
> 10,000
> 10,000
> 10,000
> 10,000
> 10,000
(5)
(3)
(4)
(2)
(2)
N.D.
N.D.
N.D.
N.D.
N.D.
All compounds displayed were best fit according to a one-site model (P > 0.05). Values are given as the
mean ± s.d. (number of experiments). N.D.; not determined. * P < 0.05 as compared with buffer without
NaCl.
Displacement by other ligands
Selective ligands for histamine Hl- (mepyramine and triprolidine) and H2-receptors
(tiotidine and amthamine) and imidazole showed a very low affinity (KD > 10 IlM)
towards the [125I]iodophenpropit binding sites (Table 1).
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Table 2. Affinities of histamine HTreceptor antagonists discriminating between [125/]iodophenpropit
binding sites.
antagonist:
burimamide KO,I (nM) R1 (%) KO,2 (nM) R2 (%)
18 ± 9 54 ± 10 725 ± 392 46 ± 9
dimaprit KO,I (I.lM) R1 (%) Ko,z<I.lM) R2(%)
0.42 ± 0.11 52 ± 6 38 ± 37 47 ± 6
Values are given as the mean ± s.d. of eight (burimamide) and five (dimaprit) separate experiments with
triplicate determinations. KO,I and KO,2 are the dissociation constants for the two different binding sites,
R1 and R2 the corresponding percentages of each site.
[/25I]/odophenpropit displacement by H3-agonists; the effect ofguanine nucleotides
Competition binding curves for histamine H3-receptor agonists were shallow and were all
best fit according to a two site model (P < 0.05), showing high and low affinity binding
sites. The rank order of potency of the five agonists used for the high affinity sites was
imetit (KH = 2.7 ±0.8 nM), immepip (KH = 2.7 ±0.5 nM), (R)a;-methylhistamine (KH
=3.5 ± 1.2 nM) > histamine (KH =38 ± 10 nM) > (S)a;-methylhistamine (KH =230 ±
97 nM) (Table 3).
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Figure 3. The effect of different nucleotides on displacement of [125/]iodophenpropit (0.25 nM). (A)
The effect of nucleotides on histamine (HA) and thioperamide competition binding curves. (e)
thioperamide, (0) thioperamide + GTPyS, ~) HA, (Ii.) HA + GTP, (CI) HA + Gpp(NH)p, (A.) HA +
GTPyS. (B) The effect ofGTPyS on (R) and (S)a-methylhistamine competition binding curves; (A.)
(R)a-methylhistamine, (Ii.) (R)a-methylhistamine + GTPyS, (e) (S)a-methylhistamine, (0) (S)a-
methylhistamine + GTPyS. Curves displayed are from representative experiments, each point determined
in triplicate. The concentration of the nucleotides used was /00 pM.
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Table 3. The effect of guanine nucleotides on the high and low affinity binding sites of histamine Hr
receptor agonists.
high affinity low affinity
agonist nucleotide KH(nM) RH(%) KL(~) RL(%)
histamine 38 ± 10 52 ±4 2.5 ±0.6 48 ±4
GTP 85 ±35* 51 ± 8 2.5 ±0.9 49 ± 8
Gpp(NH)p 137± 100* 42 ± 13 3.2 ± 1.5 58 ± 13
GTPys 0.8 ±0.1* 100**
(R)a-methylhistamine 3.5 ± 1.2 52 ± 4 1.2 ±0.3 48 ± 3
GTPys 0.1 ±0.1* 100**
(S)a-methylhistamine 230±97 39 ± 11 9.5 ± 1.8 61 ± 5
GTPys 12 ±3.9 100**
imetit 2.7 ±0.8 59 ± 5 40 ± 12 41 ± 2
GTPys 18 ± 10* 52 ± 14 35 ±20 48 ± 13
immepip 2.7 ±0.5 63 ± 3 1.0 ±0.2 37 ± 2
GTPys 20 ± 5* 67 ± 5 3.4 ± 3.4 33 ± 8
Values are given as the mean ± s.d. of six (histamine ± Gpp(NH)p) or four (remaining) separate
experiments with triplicate determinations. The concentrations of GTP, Gpp(NH)p and GTPys were 100
~. KH and KL correspond to the dissociation constants for the high and low affinity binding sites
respectively. RH and RL are the percentages of high and low affinity sites. * P < 0.05 as compared to
value without the nucleotide. ** Curve best fit according to one-site model (P>0.05).
Upon the addition of GTPyS (100 JlM) the competition binding curves of the agonists
showed a rightward shift. GTPyS completely abolished the high affinity sites for
histamine, (R)a-methylhistamine and (S)a-methylhistamine (curves were best fit to a one
site model, P> 0.05; Table 3, Figure 3). For imetit and immepip a significant increase of
the high affinity dissociation constant was observed upon addition of GTPyS (Table 3).
With respect to competition binding curves for histamine the nucleotides GTP and
Gpp(NH)p at a concentration of 100 JlM were less potent than GTPyS. Both GTP and
Gpp(NH)p significantly increased the high affinity dissociation constant for histamine
(Table 3).
GTPyS (100 JlM) did not affect the dissociation constants for the histamine H3-receptor
antagonists iodophenpropit (KD-value without GTPyS: 1.4 ± 0.4 nM, KD-value with
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GTPyS: 2.2 ± 0.8 nM, n =3), thioperamide (KD-value without GTPyS: 1.2 ± 0.4 nM,
KD-value with GTPyS: 1.3 ± 0.7 nM, n =3) and burimamide (KD,l-and KD,2- value
without GTPyS: 18 ± 9 nM and 0.7 ±0.4 11M respectively, n =8; KD,l and KD,2 -value
with GTPyS: 62 ± 44 nM and 3.1 ± 2.8 11M, respectively, n =3).
Distribution of [125I]iodophenpropit binding sites in rat brain studied by receptor
autoradiography
Incubation of rat brain cryostate sections with [l25I]iodophenpropit showed that the
radioligand binding sites were heterogeneously distributed (Figure 4A). Non-specific
binding, defined by incubation of adjacent sections in the presence of 0.3 11M
thioperamide, was low and homogeneously distributed (Figure 4B). The highest levels of
specific binding were observed in the upper frontal layers and lower temporal layers of
the cerebral cortex, the caudate-putamen complex, the nucleus accumbens, the olfactory
tubercles and the substantia nigra. A moderate density was observed in the hypothalamic
area, the hippocampal formation, the amygdala complex, and the mammillary bodies.
Densities were low in the cerebellum.
A ex DG Hi
Bs
B
Figure 4. Autoradiographic localization of [l251jiodophenpropit binding sites in rat brain. Shown is a
representative sagittal section (14 J1m). (A) total binding of [125Ijiodophenpropit; (B) non-specific
binding, as defined by the inclusion of 0.3 pM thioperamide. Indicated areas: Acb; nucleus accumbens,
Bs; brain stem, Cb; cerebellum, Cpu; caudate-putamen, Cx; cortex, DG; dentate gyrus, Tu; olfactory
tubercle, Hi; hippocampal formation, SN; substantia nigra.
Discussion
A preliminary pharmacological characterization of the radiolabelled histamine H3-receptor
antagonists [125I]iodophenpropit indicated that the radioligand is a potential tool for
histamine H3-receptor binding studies (Jansen et aI., 1992; Chapter 2). In the present
Chapter, we further characterized the binding of [l25I]iodophenpropit to rat brain.
- 66-
[125I]Iodophenpropit binding to rat brain
[l25I]Iodophenpropit meets the basic criteria for a suitable radioligand for receptor
binding studies, Le. high affinity, saturability, reversibility, selectivity and high specific
activity. The pKD-value (9.3) observed in saturation binding experiments is close to the
pA2-value (9.6) determined on the guinea-pig intestine. Binding of the radioligand to
histamine H3-receptors was validated by competition binding studies using various
selective histaminergic ligands and by receptor autoradiography.
The binding results obtained with [l25I]iodophenpropit largely correlate to data obtained
from receptor binding studies using the radiolabelled agonists [3H]histamine, [3H]NIX-
methylhistamine and [3H](R)a.-methylhistamine, however also some clear discrepancies
exist. The receptor density found using [125I]iodophenpropit (268 fmol·mg- 1 protein)
was 2 to 8-fold higher than the densities reported using radiolabelled agonists (30 to 130
fmol·mg- 1 protein). The observation that the histamine H3-receptor antagonists
clobenpropit, iodophenpropit, thioperamide and impromidine displaced [l25I]iodophen-
propit according to a one site model is a clear indication that the displaced binding
represents histamine H3-receptors. Considering the variation in chemical structure of the
four ligands mentioned it seems unlikely that the relatively high densities observed using
[125I]iodophenpropit are explained by binding of the radioligand to an additional high
affinity binding component in the membrane preparation for which all these compounds
have the same affinity as for the histamine H3-receptor. Another indication that the
specific [l25I]iodophenpropit binding sites represent histamine H3-receptors is the
stereoselective displacement by (R)a.-methylhistamine and (S)a.-methylhistamine. The
differences between Bmax-values obtained with the currently used radiolabelled Hr
agonists compared with the Bmax-values obtained with [l25I]iodophenpropit might be the
result of differences in receptor isolation and incubation procedures. Also, it may be
possible that the radiolabelled H3-agonists bind predominantly to the high affinity state
(i.e. G-protein coupled fraction) of histamine H3-receptors.
Displacement of [125I]iodophenpropit by the histamine H3-receptor antagonists
burimamide and dimaprit was shown to be biphasic. This phenomenon may be due to
discrimination between subtypes of histamine H3-receptors by these two compounds. A
two site displacement of radiolabelled histamine H3-agonists by burimamide in rat brain
has previously been reported using [3H](R)a.-methylhistamine (rat cerebral cortex
membranes; Arrang et al., 1990) and [3H]NIX-methylhistamine (whole rat brain
membranes, West et aI., 1990b; rat cerebral cortex, Kathmann et aI., 1993). However,
in another report using [3H](R)a.-methylhistamine (whole rat brain membranes, West et
al., 1990a) burimamide displacement was monophasic. A two site displacement has also
been reported for thioperamide (West et aI., 1990b; Clark & Hill, 1995), but was not
observed in other studies. Variation in the experimental conditions (membrane
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preparation, composition of the buffer) might account for the discrepancies. Considering
the different results with respect to the biphasic displacement of radioligands by H3-
antagonists, the existence of histamine H3-receptor subtypes from receptor binding
studies needs to further be explored. To validate the existence of possible subtypes, more
ligands are needed which clearly discriminate between possible subtypes.
The present study provides additional evidence for the interaction of histamine H3-
receptors with G-proteins. Displacement of [125I]iodophenpropit by histamine "3-
receptor agonists was biphasic and was modified by guanine nucleotides. Hence, the two
sites found for agonists is probably related to the formation of a ternary complex between
the agonist, the receptor and a G-protein rather than discrimination between receptor
subtypes by these agonists. The observation that biphasic competition binding curves for
the histamine H3-receptor antagonist burimamide was not significantly affected by GTPyS
is in accordance with this conclusion. The results obtained with [125I]iodophenpropit to
characterize histamine H3-receptors were comparable to those from binding studies to
other G-protein coupled receptors, such as a- (Weinshank et at., 1990) and ~­
adrenoceptors (Voss et at., 1992), histamine H1- (Hattori et at., 1991) and histamine
H2-receptors (Ruat et at., 1990), using radiolabelled antagonists. Generally, guanine
nucleotides bind to G-proteins, inducing the uncoupling of the G-protein-receptor
complex. In a receptor binding study this shows up as a conversion of agonist high
affinity binding sites into low affinity binding sites, since the high affinity binding sites
represent the binding of an agonist to the receptor - G-protein complex and the low
affinity binding sites represent the binding of an agonist to the receptor alone. In our
experiments GTPyS completely abolished the high affinity sites for histamine, (R)a-
methylhistamine and (S)a-methylhistamine. However, for imetit and immepip, a
significant increase of the high affinity dissociation constant was observed upon addition
of GTPyS. Similar results have been described for a2-adrenoceptors (Weinshank et at.,
1990). These observations are different from the generally observed reduction of the ratio
between the amount of high and low affinity binding sites by guanine nucleotides. At
present, the explanation for these differences remains to be established.
The interaction of histamine H3-receptors with G-proteins has also been indicated by
binding studies using the tritium labeled agonists histamine, (R)a-methylhistamine and
NlX-methylhistamine. In 1980, Barbin et at. described the high affinity binding of
[3H]histamine to rat brain. Although at that time histamine H3-receptors were not yet
identified, the [3H]histamine binding sites presumably represented histamine H3-
receptors. The density of the [3H]histamine high affinity binding sites was reduced by
Gpp(NH)p without altering the affinity (Barbin et at., 1980). In a study of West and
colleagues, a reduction of [3H]NlX-methylhistamine binding by GTPyS was observed
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which may be due both to a reduced density and affinity of [3H]NlX-methylhistamine
binding sites (West et al., 1990b). In this last study biphasic displacement of the
radiolabelled agonist by thioperamide and burimamide was observed. As the low affinity
sites of both antagonists were abolished by GTPyS it was concluded that [3H]NlX-
methylhistamine bound to two subtypes of histamine H3-receptors (H3A and H3B) of
which one was not detectable in the presence of GTPyS. This conclusion is not in
agreement with the results of our experiments using [l25I]iodophenpropit, as GTPyS had
no effect on displacement curves of burimamide. In another report an effect of guanine
nucleotides on [3H](R)a-methylhistamine binding was observed only when calcium was
present in the incubation medium (Arrang et al., 1990). When calcium was included in
the buffer, saturation binding curves showed a high and low affinity component, the latter
being abolished by Gpp(NH)p. From these rather unexpected results the authors
suggested that the low affinity site may be its functional receptor. Meanwhile, the guanine
nucleotide sensitivity of radiolabelled agonist binding has been described in several
reports (West et al., 1990b; Arrang et al., 1990; Kilpatrick & Michel, 1991; Zweig et
at., 1992; Clark et al., 1993; Clark & Hill, 1995). In general, these studies showed an
inhibitory effect of guanine nucleotides on radiolabelled agonist receptor binding.
Reduction of [3H]NlX-methylhistamine binding sites by Gpp(NH)p has also been shown
by in vitro receptor autoradiography (Cumming et at., 1991). Summarizing, various
studies using radiolabelled histamine H3-receptor agonists provided evidence for coupling
of the histamine H3-receptor to a G-protein. However, the binding characteristics of these
agonists are complex and results obtained by several authors appear to be to a certain
extent controversial.
The affinities of histamine H3-receptor antagonists largely correlate to the antagonistic
activities obtained from functional studies (Table 4). With respect to histamine H3-
receptor agonists, the agonistic activities are closely related to their high affinity binding
sites (Table 4). In contrast, in binding studies using radiolabelled agonists the affinities of
histamine H3-receptor agonists reported are approximately lO-fold higher than their
corresponding pD2-values. Hence, the pKD-values observed in these receptor binding
studies may not reflect their affinity for the functional histamine H3-receptor.
A detailed description of the distribution of histamine H3-receptors in rat brain has been
published using [3H](R)a-methylhistamine as a radioligand (Pollard et al., 1993). The
distribution of [l25I]iodophenpropit binding sites was essentially the same as for
[3H](R)a-methylhistamine, as observed by Pollard and colleagues. Histamine H3-
receptors showed a clearly distinct distribution compared to histamine H1- and Hr
receptors (Garbarg et al., 1992). Moreover, the distribution of histamine H3-receptors
appeared to be distinct from the distribution of histaminergic nerve endings in rat brain
(Watanabe et al., 1984). This observation may be explained by the occurrence of the
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Table 4. The affinity of histamine HTreceptor agonists and antagonists towards [125I]iodophenpropit
binding sites on rat cerebral cortex compared with theirfunctional potencies.
HTagonists: pKo pD2
histamine 7.4 7.4 c
(R)a-methylhistamine 8.5 8.4 c
(S)a-methylhistamine 6.6 6.3 c
imetit 8.7 9.3 c
immepip 8.6 8.0 d
HTantagonists: pKo pA2
clobenpropit 9.0 9.9 a
iodophenpropit 9.0 9.6 b
thioperamide 8.4 8.5 a
impromidine 7.3 7.2 c
(pKo,l) (pKO,2)
burimamide 7.7 6.1 7.2 c
dirnaprit 6.4 4.4 5.5 c
The affinities of the various ligands towards the [125I]iodophenpropit binding sites are expressed as -log
Ko (= pKo )' The pKo -value for agonists correspond to their high affinity binding site. The functional
potencies of H3-receptor agonists and antagonists are expressed as pD2- and pA2-values respectively.
aDetermined on guinea-pig intestine (Van der Goot et al., 1992); bDetermined on guinea-pig intestine
(Jansen et al., 1992); CDetermined on rat cerebral cortex (Leurs et aI., 1992); dDetermined on guinea-pig
jejunum (Vollinga et aI., 1994).
H3-receptor as a heteroreceptor. The histamine H3-receptor was first characterized as an
autoreceptor inhibiting both synthesis and release of neuronal histamine (Arrang et at.,
1983; Van der Werf et al., 1987). However, several studies have indicated the
involvement of histamine H3-receptors in modulation of the release of other
neurotransmitters such as serotonin (Fink et at., 1990), noradrenaline (Schlicker et at.,
1989) and acetylcholine (Clapham & Kilpatrick, 1992; Vollinga et at., 1992; Arrang et
at., 1995). Also, H3-receptors may be localized postsynaptically (see Chapter 6).
In conclusion, [125I]iodophenpropit binds to rat cerebral cortex membranes with a high
affinity, saturability and reversibility. [l25I]Iodophenpropit binding sites in rat brain are
likely to represent histamine H3-receptors as the binding is displaced by selective
histamine H3-receptor ligands, in contrast to ligands selective for other receptors. The
biphasic displacement of [l25I]iodophenpropit by burimamide and dimaprit may be
indicative for the existence of histamine H3-receptor subtypes. The sensitivity of
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histamine H 3-receptor agonist competition binding curves to guanine nucleotides confirms
the results of previous experiments indicating the interaction of histamine H 3-receptors
with G-proteins. [l25I]Iodophenpropit binding sites are heterogeneously distributed in rat
brain and show a distribution pattern essentially the same as previously reported for the
H 3-agonist [3H] (R)a-methylhistamine. [l25I]Iodophenpropit is a valuable new tool to
study histamine H 3-receptors.
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Characterization of histamine H3-receptors in mouse brain
using the H3-antagonist [125Il-iodophenpropit;
an in vitro study
Frank P. Jansen, Takatoshi Mochizuki*, Kazutaka Maeyarna*,
Rob Leurs, and Hendrik Timmennan
Abstract
We have characterized the binding of the histamine H3-receptor antagonist [1251]-iodophenpropit to mouse
brain. [1251]-lodophenpropit saturably bound to mouse brain membranes with a dissociation constant of
0.49 ± 0.04 nM and a receptor binding density of 290 ± 8 fmol'mg- I of protein. Saturation binding
analysis revealed binding of [1251]-iodophenpropit to a single class of sites, showing linear Scatchard plots
and Hill coefficients not different from unity (nH = 0.98 ± 0.02). At a concentration of 0.3 nM [1251]_
iodophenpropit, specific binding represented about 75% of the total binding. Competition binding curves
for H3-receptor antagonists were fitted best to a one site model, showing Ko-values in general accordance
with the pA2-values obtained in mouse cerebral cortex. Displacement of [1251]-iodophenpropit by the H3-
receptor agonists (R)a.-methylhistamine, immepip, imetit and histamine were fitted best to a two site
model. Competition binding curves of (R)a.-methylhistarnine showed a rightward shift upon incubation
with GTPyS (10 ~M) indicating the involvement of G-proteins in Hragonist binding. In contrast,
competition binding curves of the antagonists iodophenpropit, thioperamide and burimamide were not
affected by GTP"(S (10 ~M). Autoradiographic experiments showed that [125I]-iodophenpropit binding
sites were heterogeneously distributed, similarly to the distribution of histamine Hrreceptors reported in
rat brain (Jansen et aI., 1994). Highest densities were observed in the cerebral cortex, the caudate
putamen, the nucleus accumbens, the globus pallidus and the substantia nigra.
In conclusion, we have demonstrated that in mouse brain, [1251]-iodophenpropit selectively binds to
histamine Hrreceptors. We also observed that the mouse brain Hrreceptors labelled by [1251]_
iodophenpropit displayed binding characteristics and a distribution similar to rat brain.
·Department of Pharmacology, Ehime University School of Medicine, Ehime, Japan.
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Introduction
The histamine H3-receptor has been well documented as a presynaptic receptor
modulating neuronal histamine release in the CNS and the release of other
neurotransmitters, both in CNS and PNS (Schwartz et ai., 1991; Leurs & Timmerman,
1992; Schlicker et ai., 1994). Histamine H3-receptors have been identified in different
mammalian species, from rodents to primates. Activation of H3-receptors in the eNS has
been demonstrated to modulate sleep and wakefulness, cognition, locomotion, feeding
behaviour and electrically induced convulsions (for review see Schwartz et ai., 1991 and
Onodera et ai., 1994). The molecular pharmacological mechanisms underlying these
effects are likely related to modulation of the release of different neurotransmitters like
histamine (H3-autoreceptors, Arrang et ai., 1983; Van der Werf et ai., 1987), serotonin
(Fink et ai., 1990; Alves-Rodrigues et ai., 1995), noradrenaline (Schlicker et ai.,
1989), acetylcholine (Clapham & Kilpatrick, 1992; Arrang et ai., 1995) and
neuropeptides (Matsubara et ai., 1992). Histamine H3-receptors may also attain their
effects via yet unidentified postsynaptic mechanisms (Cumming et ai., 1991; Ryu et ai.,
1994).
Histamine H3-receptors have been characterized by receptor binding studies performed in
rat (Arrang et ai., 1990; West et ai., 1990a; Jansen et ai., 1994; Ligneau et ai., 1994),
guinea pig (Korte et ai., 1990; Kilpatrick & Michel, 1991) and, to a less extent, in
bovine (Zweig et ai., 1992) and primate brain (Martinez-Mir et ai., 1990).
Characterization of H3-receptors in mouse brain is based almost exclusively on functional
studies (Kathmann et ai., 1993; Leurs et ai., 1996). The mouse has been frequently
used to study the pharmacology of CNS H3-receptors in vivo, using the H3-agonist
(R)a;-methylhistamine and the H3-antagonist thioperamide (Schwartz et ai., 1991;
Onodera et ai., 1994). The in vivo potencies of both ligands in the mouse were
consistent with their potencies reported in other species. The H3-antagonist clobenpropit
however, was reported to inhibit electrically induced convulsions in mice (Yokoyama et
ai., 1994) at doses about ten fold lower than the doses required to observe CNS effects
in rats (Barnes et ai., 1993). At present it is not clear whether this difference is due to a
species difference or to H3-receptor heterogeneity.
The distribution of binding sites of the H3-agonist [3H]NlX-methylhistamine in mouse
forebrain has been visualized with autoradiography (Cumming et ai., 1994). A
pharmacological characterization of the [3H]NlX-methylhistamine binding sites using
different selective ligands was not performed however. The present study was conducted
to provide a more detailed characterization of cerebral histamine H3-receptors in mouse
brain. We have used the recently introduced H3-antagonist [125I]-iodophenpropit as a
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radioligand (Jansen et al., 1992; Jansen et al., 1994). The affinities of different ligands
for [l25I]-iodophenpropit binding sites were determined in mouse brain membrane
preparations. Moreover, we examined the distribution of [l25I]-iodophenpropit binding
sites in mouse CNS using receptor autoradiography.
Materials and methods
Preparation ofmouse cerebral membranes and receptor binding studies
Balb/c mice (20-25 g, Harlan C.P.B., Zeist, The Netherlands) were killed by decapitation
and the brains were rapidly removed. The brains were homogenized in 15 volumes (v/w)
ice-cold Tris-HCI buffer (50 mM Tris-HCI; 5 mM MgCI2, 145 mM NaCI; pH 7.4 at 4°C)
using a glass-teflon homogenizer. Subsequently membrane fractions were prepared as
previously described (Jansen et al., 1994). Receptor binding experiments were
performed at 37°C in the Tris-HCI buffer (pH 7.4 at 37°C) with a total incubation volume
of 0.5 ml. Determinations were performed in triplicate. In saturation experiments
membranes were incubated with [125I]iodophenpropit in final concentrations ranging
from 0.025 to 3 nM. In competition binding experiments a concentration of 0.25 nM
[l25I]iodophenpropit was used. There was no significant difference between
[l25I]iodophenpropit binding displaced by (R)a-methylhistamine (10 JlM; 73±2% oftotal
binding) and by thioperamide (0.3 J.lM; 77±3% of total binding, P>0.05; two tailed
unpaired Student's t-test). H3-Receptor agonists and H3-receptor antagonists displaced
[l25I]-iodophenpropit to the same level. Membrane suspensions were incubated with
[125I]iodophenpropit (Menge et al., 1992) for 60 minutes to reach equilibrium.
Incubations were started by the addition of 100 J.lI membranes (20 - 60 J.lg of protein per
tube) and were terminated by adding 2 ml of ice-cold Tris-HCI buffer (pH 7.4 at 4°C)
immediately followed by filtration through Whatman GF/C filters using a Brandel
filtration apparatus. The radioactivity bound to the filters was measured by an LKB
gamma counter. Protein concentrations were determined using the Bio-Rad Protein Assay
(Bradford, 1976). Bovine serum albumin (BSA) was used as a standard.
\
Data analysis and statistical evaluation
Dissociation constants for H3-ligands in the absence and presence of GTPyS were
compared using a two tailed unpaired Student's t-test. Saturation and competition binding
experiments were evaluated using the non-linear curve fitting program LIGAND (Munson
& Rodbard, 1980) on a Macintosh computer. Binding curves were fitted (unweighed) to
a one and a two site model respectively, and statistically tested on the increasing goodness
of the fit for a model with additional parameters, using a probability level of 5%.
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Receptor autoradiographic experiments
Balb/c mice (20-25 g, Harlan C.P.B., Zeist, The Netherlands) were killed by decapitation
and the brains were rapidly removed. Brains were frozen in isopentane at -40°C.
Cryostate sections (transversal or sagittal, 14 IJ.m) were cut, mounted onto
gelatin/chromalum-coated glass slides and were stored at -80°C until use. For the
autoradiographic experiments, tissue sections were thawed and were incubated with 0.3
nM [l25I]-iodophenpropit for 60 minutes at 37°C in 50 mM Tris-HCI buffer containing
145 mM NaCl, 5 mM MgCl2 and 0.25% BSA (pH 7.4 at 37°C). Non-specific binding
was determined by incubation of adjacent sections in the presence of 1 IJ.M (R)a-
methylhistamine. To stop the incubations the sections were rinsed once with ice-cold
Tris-HCI buffer (50 mM Tris-HCI; 5 mM MgCI2, 145 mM NaCI; pH 7.4 at 4°C) and
were subsequently washed twice for 15 minutes in ice-cold Tris-HCI buffer and 15
seconds in ice-cold distilled water. Sections were dried by a stream of cold air and were
exposed to Hyperfilm (Amersham International, U.K.) for 20 hours.
Chemicals
[l25I]-Iodophenpropit (Radionuclide Center, Leiden/Amsterdam Center for Drug
Research, Vrije Universiteit, Amsterdam) was labelled to a specific activity of 1900 Ci
mmol- 1 as described by Menge et at. (1992). The following drugs were used:
iodophenpropit dihydrobromide (laboratory stock), clobenpropit dihydrobromide
(laboratory stock), thioperamide maleate (laboratory stock), iodoproxyfan (gift from
Prof.Dr. W. Schunack, Berlin, Germany), burimamide (gift from SK&F Laboratories,
UK), impromidine trihydrochloride (gift from SK&F Laboratories), dimaprit
dihydrochloride (gift from SK&F Laboratories), histamine dihydrochloride (Sigma, St.
Louis, USA), betahistine dihydrochloride (gift from Solvay Duphar, Netherlands),
ondansetron (gift from Solvay Duphar), (R)a-methylhistarnine dihydrochloride (Research
Biochemicals International, Natick, USA), (S)a-methylhistarnine dihydrobromide (Tocris
Cookson, St. Louis, USA), imetit dihydrobromide (VUF8325, laboratory stock),
immepip dihydrobromide (VUF4708; 4-(1H-imidazol-4-ylmethyl)piperidine
dihydrobromide, laboratory stock), mepyramine hydrochloride (Sigma), tiotidine (ICI,
Macclesfield, U.K.), yohimbine (Roth KG, Karlsruhe, Germany), guanosine 5'-0-(3-
thio)triphosphate (GTPyS; Sigma), Bovine serum albumin (BSA; Sigma) and
polyethylenimine (Aldrich, Zwijndrecht, Netherlands). Ligands (solutions of 1-10 mM)
were dissolved in distilled water or in Tris-HCI buffer and were further diluted in Tris-
HCI buffer. Ondansetron (l mM) and haloperidol (10 mM) were dissolved in DMSO and
ethanol, respectively.
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Results
Binding of [l25I]-iodophenpropit to mouse brain membranes was saturable and of high
affinity (Ko = 0.49 ± 0.04 nM; Bmax = 290 ± 8 fmol'mg- 1 of protein; n =3; Figure I).
Saturation binding curves yielded linear Scatchard plots (not shown) and Hill-coefficients
not different from unity (nH = 0.98 ±0.02). The nonspecific binding as determined using
thioperamide (0.3 IlM) increased linearly with the concentration of [125I]-iodophenpropit
(Figure 1). At a concentration of 0.3 nM of [125I]-iodophenpropit the specific binding
represented 77 ± 3% of the total binding. Under the same experimental conditions 73 ±
2% of the [125I]-iodophenpropit binding was displaced by (R)-a-methylhistarnine (10
IlM).
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Figure 1. Saturation binding of [125/J-iodophenpropit to mouse brain membranes. Symbols: (Cl), total
binding; (/),), nonspecific binding; (.), specific binding. Nonspecific binding was determined in the
presence of thioperamide (0.3 JIM). A representative experiment is shown. Each experiment was
performed with triplicate determinations. Values are represented as the mean ± s.d. Membrane
suspensions were incubated with [125/J-iodophenpropit (0.03 - 3 nM) for one hour as described in
'materials and methods'.
Competition binding curves of H3-receptor antagonists were fitted best to a one site model
(P>0.05; Figure 2A, Table I). For the H3-antagoniststhe following rank order of
potency was obtained: clobenpropit, iodophenpropit > iodoproxyfan > thioperamide >
imprornidine > burimarnide > dimaprit> betahistine. GTPyS (IOIlM) did not significantly
affect competition binding curves of the antagonists iodophenpropit (Ko(-GTPyS) = 0.6
± 0.3 nM; Ko(+GTPyS) = 0.7 ± 0.2 nM, n=4; Figure 2C), thioperamide (Ko(-GTPyS)
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Figure 2. Displacement of [125/}-iodophenpropit (0.25 nM) binding to mouse brain membranes.
Competition binding curves of Hrantagonists (A) and Hragonists (B). Sensitivity of competition
binding curves of (R)a-methylhistamine and ofiodophenpropit towards GTPtJ (10 J.lM) (C). Values are
given as the mean ± V. c. of representative experiments. The specific binding, defined as the difference
between total binding and binding in the presence of 0.3 J.lM thioperamide or (R)-a-methylhistamine,
represented about 77 ± 3% and 73 ± 2% of the total binding, respectively. Membrane suspensions were
incubated with [125/J-iodophenpropit (0.25 nM) for one hour as described in 'materials and methods'.
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Table 1. Dissociation constants of histamine HTreceptor antagonists and of other ligands for
(125/J-iodophenpropit binding sites on mouse whole brain.
ligand
HTantagonists:
Ko(nM) n
c\obenpropit
iodophenpropit
iodoproxyfan
thioperamide
impromidine
burimamide
dimaprit
betahistine
0.6 ± 0.2 3
0.6 ± 0.3 4
1.5 ± 0.5 4
4.4 ± 1.2 11
174 ± 23 3
454 ± 283 4
2,800 ± 1,000 4
19,000 ± 2,000 3
other ligands:
mepyramine
tiotidine
ondansetron
yohimbine
haloperidol
> 10,000
> 10,000
> 10,000
> 10,000
6,100 ± 1,600
3
3
3
3
3
All compounds displayed were best fit according to a one-site model (P > 0.05). For burimamide and
dimaprit in one of four experiments, competition binding curves were fitted best to a two site model (P-
values of 0.046 and 0.020, respectively. Values are given as the mean ± s.d. (n: number of experiments).
= 3.8 ± 0.2 oM; Ko(+GTPyS) = 3.0 ± 0.4 oM, n=3) and burimamide (Ko(-GTPyS) =
580 ± 336 nM; Ko(+GTPyS) = 378 ± 122 oM, n=3).
Displacement of [125I]-iodophenpropit by the H3-agonists (R)a.-methylhistamine, imetit,
immepip and histamine was fitted best to a two site model (P<0.05; Figure 2B, Table 2).
Competition binding curves of (S)a.-methylhistamine were significantly fitted best to a
one site model (Table 2). A more than ten-fold difference in affinity between (R)a.-
methylhistamine and (S)a.-methylhistamine for [l25I]-iodophenpropit binding sites was
found (Figure 2B), consistent with the stereoselectivity of the enantiomers reported in
functional studies (Arrang et ai., 1987a). Competition binding curves of (R)a.-
methylhistamine showed a significant rightward shift upon incubation with the guanine
nucleotide GTPyS (10~; Figure 2C).
The histamine HI-receptor antagonist mepyramine and the HTreceptor antagonist tiotidine
showed a low affinity (Ko > 10 IlM) towards [l25I]-iodophenpropit binding sites (Table
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1). In a previous screening, [125I]-iodophenpropit was found to exhibit a high to
moderate affinity for 5-HT3 (11 nM), <X.2 (120 nM), and O'-receptors (170 nM; Leurs et
at., 1995). In our study, ligands selective for these receptors i.e. ondansetron (5-HT3),
yohimbine (<x'2) and haloperidol (0') showed dissociation constants for [1 251]-
iodophenpropit binding sites above IIJM (Table 1).
Table 2. Dissociation constants of histamine HTreceptor agonists for [125/J-iodophenpropit binding
sites on mouse whole brain.
high affinity low affinity
agonist: KH(nM) N(%) KL(nM) N(%)
histamine 17 ± 15 45 ± 21 1,500 ± 1,500 55 ± 21
(R)a-methylhistamine 12 ± 3 61 ± 3 233 ± 96 39 ± 3
" ... 10 lJM GTPyS 26 ± 7* 53 ± 10 537 ± 234 47 ± 10
(S)a-methylhistamine 1,200 ± 100 100**
imetit 0.8 ± 0.4 62 ± 4 215 ± 324 38 ± 4
immepip 0.6 ± 0.7 48 ± 18 41 ± 28 52 ± 18
Values are given as the mean ± s.d. of four experiments. *Significantly different from Kwvalue in the
absence of GTPyS (P < 0.05); **Two site model was not significantly better than the one site model (P
> 0.05 in two of four experiments). N(%): percentage of the total specific binding of the corresponding
binding site.
Autoradiograms showed that [125I]-iodophenpropit binding sites were heterogeneously
distributed in mouse brain (Figure 3). Highest densities were observed in the cerebral
cortex, the caudate putamen, the nucleus accumbens, the globus pallidus and the
substantia nigra. Moderate densities of [125I]-iodophenpropit binding sites were observed
in the thalamus, the hypothalamus and the hippocampus. The cerebellum and the brain
stem showed low binding densities. Nonspecific binding was homogeneously distributed
in all of the brain areas examined (Figure 3).
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CPu
Cx
CPu
Cx
Hy
Figure 3. Autoradiograms of [125Il-iodophenpropit binding to rat brain sections. Left column: total
binding of [125Il-iodophenpropit (0.3 nM); right column: binding in the presence of (R)a-
methylhistamine (1 J1M). Sections (14 J1m) were incubated with [J25Il-iodophenpropit (0.3 nM) for one
hour as described in 'materials and methods'. Abbreviations: Acb, accumbens; Am, amygdala; Bs, brain
stem; Cb, cerebellum; CPu, caudate putamen; Cx, cortex; DG, dentate gyrus; GP, globus pallidus; Hi,
hippocampus; By, hypothalamus; IC, inferior colliculus; DB, olfactory bulb; SN, substantia nigra.
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Discussion
The histamine H3-receptor was initially identified as the autoreceptor of histaminergic
neurons in the brain (Arrang et al., 1983). Activation of the H3-receptor resulted in an
inhibition of histamine release (Arrang et at., 1983; Van der Werf et al., 1987) and
synthesis (Arrang, 1987b) in rat brain. From studies measuring neurotransmitter release
from rat brain slices H3-receptors were demonstrated to modulate the release of other
transmitters like noradrenaline (Schlicker et al., 1989), serotonin (Fink et at., 1990;
Alves-Rodrigues et al., 1995), dopamine (Schlicker et at., 1993), acetylcholine
(Clapham & Kilpatrick, 1992; Arrang et al., 1995) and neuropeptides (Matsubara et
at., 1992). The modulation of neurotransmitter release is a conceivable mechanism
underlying the CNS effects of H3-ligands in vivo.
The mouse is a frequently used species for in vitro and in vivo studies on H3-receptor
function. Activation of histamine H3-receptors has been reported to cause an inhibition of
electrically induced release of noradrenaline (Schlicker et al., 1989) from mouse cerebral
cortex slices in vitro. The histamine H3-receptor mediated inhibition of noradrenaline
release has been used as a model system to determine the activity of potential new H3-
receptor ligands (Kathmann et at., 1993; Leurs et at., 1996). From in vivo studies, the
activation of mouse brain H3-receptors was demonstrated to affect feeding (Oishi et at.,
1987), cognition (Meguro et at., 1995), anxiety (Imaizumi & Onodera, 1993),
locomotion (Sakai et at., 1991; Clapham & Kilpatrick, 1994) and convulsions
(Yokoyama et al., 1993; Yokoyama et at., 1994). Despite various reports on functional
studies on mouse histamine H3-receptors, little information has been presented on the
pharmacological characteristics of these receptors with receptor binding studies. In one
report the H3-agonist [3H]NX-methylhistamine has been used to study the distribution of
H3-receptors by means of autoradiography (Cumming et al., 1994). Binding sites of the
radiolabelled agonist showed a heterogeneous distribution which was essentially the same
as for rat and for guinea pig brain. A pharmacological characterization of the [3H]Na _
methylhistamine binding sites using different selective ligands was not performed in this
study however. In the present report we describe the pharmacological characterization of
histamine H3-receptor binding sites in mouse brain, using a radiolabelled antagonist.
[1 251]-lodophenpropit has been successfully introduced as a tool for H3-receptor binding
studies in rat brain (Jansen et at., 1992; Jansen et at., 1994). Binding of [1 251]-
iodophenpropit to membranes of rat cerebral cortex was of high affinity, saturable and
reversible in nature. Saturation binding experiments performed on mouse whole brain
membranes revealed binding of [1 251]-iodophenpropit to a single site with a KD-value in
accordance with a KD-value found in rat cerebral cortex slices (Table 3). Affinities of
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both, H3-antagonists and H3-agonists, were in general accordance with their functional
potencies as detennined in mouse brain (Table 3). The sensitivity of competition binding
curves of the H3-agonist (R)a-methylhistamine to GTPyS is in line with the previously
indicated interaction of H3-receptors with G-proteins (Arrang et at., 1990; West et at.,
1990b; Jansen et at., 1994; Clark & Hill, 1996). The receptor autoradiographic studies
revealed that the distribution of [l25I]-iodophenpropit binding sites in mouse brain was
comparable to the distribution of [l25I]-iodophenpropit binding sites in the rat (Jansen et
at., 1994) and to the distribution of radiolabelled agonist binding sites described in rat
Table 3. Affinities of histamine HTreceptor agonists and antagonists for rI25/]-iodophenpropit binding
sites in mouse brain. A comparison with their functional potencies and with their binding affinities in rat
cerebral conex.
mouse brain rat cerebral cortex1
compounds
pKo pA2 pKo
HTantagonists:
clobenpropit 9.3 9.6a 9.0
iodophenpropit 9.2 9.0
iodoproxyfan 8.8 9.0b 8.6
thioperamide 8.4 8.4c 8.4
imprornidine 6.8 6.9c 7.3
betahistine 4.7 <5
burimamide 6.3 7.1c 8.0, 6.6
dimaprit 5.6 6.2a 6.4, 4.4
pK0 2 pD2 pK0 2
HTagonists:
histamine 7.8 7.0a 7.4
(R)a-methylhistarnine 7.9 7.8a 8.5
(S)a-methylhistamine 5.9 5.7d 6.6
imetit 9.1 8.9a 8.7
immepip 9.2 9.3e 8.6
Receptor binding affinities are expressed as the -logKo (pKo)' pDr and pA2-Yalues correspond to the Hr
receptor mediated inhibition of [3H]noradrenaline release from mouse cerebral cortex slices. lYalues from
Jansen et al., 1994. 2The pKo-values for agonists correspond to their high affinity binding site, except
for (S)a-methylhistamine (two site fit not significantly better than one site fit, P>0.05). aKathmann et
al., 1993; bSchlicker et al., 1996; cSchlicker et al., 1989; dLeurs et al., 1996; eAlves-Rodrigues,
1996.
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(Cumming et al., 1991; Pollard et aI., 1993), mouse (Cumming et aI., 1994) and
guinea-pig brain (Cumming et aI., 1994). In mouse brain, a relatively high [1 251]-
iodophenpropit binding was seen in the globus pallidus as compared to rat brain. Minor
species differences have also been reported between mouse and guinea-pig (Cumming et
al., 1994). [3H]Nll-Methylhistamine binding in the guinea-pig insular cortex exceeded
binding in the striatum, whereas in the mouse the ratio between the two brain areas was
reverse (Cumming et al., 1994). Although there may be small species differences
between rat, mouse and guinea-pig, the overall distribution of histamine H3-receptor
binding sites in these species is the same. With this respect, cerebral histamine H3-
receptors differ from H1- and Hrreceptors displaying considerable distributional
differences between species (Garbarg et al., 1992).
Recently, the affinity of iodophenpropit for a variety of different receptors has been
determined (Leurs et aI., 1995). lodophenpropit displayed a high to moderate affinity
towards 5-HT3-serotonergic(1l nM), a2-adrenergic (120 nM), and (}'-receptors (170
nM). Ligands selective for these receptors showed a low affinity for [1251]_
iodophenpropit binding sites on mouse brain homogenates, indicating that binding of
[1251]-iodophenpropit to these receptors was not observed at the experimental conditions
used. Receptor binding studies using the radiolabelled H3-antagonists [1 251]-
iodoproxyfan (Ligneau et al., 1994), [3H]-thioperamide (Alves-Rodrigues et al., 1996)
and [1251]-iodophenpropit (see Chapter 5) indicated that these ligands show a relatively
high affinity towards non-H3-receptor components, in rat brain. This phenomenon was
apparent from the observation that, in specific brain areas, the total radioligand binding
displaceable by H3-antagonists exceeded the total radioligand binding displaceable by H3-
agonists (Ligneau et al., 1994; Alves-Rodrigues et al., 1996). Thus, the definition of
the nonspecific binding of these radioligands needs critical evaluation. In rats, for [1251]-
iodophenpropit, depending on the rat brain area used, 8% to 40% of the total binding
displaced by antagonists was not displaced by agonists (see Chapter 5). In mouse whole
brain membranes, binding displaced by (R)a-methylhistamine was not significantly
different from binding displaced by thioperamide, indicating that the non-H3-receptor
component as observed in rats is not detected in mouse brain. Moreover, it is noteworthy
that the specific [l251]-iodophenpropit binding observed in mouse brain membranes
(-75% of total binding) was higher as compared to rat cerebral cortex (50-60% of total
binding; (Jansen et al., 1994).
Although in mouse brain homogenates the receptor binding affinities of most ligands
closely parallelled the affinities found in rat brain, some minor differences between the
two species were observed as well (Table 3). Previously, we have reported on the
biphasic displacement of [1251]-iodophenpropit from rat cerebral cortex membranes by
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burimamide and by dimaprit (Jansen et al., 1994). A biphasic displacement by these
ligands was not observed in mouse whole brain homogenates. These discrepancies might
reflect a species difference. However, the differences may also result from the different
tissue preparation used (Le. mouse whole brain versus rat cerebral cortex). Biphasic
competition binding curves of burimamide (Arrang et al., 1990; West et al., 1990b) and
of thioperamide (West et al., 1990b) have previously been reported in rat brain using
radiolabelled agonists. From the biphasic displacement the existence of H3-receptor
subtypes (H3A and H3B) was proposed (West et al., 1990b). It should be noted however
that reports on the biphasic displacement were not always consistent (West et al., 1990a;
Kilpatrick & Michel, 1991; Clark & Hill, 1995). The discrepancies might in part result
from the relatively small differences in affinities between the two binding sites in rats.
Hence, this could also explain the monophasic nature of competition binding curves for
burimamide and dimaprit in the mouse brain as observed in the present study.
In vivo studies provided evidence for a possible species difference between rat and
mouse, based on the studie with the H3-antagonist clobenpropit. In rats, (R)a:-
methylhistamine induced water consumption (Barnes et al., 1993) and neuronal
histamine release (see Chapter 8) were modulated by clobenpropit at doses of 10 to 15
mg/kg. In mice however, at about ten fold lower doses (- 1mg/kg) clobenpropit
antagonized electrically induced convulsions, decreased central histamine levels and
increased brain histidine decarboxylase activity (Yokoyama et al., 1994). The difference
in potency of clobenpropit between rat and mouse may result from (a combination of)
several mechanisms Le. a species difference in pharmacokinetics of the compound, a
species difference of H3-receptors and/or the existence of H3-receptor subtypes. We
recently investigated the brain penetration of clobenpropit in rats and mice by ex vivo
receptor binding. In both species, the ex vivo displacement of [l25I]-iodophenpropit by
clobenpropit was observed at the same dose range however (Mochizuki et al., 1996).
Additionally, in the present study the affinity of clobenpropit for [125I]-iodophenpropit
binding sites in mouse (KD =0.6 ± 0.2 nM) was not different from the affinity in rat
cerebral cortex (KD =0.9 ± 0.4 nM, see Chapter 3). Altogether, these results do not
explain the differential effects of clobenpropit in rats and mice from a pharmacokinetic or
a pharmacodynamic difference. Yet, a satisfactory explanation for the differential potency
of clobenpropit between rats and mice cannot be given.
In conclusion, in the present study we have demonstrated that [l25I]-iodophenpropit
bound with high affinity and saturably to mouse whole brain membranes. The affinities of
H3-receptor agonists and antagonists for the [l25I]-iodophenpropit binding sites were in
accordance with the functional potencies on the H3-receptor mediated modulation of
electrically evoked noradrenaline release, indicating that the [125I]-iodophenpropit binding
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sites represented functional H3-receptor binding sites. Autoradiographic studies
demonstrated that [l25I]-iodophenpropit binding sites were distributed heterogeneously,
showing a general overlap with the distribution of histamine H3-receptor binding sites
observed in the rat. [125I]-Iodophenpropit can be regarded as a reliable radioligand to
study histamine H3-receptors in mouse brain.
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The distribution of binding sites of the histamine H3-receptor
antagonist [125I]iodophenpropit in rat brain studied by storage
phosphor autoradiography; chemically unrelated H3-antagonists
reveal a homogenous population of binding sites
Frank P. Jansen, Harry W.M. Steinbusch*, Aalt Bast, and Hendrik Timmerman
Abstract
We have further characterizeq the binding sites of the histamine H3-receptor antagonist
[125Ijiodophenpropit in the eNS of the rat using autoradiography. Radiolabelled sections of different rat
brain regions were quantified applying the storage phosphor imaging technique. [125IjIodophenpropit
binding sites showed a heterogeneous distribution. Highest densities were found in the cerebral cortex, the
striatum and the substantia nigra. In order to study a possible heterogeneity of histamine Hrreceptors,
[125Ijiodophenpropit binding sites were characterized in different rat brain areas Le. cortical areas, caudate
putamen, nucleus accumbens, hippocampus, thalamus, hypothalamus and substantia nigra. Displacement
studies of [125Ijiodophenpropit using a chemically heterogeneous group of Hrantagonists did not reveal a
heterogeneity of [125Ijiodophenpropit binding sites in the above mentioned brain areas. Affinities of the
histaminergic ligands determined in the autoradiographic studies related well to their functional potencies
described in literature so far. In some brain areas, a difference was found between [125Ijiodophenpropit
binding displaceable by agonists and by antagonists which has implications for the definition of the
specific binding in these regions.
In conclusion, we have shown that [l25Ijiodophenpropit is a suitable radioligand for the characterization of
histamine H3-receptors in rat brain. [125IjIodophenpropit binding sites in different brain areas were not
discriminated by a chemically heterogeneous group of H3-receptor antagonists.
"European Graduate School of Neuroscience, EURON, Maastricht University, Department of Psychiatry
and Neuropsychology, Maastricht, The Netherlands.
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Introduction
The histamine H3-receptor has been characterized as an auto- and a heteroreceptor
regulating the synthesis and release of neuronal histamine in the CNS and the release of a
variety of other neurotransmitters in the CNS and PNS (Schwartz et at., 1991; Leurs &
Timmerman, 1992; Schlicker et at., 1994b). The H3-receptor plays an important role
mediating functions of neuronal histamine (for review see: Schwartz et al., 1991;
Onodera et at., 1994) and in the interaction of histaminergic system with other
neurotransmitter systems.
The pharmacology of histamine H3-receptors has previously been studied in membrane
preparations using the radiolabelled agonists [3H]histamine, [3H](R)a-methylhistamine
and [3H]Na.-methylhistamine (review see: Leurs et at., 1995b). In these studies evidence
was provided for the coupling of the histamine H3-receptor to G-proteins. Autoradio-
graphic studies using radiolabelled agonists revealed that histamine H3-receptors are
widely distributed in rat CNS (Arrang et al., 1987 ; Cumming et al., 1991; Pollard et
at., 1993). There is some evidence for the existence of H3-receptor subtypes based on
the biphasic displacement of the tritiated agonists by burimamide and thioperamide (West
et al., 1990b). However, due to controversial reports on this matter the existence of
subtypes has to be further explored.
One of the drawbacks of the use of radiolabelled histamine H3-receptor agonists in
receptor binding studies is that their binding dynamics are complicated as they include
both, information on ligand-receptor interaction and ternary complex formation of the
agonist with the receptor and G-proteins ("high affinity state"). Hence, radiolabelled
antagonists are expected to constitute more reliable tools for receptor binding studies. We
have previously introduced [l25I]iodophenpropit, a potent member of a group of
isothiourea derived histamine H3-receptor antagonists (Van der Goot et al., 1992) as the
first radiolabelled H3-receptor antagonist (Menge et al., 1992; Jansen et al., 1992).
[125I]Iodophenpropit has been shown to be a suitable radioligand for in vitro
characterization of H3-receptors in rat cerebral cortex. The sensitivity to guanine
nucleotides of [125I]iodophenpropit displacement from rat cortical membrane preparations
by agonists confirmed the interaction of H3-receptors with G-proteins (Jansen et al.,
1994; Leurs et at., 1996). Preliminary qualitative autoradiographic studies revealed that
[l25I]iodophenpropit binding sites are heterogeneously distributed in rat CNS (Jansen et
al., 1994; see also Chapter 3). In addition to [l25I]iodophenpropit, more recently the H3-
receptor antagonists [l25I]iodoproxyfan (Ligneau et at., 1994), [3H]S-methyl-
thioperamide (Yanai et at., 1994), [3H]thioperamide (Alves-Rodrigues et at., 1996) and
[3H]GRI68320 (Brown et al., 1996) have been described as probes as well.
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In the present study [l25I]iodophenpropit binding sites in rat CNS are further
characterized using quantitative autoradiography. Performing binding studies on tissue
sections allows the simultaneous determination of affinities in distinct brain areas located
on the same section and has the additional advantage of a higher anatomical accuracy as
compared to studies using membrane preparations. As a quantification method of the
[l25I]labelled tissue sections we have used storage phosphor autoradiography, a new
method which has several advantages compared to conventional methods used for
computer assisted image analysis (Yanai et aI., 1992; Kanekal et al., 1995; Tang et aI.,
1995). We have therefore applied this procedure to determine the density of
[l25I]iodophenpropit binding sites in various rat brain areas. To study a possible
heterogeneity of histamine H3-receptors in rat CNS, the affinities for the
[l25I]iodophenpropit binding sites of a chemically heterogeneous series of histamine H3-
receptor antagonists were determined in ten different brain areas.
Materials and methods
Receptor autoradiographic procedure
Male Wistar rats (200-250 g, Harlan c.P.B., Zeist, The Netherlands) were decapitated.
The brains were immediately removed and were frozen in isopentane at -40°C. Cryostate
sections (transversal or sagittal, 14 J..Lm) were cut, mounted onto gelatin/chromalum-
coated glass slides and stored at -80°C until use. For receptor autoradiography, the tissue
sections were thawed and incubated with 0.3 nM [l25I]iodophenpropit for 60 minutes at
37°C in 50 mM Tris-HCl buffer containing 145 mM NaCl, 5 mM MgCl2 and 0.25% BSA
(pH 7.4 at 37°C). To determine the densities of [125I]iodophenpropit binding sites in
different brain areas adjacent tissue sections were incubated (in triplicate or quadruplicate)
with [125I]iodophenpropit (0.3 nM) in the presence of either (R)a-methylhistamine (l
J..LM) or thioperamide (0.3 J..LM) to define the nonspecific binding. In displacement
experiments transversal tissue sections were incubated (in duplicate) with
[l25I]iodophenpropit (0.3 nM) in the presence of different concentrations of selected
ligands. The tissue sections were randomized prior to the experiment to minimize the
effect of (possible) rostro-caudal variation in receptor densities. To stop the incubations
the sections were rinsed once with ice-cold Tris-HCl buffer (50 mM Tris-HCl; 5 mM
MgCI2, 145 mM NaCl; pH 7.4 at 4°C) and were subsequently washed twice for 15
minutes in ice-cold Tris-HCl buffer and 15 seconds in ice-cold distilled water. Sections
were dried by a stream of cold air and were exposed to Hyperfilm (Amersham
International, U.K.) for 20 hours and subsequently to a storage phosphor screen. Proper
images were obtained already several hours after exposure. To increase the resolution of
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the images the screens were exposed up to three days. Phosphor screens were scanned
with a Phosphor Imager® (Molecular Dynamics, Sunnyvale, CA, USA) to obtain the
digitized images. In some experiments, tissue sections were scraped from the slides with
a razor blade in order to count the radioactivity by an LKB gamma counter.
Data analysis and statistical evaluation:
The storage phosphor images were analyzed and quantified using the program
ImageQuant® (Molecular Dynamics). Brain areas of interest (l00 to 600 pixels, pixel size
88 x 88 11m) were selected and the density was expressed as the average counts per pixel-
value in the selected brain areas. Specific binding was calculated by substracting the
nonspecific binding from the total binding. Binding displaced by (R)a-methylhistamine
(l 11M) and thioperamide (0.3 /lM) was compared using a two tailed unpaired Student's t-
test. Differences were considered statistically significant at a probability level of 5%.
Competition binding experiments were evaluated using the non-linear curve fitting
program LIGAND (Munson & Rodbard, 1980) on a Macintosh computer. With the aid
of this program binding curves were fitted (unweighed) to a one and a two site model
respectively, and statistically tested on the increasing goodness of the fit for a model with
additional parameters, based on the 'extra sum of squares' principle (Draper & Smith,
1966) using a probability level of 5%. Dissociation constants of H3-ligands in different
brain areas were compared using a two tailed, unpaired Student's t-tests with a
Bonferroni correction.
Ligands
[l25I]Iodophenpropit (Radionuclide Center, Leiden/Amsterdam Center for Drug
Research, Vrije Universiteit, Amsterdam) was labelled to a specific activity of 1900 Ci
mmol- l as described by Menge et al. (1992). The following drugs were used:
iodophenpropit dihydrobromide (laboratory stock), thioperamide maleate (laboratory
stock), iodoproxyfan (gift from Prof.Dr. W. Schunack, Berlin, Germany), burimamide
(gift from SK&F Laboratories, UK), VUF4616 (N-(iso-propyl)-N'-[5-(4(5)-
imidazolyl)pentyl]thiourea oxalate; laboratory stock), (R)a-methylhistamine
dihydrochloride (Research Biochemicals International, Natick, USA), (S)a-
methylhistamine dihydrobromide (Tocris Cookson, St. Louis, USA). Ligands (solutions
of 1-10 mM) were dissolved in distilled water or in Tris-HCl buffer and were further
diluted in Tris-HCl buffer.
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Results
Storage phosphor imaging method
Autoradiograms of [l25I]iodophenpropit binding to sagittal sections of rat brain obtained
after exposure to film and to storage phosphor screen are displayed in Figure 1. Both
methods yield the same overall distribution pattern, but with respect to resolution, best
images are obtained using film autoradiography, i.e. the laminar distribution in the cortex
and hippocampus is not clearly observed in the phosphor autoradiographic image.
Different brain areas were still clearly recognized on the phosphor autoradiographic image
enabling the use of this method to quantify different brain regions. A linear relation
between quantification with the phosphor imaging method compared to direct gamma
counting was observed over a wide range of radioligand binding (Figure 2).
A
c
Hi DG
SN Bs
B
D
Figure 1. Autoradiograms of [1251]iodophenpropit binding to sagittal rat brain sections. (A, C and D)
autoradiograms obtained from exposure to Hyperfilm. (B) the storage phosphor autoradiogram ofpanel
A. (A) and (B): total binding; (C): nonspecific binding as determined with thioperamide (0.3 pM); (D):
nonspecific binding as determined with (R)a-methylhistamine (I pM). Tissue sections were incubated
for one hour with [1251]iodophenpropit (0.3 nM). Sections were exposed to Hyperfilm and storage
phosphor screen, respectively (see 'materials and methods'). Representative autoradiograms are shown.
Abbreviations: Bs, brain stem; Cb, cerebellum; Cx, cortex; DO, dentate gyrus; Hi, hippocampus; IC,
inferior colliculus; SN, substantia nigra; Str, striatum; Th, thalamus.
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Figure 2. Linear relation between quantification with storage phosphor autoradiography and gamma
counting. Sections with different radioligand binding were exposed to a storage phosphor screen for 72
hours and subsequently scraped offfor gamma counting. The densities of the sections ranged from 8 to
90 cpm / mm2, as measured by gamma counting (efficiency of 60%). Values are expressed as cpm /
section. SPS: storage phosphor screen.
Distribution of[125/jiodophenpropit binding sites in rat brain.
As reported previously, [l25I]iodophenpropit binding sites were heterogeneously
distributed in rat brain (Figure 1, Figure 3). The densities of [125I]iodophenpropit binding
in different brain areas as quantified using storage phosphor method are given in Table 1.
[l25I]Iodophenpropit binding in the presence of 1 IlM (R)a-methylhistarnine (Figure 10)
and of 0.3 IlM thioperamide (Figure lC) were homogeneously distributed. Specific
binding as defined using (R)a-methylhistarnine OIlM) ranged from 45% to 55% in most
areas (cortical, striatal, see Table 2, see page 101) but was small in areas with the lowest
H3-receptor densities (cerebellum: 10 ± 8%, n=8; brain stem: 24 ± 14%, n=8). The
highest densities of [125I]iodophenpropit binding sites were found in the substantia nigra,
the cerebral cortex, the olfactory tubercle, the nucleus accumbens, the caudate putamen
and the anterior amygdaloid area (Table 1). Moderate densities were present in the
hippocampus, thalamus, hypothalamus, and the caudal part of the amygdala. The
cerebellum and the brain stem showed the lowest [l25I]iodophenpropit binding densities.
In some brain areas a heterogeneous distribution pattern was observed. A laminar
distribution was seen in the cortex with high densities in the upper frontal layers and
lower temporal layers. In the hippocampus a relatively dense labeling was found in
dentate gyrus.
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Figure 3. Autoradiograms of [125l]iodophenpropit binding to transversal sections of rat brain.
Abbreviations used: Acb, nucleus accumbens; CPu, caudate putamen; Cx, cortex; Hi, hippocampus; Hy,
hypothalamus; Sep, septum; SN, substantia nigra; Th, thalamus; Tu, olfactory tubercle.
Competition binding curves ofhistamine HTreceptor ligands
In order to study the possible heterogeneity of [l25I]iodophenpropit binding sites in rat
brain competition binding experiments were performed in ten different brain areas using a
chemically heterogeneous group of H3-antagonists (Figure 4). In all areas examined the
H3-antagonists showed monophasic competition binding curves (Le. curves are best fitted
to a one site model, P > 0.05) with a high affinity for the [l25I]iodophenpropit binding
sites (Table 2, Figure 5). Statistical analysis revealed no significant differences in KD -
values of the antagonists for the [l25I]iodophenpropit binding sites between the different
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Table 1. Comparison of [125/jiodophenpropit and [3H](R)a-methyihistamine binding sites in rat brain.
radioligand binding (% oftotal cerebral cortex)
anterior cerebral cortex
medial cerebral cortex
posterior cerebral cortex
olfactory tubercle
hippocampus
caudate putamen
nucleus accumbens
septum
hypothalamus (anterior)
hypothalamus (posterior)
hypothalamus (lateral)
hypothalamus (YMH)
thalamus
anterior amygdaloid area
amygdala (posterior)*
substantia nigra
pons
cerebellum
[125I]iodophenpropit1)
(autoradiography)
97 ± 8
96 ± 11
110 ± 13
121 ± 13
53 ± 8
127 ± 10
133 ± 7
77 ±4
67 ±5
61 ± 7
68 ±4
78 ± 13
54± 16
98 ± 6
69 ± 10
141 ± 21
33 ± 14
8±5
[3H](R)a-methylhistamine2)
(membrane preparations)
108±2
100±2
85 ±6
103±8
48 ±4
108 ± 11
126 ± 12
N.D.
70±2
54 ± 8
N.D.
N.D.
N.D.
N.D.
N.D.
97 ± 7
28 ±5
7±3
I)Specific binding was determined using 1 ~M (R)a-methylhistamine. 2)Yalues reported by Pollard et
ai., 1993. *Including: amygdalohippocampal area (AHi) and posteromedial cortical amygdaloid nucleus
(PMCo). N.D.: not described. The density of [125I]-iodophenpropit binding sites in the cortex is 268
fmoUmg of protein (Jansen et aI., 1994). Randomized brain sections of three to five rats were used.
Yalues are expressed as mean ± SD of three to five separate determinations of which each was performed
at least in triplicate.
brain areas (Table 2). The rank order of potency of the antagonists, based on the average
affinities in the ten brain areas is: iodophenpropit (1.9 ± 0.6 nM), iodoproxyfan (2.9 ±
0.8 nM) > thioperarnide (4.3 ± 1.0 nM) > VUF4616 (22 ± 6 nM) > burimamide (262 ±
60 nM).
Competition binding curves of the H3-receptor agonists (R)cx-methylhistarnine and (S)cx-
methylhistarnine were best fit to a one site model. For both agonists the affinities did not
vary between different brain areas (average affinities: 3.3 ± 1.0 nM and 159 ± 115 nM,
respectively) and were close to their KD-values for the high affinity site previously
described in membrane preparations of the cerebral cortex (3.5 ± 1.2 nM and 230 ±97
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Figure 4. Structures ofthioperamide, iodophenpropit, iodoproXYfan, burimamide and VUF4616.
Table 2. Dissociation constants of different HTreceptor ligands for [125IJ-iodophenpropit binding sites
in various rat brain areas.
brain areas KD-values, nM
thioperamide iodophenpropit iodoproxyfan burimamide VUF4616 (R)a-MeHa (S)a-MeHa
fronlal cortex 3.2± 1.5 1.7±0.4 3.6 ± 2.7 176±64 15±6 4.3 ±2.6 293 ±230
parietal cortex 5.1 ±2.9 1.4±0.5 2.0± 1.5 N.D. 24±1O 1.9 ± 0.3 241± 151
occipital cortex 5.3 ±4.9 1.9±0.6 1.7 ±0.9 N.D. 21±3 2.0±0.9 204± 163
caudate putamen (D) 2.7 ±0.6 1.4±0.2 3.6±2.1 289 ± 137 19±5 4.3 ± 1.9 123 ±58
caudate putamen (V) 3.5 ± 1.0 1.4±0.2 3.6±3.0 273 ± 122 25± 12 3.9 ± 2.6 132±72
nucleus accumbens 3.8 ±2.3 I.3 ±0.2 2.7 ±2.2 312 ± 218 17±7 4.5 ±2.9 138 ± 85
hypothalamus 5.6± 1.0 2.4±1.8 2.9 ± 2.9 N.D. 19±2 4.4± 1.4 429 ±343
hippocampus 3.8 ±4.7 2.5 ± 1.4 3.0 ±2.7 N.D. 24±6 3.4±2.9 415 ±205
thalamus 5.1 ± 3.5 3.2±1.2 3.8 ±3.6 N.D. 21±9 2.2± 1.7 365 ± 375
substantia nigra 4.7±2.0 1.5±0.5 2.0±0.9 N.D. 37±8 2.3 ± 1.5 252± 194
Transversal sections were incubated with 0.3 nM rl2SIl-iodophenpropit as described in 'materials and methods'. KD-Values are
expressed as average of three to six separate observations determined in two or three separate experiments. *P < 0.05, as
compared to other brain areas using a Student's t-test with a Bonferroni correction. The percentage of specific binding as defined
with I I-lM (R)lX-methylhistamine was: frontal cortex: 51 ± 7%; parietal cortex: 47 ± 11%; occipital cortex: 49 ± 10%, caudate
putamen (V; ventral aspect) 51 ± 6%; caudate putamen (D; dorsal aspect): 48 ± 6%; nucleus accumbens: 53 ± 7%; hippocampus
33 ± 17%; hypothalamus: 30 ± 14%; thalamus: 22 ± 10%; substantia nigra: 55 ± II %. Abbreviations used: (R)lX-MeHa: (R)lX-
methylhistamine; (S)lX-MeHa: (S)lX-methylhistamine. Sections were used from the following brain areas: striatal areas and frontal
cortex: AP, -1.7 mm to -0.7 mm; hypothalamus, thalamus, hippocampus and parietal cortex: AP, 2.3 mm to 2.8 mm; substantia
nigra and occipital cortex: AP, 4.8 mm to 5.8 mm, according to the atlas of Paxinos and Watson (1982).
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Figure S. Competition binding curves of different HTreceptor ligands in the ventral part of the caudate
putamen. Transversal tissue sections were incubated with for one hour [125[]iodophenpropit (0.3 nM) in
presence ofdifferent concentrations ofdrugs. Specific binding was determined using thioperamide (0.3
J.l.M).
nM, respectively, Jansen et al., 1994). The clear difference in the affinity between both
enantiomers is in accordance with displacement of [l25I]iodophenpropit from histamine
H3-receptor sites. Competition binding curves of the H3-receptor ligands in the caudate
putamen are shown in Figure 5.
Comparison ofH3-agonist and H3-antagonist displacement
In studies using the H3-receptor antagonist [125I]iodoproxyfan, it was observed that
[l25I]iodoproxyfan binding to membranes of rat striatum was only partially displaced by
agonists (60% of the total binding), whereas the binding was completely and
monophasically displaced by most antagonists, including iodoproxyfan itself (Ligneau et
al., 1994). Thus, it seems that about 40% of the binding displaced by H3-receptor
antagonists is not likely to reflect H3-receptors due to binding of [l25I]iodoproxyfan and
of the other antagonists with high affinity to a non H3-receptor site. Recently, our
laboratory reported similar findings with [3H]thioperamide (Alves-Rodrigues et al.,
1996). Therefore, we have made a comparison between [l25I]iodophenpropit binding
displaceable by the H3-agonist (R)a-methylhistamine and by the Hrantagonist
thioperamide. Competition binding curves for (R)a-methylhistamine and for thioperamide
reached a plateau at 1 llM and 0.3 llM respectively. In most of the brain areas a small
difference was observed between [l25I]iodophenpropit binding displaced by (R)a-
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methylhistamine (111M) and binding displaced by thioperamide (0.3 11M) Le. the binding
displaced by (R)a-methylhistamine as percentage of binding displaced by thioperamide
ranging from 80 to 90 percent. More marked differences were observed in the
hippocampus (70 ± 24%, P > 0.05), the hypothalamus (72 ± 34%, P > 0.05) and the
thalamus (59 ± 27%, n=8, P < 0.05). A significant difference was also found in the
frontal cortex and in the occipital cortex (81 ± 16%, n=9, P < 0.05 and 78 ± 18%, n=ll,
P < 0.05, respectively). Hence, in most of the areas studied a minor non-H3"·receptor
component may be included in the competition binding curves for thioperamide which is
not recognized by the curve fitting procedure as a separate site, possibly due to its
relatively low abundance and / or its small difference in affinity compared to the H3-
receptor. Though, a good correlation was found between the [l25I]iodophenpropit
binding displaced by (R)a-methylhistamine (lI1M) and by thioperamide (0.3 11M) in the
different brain areas (Figure 6). The other H3-receptor antagonists displaced
[l25I]iodophenpropit binding approximately to the same level as thioperamide (0.3 11M).
For all antagonists studied, the [l25I]iodophenpropit binding at this level was not further
displaced by addition of (R)a-methylhistamine (l 11M) indicating that these ligands
displace essentially the same component as (R)a-methylhistamine (l 11M).
20 40 60 80 100 120 140 160
nonspecific binding detennined with 0.3 11M thioperamide
(% of cortical binding)
Figure 6. [125Ijlodophenpropit binding in rat brain areas; comparison between the nonspecific binding
defined with (R)a-methylhistamine (l J.lM) and with thioperamide (0.3 J.lM). [125Ijlodophenpropit
binding in the different brain areas is expressed as percentage of the cortical binding. Abbreviations: Aa,
anterior amygdala; Acb, nucleus accumbens; Bs, brain stem; Cb, cerebellum; CPu, caudate putamen;
Cx/. frontal cortex; Cxo, occipital cortex; Cxp, parietal cortex; Hi, hippocampus; Hy, hypothalamus;
Pa; posterior amygdala; Sep, septum; SN, substantia nigra; Th, thalamus; Tu, olfactory tubercle.
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Discussion
We have previously introduced [l25I]iodophenpropit as the first radiolabelled histamine
H3-receptor antagonist (Jansen et at., 1992). [l25I]Iodophenpropit meets the criteria for a
suitable radioligand for histamine H3-receptor binding studies in rat cerebral cortex,
showing a high selectivity, reversibility, a high affinity (KD =0.6 ±0.2 nM), saturability
(Bmax =268 ± 119 fmoVmg) and an acceptable amount of specific binding (50 to 60% of
total binding, Jansen et at., 1992; Jansen et at., 1994). Moreover, the binding affinities
of different H3-receptor agonists and antagonists for [l25I]iodophenpropit binding sites in
the cerebral cortex are in agreement with their potencies measured by functional in vitro
H3-receptor test systems, indicating [l25I]iodophenpropit binding sites are related to
functional histamine H3-receptor sites.
In the present study we extended the characterization of [l25I]iodophenpropit binding in
the rat eNS studying different brain areas using quantitative autoradiography. A benefit
of the use autoradiography as compared to binding experiments on membrane
suspensions is that binding studies performed on tissue sections have a higher anatomical
accuracy. In addition, it allows the simultaneous determination of KD-values in distinct
brain areas located on the same section. Radiolabelled tissue sections were quantified
using the storage phosphor imaging technique which has on its turn several advantages
over conventionally used computer assisted methods Le.: a wide dynamic range, high
accuracy of determination and sensitivity (Kanekal et at., 1995). The method can be used
for many ~- and y- emitting radionuclides. Its application for the use of [l25I]-labelled
ligands has recently been demonstrated for the quantification of autoradiographic images
of cholecystokinin receptors in rat brain (Tang et at., 1995). The wide dynamic range of
this method was apparent by the high linearity between phosphor image quantification and
measurement of radioactivity by gamma counting. Although the image resolution is lower
as compared to conventional film, storage phosphor autoradiography proves to be a very
useful method for image quantification.
A detailed mapping of [3H](R)a.-methylhistamine binding sites has been described by
Pollard et al. (1993). The quantitative distribution of [l25I]iodophenpropit binding sites as
reported in the present study is comparable to the distribution of [3H](R)a.-
methylhistarnine binding sites. However, especially in the substantia nigra, densities
found with [125I]iodophenpropit were higher as compared to [3H](R)a.-methylhistamine
binding sites. Although a straightforward explanation for this difference cannot be given,
these findings may be related to the role of G-protein interaction involved in binding of
the radiolabelled agonist. The distribution of [l25I]iodophenpropit binding sites is also in
general agreement with the qualitative distribution of the binding sites as described with
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[3H]S-methylthioperamide (Yanai et at., 1994) and [l25I]iodoproxyfan (Ligneau et al.,
1994).
As mentioned previously (Arrang et al., 1987; Pollard et al., 1993), there is no
consistent overlap of the H3-receptor densities with the distribution of the histaminergic
cell bodies and varicose fibers in the CNS. It is tempting to relate this phenomenon to the
presence of the H3-receptor as a heteroreceptor. A modulatory effect of Hrreceptor
activation on the release of various transmitters, such as serotonin (Fink et al., 1990),
noradrenaline (Schlicker et al., 1989), acetylcholine (Clapham & Kilpatrick, 1992) and
neuropeptides (Matsubara et al., 1992) has been reported. Moreover, postsynaptic
localization of histamine H3-receptors have been indicated (Cumming et at., 1991;
Pollard et al., 1993; Ryu et al., 1994). Finally, the 'mismatch' between the
histaminergic system and histamine H3-receptors could, in a speculative way, also be
explained from a different expression of histamine H3-receptors in different brain areas.
However, at present there is no evidence for the latter suggestion.
Some evidence exists that the actions through H3-receptors are mediated by a
heterogeneous population of receptor sites. In receptor binding studies the antagonists
burimamide and thioperamide biphasically displaced the radiolabelled H3-receptor agonist
[3H]NlX.-methylhistamine from rat brain (West et al., 1990b; Cumming & Gjedde,
1994). From these observations the existence ofH3A and H3B-receptor subtypes has been
suggested (West et al., 1990b). The biphasic nature of burimamide displacement curves
has been confirmed by other laboratories, using the agonists [3H](R)a-methylhistamine
(Arrang et al., 1990), [3H]NlX.-methylhistamine (Kathmann et al., 1993; Brown et al.,
1996) and the antagonist [125I]iodophenpropit (Jansen et at., 1994). However, this
biphasic displacement was not observed in some other reports (West et al., 1990a;
Kilpatrick & Michel, 1991; Clark & Hill, 1995). To our knowledge, for thioperamide
the biphasic nature was described in two additional studies (Clark & Hill, 1995; Brown
et at., 1996).
At present, data with respect to the regional distribution of the possible subtypes are
scarce. In the rat striatum and the surrounding cortical areas the ratios between the two
putative binding sites for burimamide showed no variation (Cumming & Gjedde, 1994).
No data are available in other brain areas with this respect. Yet, information about binding
affinities ofH3-receptor ligands in rat brain is largely confined to the cerebral cortex and
the striatum. Therefore, we have determined the affinities for the [l25I]iodophenpropit
binding sites of a chemically heterogeneous group of H3-antagonists in ten different rat
brain areas. From these studies no heterogeneity of the [125I]iodophenpropit binding sites
was found in the different brain areas studied. For all antagonists, displacement curves
were best fitted according to a one site model showing no significant variation in KD-
values between the different brain areas. The KD-values of iodophenpropit, thioperamide
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Table 3. Comparison of the potencies of the histamine Hrreceptor agonists and antagonists, as
determined in receptor binding experiments and in functional studies.
RECEPTOR BINDING AFFINITIES RJNCflONAL POTENCIES
cerebral cortex (membrane suspensions)1 cerebral cortex (.utoradiogl1lphy)Z cerebral cortex3 jejunum4
[3H]NAMH binding (pKo ) [125]lpp binding (pKo)b [l25Jlpp binding (pKo ) (pAZ)
HJ-olltagollists:
indophenpropil
indoproxyfan
thioperamide
burimamide
YUF4616
(R)ct-meIhylhislamine
(S)ct-meIhy1hisIamine
N.D.
9.5c
8.7d
(pKo •t) (pKO.Z)
7.08 5.5g
N.D. N.D.
9.3d
7.3i• **
9.0
8.6'
8.4
(pKo. t ) (pKo.Z)
7.7 6.1
9.4' 7.6'
(pKH) (pKL)
8.5 5.9
6.6 5.0
8.8
8.6
8.3
6.8
7.7
8.6
6.6
9.4'
9.00, •
8.7 e
6.8e
N.D.
(pDz)
7.0f
7.7f
(pDZ)
7.8f
Mf
lAs detennined on rat brain; 2Average values of the frontal, parietal and occipital cortex; 3H3-Receptor mediated inhibition of [3H]noradrenaline release
(except for iodophenpropit: r3H]serotonin release); 4H3-Receptor mediated inhibition of the neurogenic contraction of the guinea-pig jejunum.
*Iodoproxyfan also acts as a partial agonist on these assays (Schlicker et 01.. 1996); **r3H](R)a.-methylhistamine binding. aUnpublished observation;
bJ.usen et of.. 1994; cSchlicker el of.. 1996; dBrown el of.. 1996; eSchlicker el of.. 1992; fYolling. el 01.. 1995; gWest el of.. 1990b; hLeurs el
of.. 1996; iArrang el 01.• 1990. Abbreviations: [3H]NAMH, [3H]N"-methylhislamine; [l25]lpp, [1251]-iodophenpropit.
and iodoproxyfan found in this study are in accordance with the values obtained from rat
cerebral cortex membrane preparations (Table 3). For the histamine H3-receptor
antagonist burimamide and its 5-fold more potent derivative VUF4616 (Vollinga et al.,
1995) the monophasic nature of the competition binding curves was rather unexpected as
we have previously observed two distinct affinities of burimamide (Jansen et at., 1994)
and of VUF4616 (unpublished observations) for [125I]iodophenpropit binding sites in
whole cerebral cortex membrane suspensions. The KD-values observed in the
autoradiographic study are in agreement however with their antagonistic activities (Table
3). A possible explanation of the differences in our studies, and of those reported in
literature, with respect to discrimination between the two binding sites may relate to the
relative small difference in binding affinity (about 40-fold) of the ligands for the two
different sites. The significant 'increased goodness' ofthe two-site fit (as compared to the
one-site fit) will decrease when the difference between the affinities of two different sites
becomes smaller. Hence, the failure to detect different binding sites may be related to this
phenomenon. Additionally, the relatively higher variance in the autoradiographic studies
(as compared to membrane preparation experiments) may also attribute to the failure of
finding two sites. Nevertheless, if histamine H3-receptor subtypes would exist, they
would probably show a distinct distribution in the different brain areas studied, which
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would likely be reflected in the displacement curves, as the difference between the two
affinities is large enough to distinguish the subtypes individually.
An important criterion for the establishment of receptor subtypes is that they are related to
distinct functional receptor responses. Presently, the existence of H3A- and H3B-receptors
as suggested from receptor binding experiments has not much support from functional
studies. West et al. (West et al., 1990b) suggested these subtypes to be related to
modulation of histamine release and histamine synthesis, respectively. The histamine H3-
receptors inhibiting the release of noradrenaline in mouse brain cortex slices have been
suggested to represent the H3A-receptor subtype (Schlicker et al., 1992; Schlicker et at.,
1994a). To our knowledge, additional functional responses in brain tissue related to the
H3B-receptor have never been observed however. It should be noted that a possible
negative co-operativity could also explain the biphasic nature of burimamide displacement
curves. Moreover, the biphasic nature of the displacement curves of thioperamide has
been proposed to arise from different conformational states of the histamine H3-receptor,
dependent on the buffer composition (Clark & Hill, 1995). In conclusion, the possible
existence of H3-receptor heterogeneity in the CNS needs further exploration.
Similarly to the observations for H3-receptor antagonists, the H3-receptor agonists (R)a-
methylhistamine and (S)a-methylhistamine showed no variation in affinities between
different brain areas. Curves for (R)a-methylhistamine and (S)a-methylhistarnine were
best fitted to a one-site model. The affinities are close to the values of the high affinity
binding sites found in membrane preparations of cerebral cortex (see Table 3). Hence, it
may be speculated that in the autoradiographic preparation the low affinity site of the
agonist is not recognized as a separate site as a consequence of a higher fraction in the
high affinity state as compared to membrane preparations. In all ten brain areas a clear
difference in affinity between the stereoisomers (R)a-methylhistamine and (S)a-
methylhistamine was found, which is in accordance with the displacement of
[125I]iodophenpropit from H3-receptor sites by these agonists.
In studies using [l25I]iodoproxyfan, it was observed that [l25I]iodoproxyfan binding to
membranes of rat striatum was partially displaced by agonists (60% of the total binding),
whereas the binding was completely and monophasically displaced by most antagonists,
including iodoproxyfan itself (Ligneau et at., 1994). Apparently, [l25I]iodoproxyfan
binds with a comparable high affinity to a non-H3-receptor site, representing about 40%
of the total [125I]iodoproxyfan. For the binding of [3H]thioperarnide to rat cerebral
cortical membranes, our group recently obtained similar findings (Alves-Rodrigues et
al., 1996). Based on these findings, in the present study we have made a similar
comparison with [l25I]iodophenpropit. In most of the brain areas a difference of 10 to
20% was found between [125I]iodophenpropit binding displaced by the H3-receptor
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agonist (R)a-methylhistamine and by the H3-receptor antagonist thioperamide. Although,
a similar phenomenon is observed with [l25I]iodophenpropit, the non-H3-receptor
component included in antagonist displacement of [l25I]iodophenpropit seems to be
smaller as compared to [125I]iodoproxyfan Le. 15% versus 40%, in striatal tissue. Yet, in
other regions the non-H3-receptor component of [l25I]iodophenpropit could amount 30-
40% (e.g. hippocampus and thalamus). Using rat hippocampal membrane preparations
we recently obtained similar results (Alves-Rodrigues, unpublished observations). With
respect to the nonspecific binding of radiolabelled H3-antagonists it is noteworthy that a
new tritiated derivative of thioperamide has been recently reported, Le. [3H]GR168320
(Brown et al., 1996). The binding of [3H]GR168320 to rat cerebral cortex membranes
was equally and almost fully displaced both, by H3-agonists and by H3-antagonists. The
apparent absence of non-H3-receptor components in the binding of [3H]GR168320 to rat
cerebral cortex membranes might be related to the high affinity of [3H]GR168320 for the
cortical H3-receptors (Ko of 0.1 nM), as compared to [3H]thioperamide (Ko of 0.8 nM,
Alves-Rodrigues et al., 1996), resulting in a more selective labelling of histamine H3-
receptors.
Iodophenpropit and thioperamide have recently been screened on a large variety of
receptor assays (Leurs et al., 1995a). Iodophenpropit showed a high selectivity towards
H3-receptors. The difference in affinity for other receptors tested was 100-fold or more,
except for 5-HT3-receptors (Ko =11 nM, lO-fold lower as compared to H3-receptor).
Also thioperarnide displayed moderate activity towards 5-HT3-receptors (Ko =120 nM,
30-fold lower as compared to H3-receptor). Considering the affinity of iodophenpropit
for 5-HT3-receptors and the low density of 5-HT3-receptors in the CNS « 10 fmoUmg,
Kilpatrick et al., 1990), it can be predicted that binding of [125I]iodophenpropit to 5-
HT 3-receptors is negligible at the experimental conditions used. Indeed,
[125I]iodophenpropit binding to rat cortical membranes was not displaced by the selective
5-HT3-receptor antagonist ondansetron (Leurs et aI., 1995a). For [3H]thioperamide,
there is some evidence that its non-H3-receptor binding includes binding to cytochrome
p 450 isoenzymes (Alves-Rodrigues et al., 1996). Whether the binding of
[125I]iodophenpropit to these proteins contributes to the non-H3-receptor binding has to
be investigated.
In conclusion, in the present study we have shown that [l25I]iodophenpropit is a suitable
radioligand for the characterization of histamine H3-receptors throughout the rat brain.
Storage phosphor autoradiography proves to be a valuable method for the quantification
of the radio1abelled autoradiographic images. Specific binding was detected throughout
the brain, with densities essentially the same as reported for the agonist [3H](R)a-
methylhistarnine. The difference observed between binding displaceable by agonists and
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antagonists in some areas (thalamus, hippocampus and hypothalamus) has implications
for the definition of the specific binding in these regions. From displacement studies of
[l25I]iodophenpropit with a chemically heterogeneous group of H 3-antagonists we have
not been able to provide any further evidence for a heterogeneity ofH3-receptors in the rat
eNS.
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Unilateral 6-hydroxydopamine denervation of the nigrostriatal
pathway in the rat differentially affects histamine H3-receptors
in the striatum and in nuclei of striatal efferents
Frank P. Jansen, Harry W.M. Steinbusch*, and Hendrik Timmerman
Abstract
We have studied the interaction between histamine Hrreceptors and the dopaminergic neuron system in rat
brain. Rats were unilaterally denervated with 6-hydroxydopamine injected into the substantia nigra and the
ventral tegmental area. The effect of dopaminergic lesions on binding of the histamine H3-receptor
antagonist [125I]iodophenpropit was studied at three and at twelve weeks post-Iesioning, using quantitative
receptor autoradiography. Radioactive images were quantified applying storage phosphor autoradiography.
Denervation caused an increase of [125I]iodophenpropit binding in the dorsal aspect of the ipsilateral
striatum both at three weeks (+18%, as compared to the contralateral side) and at twelve weeks (+12%)
post lesioning. 6-Hydroxydopamine treatment also affected [125I]iodophenpropit binding in striatal output
nuclei. A pronounced increase was observed in the entopeduncular nucleus (+44% to +65%) and in the
substantia nigra (+64% to +81 %) three and twelve weeks post-Iesioning. In the globus pallidus a small
decrease (-6%) of [125I]iodophenpropit binding was observed, which was only significant at twelve weeks
post-Iesioning. In general, similar changes of [125I]iodophenpropit binding were observed at three months
as compared to twelve months post-Iesioning. Hence, these changes seem to be related directly to the
sustained destruction of dopaminergic neurons in 6-hydroxydopamine treated rats. The changed histamine
H3-receptor binding may be of importance in the pathology of motor disorders like Parkinson's disease.
*European Graduate School of Neuroscience, EURON, Maastricht University, Department of Psychiatry
and Neuropsychology, Maastricht, The Netherlands.
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Introduction
The role of histamine as a neurotransmitter in the CNS has been well established
(Schwartz et at., 1991; Onodera et at., 1994; Schwartz et at., 1995). The histaminergic
system has been described to playa role in different processes such as arousal state, sleep
and wakefulness, locomotor activity, feeding, cognition and pituitary hormone secretion
(for review see: Onodera et at., 1994; Schwartz et at., 1995). Histaminergic neurons
originate from the posterior hypothalamic area and send varicose fibers towards all parts
of the CNS through ascending and descending projections (Tohyama et at., 1991; Panula
& Airaksinen, 1991; Wouterlood & Steinbusch, 1991; Schwartz et at., 1995). Release
and synthesis of neuronal histamine are both inhibited upon activation of the histamine
H3-receptor, the autoreceptor of histaminergic neurons (Arrang et at., 1983).
Autoradiographic studies showed that there is no clear overlap between the distribution of
H3-receptors and the distribution of histaminergic neurons (Arrang et at., 1987; Pollard
et at., 1993). This observation may be partly explained by the presence of the H3-
receptor as a heteroreceptor (for review see: Schlicker et at., 1994). Activation of the
histamine H3-receptor has been shown to inhibit the release of noradrenaline, serotonin
and acetylcholine from rat brain slices (Schlicker et at., 1994). In addition, from
autoradiographic studies, postsynaptic H3-receptors have been proposed (Cumming et
at., 1991; Pollard et at., 1993; Ryu et at., 1994). Intrastriatal quinolinic acid or kainic
acid lesions, destroying postsynaptic components (Schwarcz et at., 1983; Nicholson et
at., 1995), caused a marked reduction of H3-receptors in the striatum as evidenced from
receptor binding studies with the radiolabelled H3-agonists [3H](R)a.-methylhistamine
(Pollard et at., 1993; Ryu et at., 1994) and [3H]NU-methylhistamine (Cumming et at.,
1991). Lesion of dopaminergic neurons originating from the substantia nigra, pars
compacta resulted in an increase of [3H](R)a.-methylhistamine binding in the striatum and
in the substantia nigra (Ryu et at., 1994; Ryu et at., 1996). Hence, the H3-receptor may
play a functional role in the nigrostriatal tract, which was shown to be endowed with
histamine H3-receptors.
Up till now, autoradiographic reports on histamine H3-receptors in the nigrostriatal tract
have focussed almost exclusively on transversal sections of the rostral striatum and of the
substantia nigra. Moreover, in these studies predominantly radiolabelled histamine H3-
receptor agonists were used to determine the density of H3-receptors. Radiolabelled H3-
receptor agonists show a rather complex receptor binding profile as a consequence of
involvement of coupling of the agonist-receptor complex to G-proteins (for review see:
Leurs et at., 1995).
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In the present study we investigated the interaction between H3-receptors and the
dopaminergic system, using the iodinated H3-receptor antagonist [1251]-iodophenpropit
(Jansen et at., 1992; Jansen et at., 1994). Dopaminergic neurons originating from the
substantia nigra and the ventral tegmental area were treated with the neurotoxin 6-
hydroxydopamine (6-0HDA) and subsequently, the effect of denervation on [1 251]-
iodophenpropit binding was studied with quantitative autoradiography.
Materials and methods
Lesions with 6-0HDA
Male rats (T~Maze Bright (TMB), 200-250g, Central Animal Facility, Maastricht
University) were housed in pairs under standard conditions (12 hr light-dark cycle, 23°C,
55% relative humidity) in macrolon cages (25x20x30 cm) receiving water and standard
food pellets (Hope Farms) ad libitum. Rats were subjected to unilateral 6-0HDA
lesioning. Two hours prior to lesion-surgery rats received an injection with
desmethylimipramine (25mglkg Lp., dissolved in 0.9% NaCl), to prevent 6-0HDA
uptake into noradrenergic neurons. Under anaesthesia, using a combination of xylazine
(2mglkg, s.c.) and ketamine (50mglkg, Lm.), 6-0HDA was injected stereotaxically in the
ventral tegmental area and in the medial forebrain bundle. 6-0HDA was dissolved in
saline (0.9% NaCl) containing 0.02% (wt/vol) ascorbic acid. Following the injection
(injection rate of 1 ~l/min) the needle was left in place for an additional minute. Co-
ordinates (according to Paxinos & Watson, 1982) and volumes used were: B -4.0 mm, L
0.8 mm, V 8.0 mm; 2.0 ~l and B -4.4 mm, L 1.1 mm, V 7.8 mm; 2.5 ~l, for the ventral
tegmental area and the medial forebrain bundle, respectively.
Receptor autoradiographic procedure
Male TMB rats were decapitated and the brains were immediately removed and frozen
using dry ice. Transversal cryostat sections (14 ~m) were cut, mounted onto
gelatinlchromalum-coated glass slides and stored at -80°C until use. The tissue sections
were thawed and incubated with 0.3 nM [1251]-iodophenpropit for 60 minutes at 37°C in
50 mM Tris-HCI buffer containing 145 mM NaCl, 5 mM MgCl2 and 0.25% BSA (pH
7.4). Nonspecific binding was determined with thioperamide (0.3 ~). In displacement
experiments tissue sections were incubated (in duplicate) with [1251]-iodophenpropit (0.3
nM) in the presence of different concentrations of cold iodophenpropit (0.1 nM to 100
nM). The tissue sections were randomized prior to the experiment to minimize the effect
of possible rostro-caudal variation in receptor densities. To stop the incubations the
sections were rinsed once with ice-cold Tris-HCI buffer (50 mM Tris-HCI; 5 mM MgCI2,
145 mM NaCl; pH 7.4 at 4°C) and were subsequently washed twice for 15 minutes in
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ice-cold Tris-HCI buffer and 15 seconds in ice-cold distilled water. Sections were dried
by a stream of cold air and were exposed to Hyperfilm (Amersham International, U.K.)
for 20 hours and subsequently to a storage phosphor screen. Phosphor screens were
scanned with a Phosphor Imager® (Molecular Dynamics, Sunnyvale, CA, USA) to
obtain the digitized images. Proper images were obtained already several hours after
exposure. To increase the resolution of the digitized images the screens were exposed up
to three days. In some experiments, tissue sections were scraped from the slides with a
razor blade in order to count the radioactivity by an LKB gamma counter.
Data analysis and statistical evaluation:
The storage phosphor images were analyzed and quantified using the program
ImageQuant® (Molecular Dynamics). Brain areas of interest (l00 to 600 pixels, pixel size
88 x 88 llm) were selected and the density was expressed as the average counts per pixel-
value in the selected brain areas. A linear relation between quantification with the
phosphor imaging method compared to direct gamma counting was observed over the
range of densities used in the experiments. (For a more detailed description of this
method: see Kanekal et al., 1995; Tang et al., 1995). Specific [l25I]-iodophenpropit
binding was calculated by substracting the nonspecific binding from the total binding. In
each experiment specific binding of the ipsilateral side was expressed as percentage of the
binding in the contralateral side. The specific binding in the ipsilateral side was compared
to the contralateral side (population mean of 100%) by a one sample unpaired Student's t-
test using the program StatWorks™1.2 on a Macintosh computer. Differences were
considered statistically significant at a probability level of 5%. Competition binding
experiments were evaluated using the non-linear curve fitting program LIGAND (Munson
& Rodbard, 1980) on a Macintosh computer as previously described (Jansen et al.,
1994). Binding curves were fit (unweighed) to a one and a two site model respectively,
and statistically tested on the increasing goodness of the fit for a model with additional
parameters using a probability level of 5%. Displacement curves of iodophenpropit were
best fitted to a one-site model. Dissociation constants of iodophenpropit in lesioned and
unlesioned side of the sections were compared using unpaired two-tailed Student's t-tests.
Ligands
[l25I]-Iodophenpropit (specific activity of 1900 Ci mmol-1) was synthesized at the
Radionuclide Center, Leiden/Amsterdam Center for Drug Research (Vrije Universiteit,
Amsterdam), as described previously (Menge et al., 1992). The following drugs were
used: iodophenpropit dihydrobromide (laboratory stock), thioperamide maleate
(laboratory stock) All compounds (solutions of 1-10 mM) were dissolved in distilled
water or in Tris-HCI buffer and were further diluted in Tris-HCI buffer.
- 116-
Link between H3-receptors and the dopaminergic system
Results
In a separate study, rats received identical 6-0HDA lesions and the brains were
perfusion-fixated with either glutaraldehyde or paraformaldehyde for dopamine or
tyrosine-hydroxylase-immunohistochemistry, respectively. (Details about both
procedures have been published previously by Steinbusch et at., 1988 and Steinbusch et
at., 1991). 6-0HDA lesions of dopaminergic neurons originating from the substantia
nigra pars compacta and the ventral tegmental area resulted in selective and prolonged loss
of doparninergic neuronal pathways in the eNS (Steinbusch et at., 1988; Steinbusch et
at., 1991).
Lesions with 6-0HDA resulted in a moderate increase of [l25I]iodophenpropit binding in
the dorsal aspects of the striatum (Table 1). A significant increase was found in the
dorsolateral aspect (+18%) at three weeks post-lesioning and in the dorsomedial aspect
(+12%) at twelve weeks post-lesioning. [l25I]Iodophenpropit binding was markedly and
significantly increased in the entopeduncular nucleus (+44%) and in the substantia nigra
pars reticulata (+81 %), at three weeks post-lesioning (Table 1). A similar increase of
Table 1. Effect of lesions with 6-0HDA on [125/j-iodophenpropit binding sites in rat brain.
[1251j-iodophenpropit binding (% of contralateral site)
time after lesion
brain area 3 weeks 12 weeks
cerebral cortex 101 ± 4 100 ± 11
striatum:
DM 114 ± 9 112 ± 6*
DL 118 ± 6* 113±9
VM 108±6 104±7
VL 110±6 104 ± 10
globus pallidus 95 ± 7 94 ± 3*
entopeduncular nucleus 144 ± 14* 165 ± 7*
substantia nigra 181 ± 12* 164 ± 18*
*p < 0.05, as compared to the contralateral side. Tissue sections were incubated with 0.3 nM [1251j_
iodophenpropit as described in 'materials and methods'. Values are expressed as average ± SD of at least
three separate experiments with sections obtained from three or four 6-0HDA lesioned rats (3 and 12
weeks post-lesion interval, respectively). Abbreviations: DM, dorsomedial. DL, dorsolateral; VM,
ventromedial; VL, ventrolateral.
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Str
SNR
Figure 1. Autoradiograms of [J25/J-iodophenpropit binding after lesions with 6-0HDA. Shown are
transversal sections of rats at twelve weeks after 6-0HDA lesions. Sections were incubated with 0.3 nM
[125/J-iodophenpropit as described in 'materials and methods'. Left column: total binding; right column:
binding in the presence of 0.3 J.lM thioperamide. The left side of each section corresponds to the 6-
OHDA lesioned side. Abbreviations: Str, striatum; GP, globus pallidus; EPN: entopeduncular nucleus;
SNR, substantia nigra.
- 118-
Link between HTreceptors and the dopaminergic system
[l25I]iodophenpropit binding in both areas was also observed at twelve weeks post
lesioning (Table 1, Figure 1). Analysis of the autoradiograms revealed a marginal
decrease of [l25I]iodophenpropit binding in the globus pallidus, both at three and twelve
weeks post lesioning (Figure 1). A significant reduction (-6%) of [125I]iodophenpropit
binding in the globus pallidus was found at twelve weeks after the lesions (Table 1). No
interhemispheric differences of [125I]iodophenpropit binding were observed in cortical
areas (Table 1). 6-0HDA lesions caused no differences in KD-values of
[125I]iodophenpropit binding between ipsilateral and contralateral hemispheres of the
cortex, striatum and the substantia nigra (Table 2, Figure 2).
Table 2. Dissociation constants of iodophenpropit in 6-0HDA lesioned rats.
KD-value (nM)
brain area
cortex
sUiatum, dorsal aspect
striatum, ventral aspect
globus pallidus
entopeduncular nucleus
substantia nigra
ipsilateral side
1.7 ± 0.3
1.9 ± 0.9
1.5 ± 0.2
NO.
NO.
104 ± 004
contralateral side
1.7 ± 0.3
1.3 ± 0.3
1.3 ± 0.3
NO.
NO.
104 ± 0.6
Dissociation constants were determined from displacement of 0.3 nM [l25II-iodophenpropit with cold
iodophenpropit (see 'materials and methods' section). KD-Values are expressed as average ± SD of three to
five separate experiments. NO, not determined.
Discussion
The histamine H3-receptor was identified as the autoreceptor of histaminergic neurons in
the brain (Arrang et ai., 1983). Soon it became clear that the histamine H3-receptor is not
solely present as an autoreceptor. Conclusive evidence was provided for the occurrence of
histamine H3-heteroreceptors modulating the release of various neurotransmitters (for
recent review: see (Schlicker et at., 1994). Moreover, from receptor autoradiographic
studies the existence of postsynaptic H3-receptors has been indicated (Cumming et ai.,
1991; Pollard et at., 1993; Ryu et ai., 1994). Hence, the H3-receptor may play an
important role both, in regulating the activity of histaminergic neurons and in the cross-
talk of neuronal and non-neuronal histamine with other neuronal systems.
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Figure 2. Competition binding curves for iodophenpropit in the substantia nigra. Total [125I]_
iodophenpropit binding is expressed as average counts per pixel in the substantia nigra pars reticulata.
Curves are from a single experiment with duplicate determinations. Symbols: (0) control side; (e)
lesioned side. Indicated with the arrow: total [125IJ-iodophenpropit binding displaced by 0.3 J.lM
thioperamide.
We have studied the interaction between histamine H3-receptors and the dopaminergic
system in rat brain. The effect of unilateral lesions of dopaminergic neurons induced by
the neurotoxin 6-0HDA on the binding of the histamine H3-receptor antagonist
[125I]iodophenpropit to rat fore- and midbrain was examined. [l25I]Iodophenpropit was
previously demonstrated to be a suitable radioligand to study characteristics and
distribution of histamine H3-receptors in rat brain (Jansen et at., 1992; Jansen et at.,
1994). In brief, unilateral 6-0HDA denervation of the nigrostriatal dopaminergic pathway
in rat brain moderately increased [l25I]iodophenpropit binding in the dorsal aspects of the
striatum. Additionally, lesions also altered [l25I]iodophenpropit binding in striatal output
nuclei. A pronounced increase of [l25I]iodophenpropit binding was found in the
substantia nigra (SNR) and in the entopeduncular nucleus (EPN). In the globus pallidus
(GP) a small but significant decrease of [125I]iodophenpropit binding was observed at
twelve weeks after 6-0HDA lesions. In general, comparable changes of
[l25I]iodophenpropit binding were found at three and at twelve months post-Iesioning.
The static nature of the changed [l25I]iodophenpropit binding may directly be related to
the sustained denervation of dopaminergic neurons in the brains of 6-0HDA treated rats
(Steinbusch et at., 1988). Lesions with 6-0HDA did not change the dissociation
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constants of iodophenpropit (in the cortex, striatum and the SNR). Consequently,
changes of [125I]iodophenpropit binding are likely to reflect changes in densities of
[l25I]iodophenpropit binding sites.
A previous report described the effect of 6-0HDA lesions in rat brain on histamine H3-
receptor binding using the histamine H3-receptor agonist [3H](R)a-methylhistamine as a
radioligand (Ryu et al., 1994). The increased binding of [3H](R)a-methylhistamine in
the dorsal striatum (+20%) and in the SNR (+70%) as observed by Ryu et at. are
comparable to the increased binding of the radiolabelled antagonist [125I]iodophenpropit
in these areas. In addition, in our study, we observed changes of [l25I]iodophenpropit
binding in two other areas i.e. an increase in the EPN and a decrease in the GP. In
another autoradiographic study using the agonist [3H]Na.-methylhistamine, dopaminergic
lesions were reported not to affect radioligand binding (Cumming et at., 1991) to rat
fore- and midbrain. In the latter study, rats were sacrificed already seven days post-
lesioning. Possibly, the increased radioligand binding was not yet apparent at this
relatively short time interval. It has been demonstrated that changes of dopamine receptor
binding were only found in animals with >90% lesion of the nigrostriatal pathway, thus
showing the requirement of a fully completed lesion for the altered receptor densities to be
detected (Pan et al., 1985). In a recent study by Ryu et aI., a marked increase of
radiolabelled agonist binding was already observed at one week after lesions with 6-
OHDA however (Ryu et al., 1996).
The increased binding of [l25I]iodophenpropit in the dorsal striatum and the unaffected
[l25I]iodophenpropit binding in the ventral striatum of 6-0HDA denervated rats suggests
that striatal histamine H3-receptors are not predominantly located presynaptically on
dopaminergic afferents. In accordance with this suggestion, H3-receptor mediated
modulation of dopamine release from rat striatal slices could not be demonstrated so far
(Smits & Mulder, 1991; Schlicker et al., 1993).
Histamine H3-receptors in the striatum may be tonically regulated by neuronal dopamine
released from dopaminergic neurons. Additionally, striatal H3-receptors may also be
tonically influenced by neuronal histamine. Electrocoagulation of the lateral hypothalamic
area, destructing both histaminergic afferentiation and other aminergic ascending
pathways, resulted in a marked increase of [3H](R)a-methylhistamine binding in the
striatum (Pollard et at., 1993). Moreover, inhibition of histamine synthesis with the
histidine decarboxylase inhibitor a-fluoromethylhistamine increased the binding of the
H3-receptor agonist [3H](R)a-methylhistamine in the striatum of developing rats (Ryu et
al., 1995). The rat striatum has been demonstrated to contain a diffuse network of
histaminergic varicose fibers (Steinbusch et at., 1986). Thus, striatal histamine H3-
receptors may be tonically regulated by neuronal histamine.
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GABA-ergic neuron
GABA-ergic neuron
nigrostriatal pathway
Dopaminergic neuron
Figure 3. Schematic representation of the effect of 6-0HDA lesions on the density of Hrreceptors in
the striatum and its output centers. A hypothetic model of their localization and the overlap with
GABAA-receptors. Dopaminergic neurons of the nigrostriatal pathway originate from the substantia
nigra, pars compacta (SNc) and terminate in the striatum. The striatal efferents to the entopeduncular
nucleus (EPN), the substantia nigra pars reticulata (SNr) and to the globus pallidus (GP) use GABA as
neurotransmitter (Kita & Kitai, 1988). (For references underlying the scheme: see 'discussion'). The
neuronal scheme as presented is part ofthe basal ganglia thalamocortical circuit (Alexander & Cruther,
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6-0HDA
Striatum
GABA-ergic neuron
t
striatopallidal pathway
1990; Gerfen et al., 1990). The striatoentopeduncular and striatonigral routes are commonly referred to as
the 'direct pathway', and the striatopallidal route as the 'indirect pathway'. The latter pathway projects via
the subthalamic nucleus to the substantia nigra and the entopeduncular nucleus. Stimulation and
inhibition by dopamine of the direct- and of the indirect pathway, respectively, synergistically inhibits
the GABA-ergic output of the SNrlEPN to the thalamus resulting in a stimulation of glutaminergic
thalamocortical neurons.
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Although no direct proof has been provided, several studies indicate that striatal H3-
receptors are largely of postsynaptic origin (Cumming et at., 1991; Pollard et at., 1993;
Ryu et at., 1994). Intrastriatal lesions with quinolinic acid or kainic acid, destroying
postsynaptic structures (Schwarcz et at., 1983), resulted in a marked loss (-60% to -
70%) of striatal H3-receptor binding sites (Cumming et at., 1991; Pollard et at., 1993;
Ryu et at., 1994). At least 85% of the striatal efferents were estimated to utilize y-
aminobutyric acid (GABA) as a neurotransmitter (Kita & Kitai, 1988). Consequently,
striatal H3-receptors may be located largely on GABA-ergic efferents.
The different effects of 6-0HDA treatment on [l25I]iodophenpropit binding in the SNR,
the EPN and the GP may be explained neurochemically. The three areas are innervated by
projection neurons of the striatum Le. the striatonigral, the striatoentopeduncular, and the
striatopallidal pathways, respectively (see Figure 3). As mentioned, these striatal efferents
have been demonstrated to use GABA as their primary neurotransmitter (Kita & Kitai,
1988). The striatonigral and the striatoentopeduncular neurons contain substance P and
dynorphin as co-transmitters, whereas striatopallidal neurons utilize enkephalin as co-
transmitter (Gerfen et al., 1990). These neurochemical differences reflect a heterogeneity
of these striatal efferents. Interestingly, the altered binding of [125I]iodophenpropit in the
three areas mentioned above after lesions with 6-0HDA shows the same pattern as
changes of GABAA-receptor binding after lesions with 6-0HDA Le. increased binding in
the SNR (+32%) and in the EPN (+32%) and decreased binding in the GP (-44%) (Pan
et al., 1985; Gnanalingham & Robertson, 1993). These bi-directional changes of
GABAA-receptor binding were proposed to be related to the functional heterogeneity of
the different pathways (Pan et at., 1985). The striatonigral and striatoentopeduncular
neurons have been demonstrated to be stimulated by striatal dopamine activating
dopamine D1-receptors (Robertson et at., 1992; Pan et al., 1985). Oppositely,
striatopallidal neurons are inhibited by striatal dopamine through activation of dopamine
D2-receptors (Robertson et al., 1992; Pan et at., 1985). Thus, the increased radioligand
binding in the SNR and in the EPN may be compensatory mechanisms to a reduced
stimulation of both neuronal pathways due to striatal dopamine depletion. Similarly, the
decreased binding in the GP may result from a reduced inhibition of striatopallidal
neurons caused by striatal dopamine depletion. In line with this theory, increased binding
of the histamine H3-receptor agonist [3H](R)a.-methylhistamine in the SNR of 6-0HDA
lesioned rats was reversed by administration of the D1-agonist SKF38393 but was not
affected by the D2-agonist quinpirole (Ryu et al., 1996). The densities of other
neurotransmitter receptors like Jl- and 0- opioid receptors were differently affected by 6-
OHDA lesions as compared to GABAA-receptors (Pan et at., 1985). The similarities
between the changes in histamine H3-receptor binding compared to changes of GABAA-
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receptors suggest that the localization of H3-receptors in the SNR, the EPN and the GP
may partially overlap with GABAA -receptors, which are predominantly localized
postsynaptically (see Figure 3).
The presence of histamine H3-receptors in the striatum and on the striatal output nuclei
implies a role of central histamine in functions related to these areas. Evidence has been
presented for the involvement of the central histaminergic system in locomotor activity
(for review see: Onodera et at., 1994). In rats, intra-accumbens administration of the H3-
receptor agonist Nll-methylhistamine produced hypoactivity, followed by a hyperactivity
(Bristow & Bennet, 1988). Degeneration of striatal afferent and efferent pathways have
been related to the etiology of different motor disorders. Experimental disruption of
nigrostriatal and of striatal efferent pathways are used as model systems for Parkinson's
disease (Gerfen et aI., 1990) and Huntington's disease (Figueredo-Cardenas et at.,
1994; Nicholson et aI., 1995), respectively. Therefore, the changed histamine H3-
receptor binding in rats after disruption of the nigrostriatal tract described in the present
study, and the decreased H3-receptor binding upon destruction of intrinsic striatal neurons
might imply an involvement of histamine H3-receptors in primate motor disorders. Also,
striatal afferent and efferent pathways have been indicated to modulate epileptic seizure
threshold (Turski et at., 1990; Turski et at., 1991). A role of the central histaminergic
neuron system in the inhibition of seizures has been indicated (Yokoyama et ai., 1992;
Yokoyama et ai., 1993c; Kiviranta et ai., 1995). Brain penetrating histamine H1-
receptor antagonists have been shown to exhibit proconvulsive activity in mice and in
primates (Yokoyama et ai., 1993a; Yokoyama et ai., 1993b). Convulsions in mice were
inhibited by the histamine H3-receptor antagonists thioperamide and c1obenpropit
(Yokoyama et aI., 1993c; Yokoyama et ai., 1994). The precise mechanism of the
anticonvulsive activity of histaminergic ligands is presently unknown. Modulation of
GABA mediated neurotransmission is a target for development anti-epileptic drugs
(Turski et ai., 1991; Palmer & Miller, 1996). With this respect, a possible co-
localization of histamine H3-receptors with GABAA -receptors may be of interest.
Electrophysiological and microdialysis studies have indicated a link between the
histaminergic and the GABA-ergic system (Yokoyama, 1994; Okakura-Mochizuki et
ai., 1996; Blandina 1996, personal communication). In the SNR, H3-receptors were
recently shown to inhibit the dopamine stimulated GABA release (Garcia et aI., 1997).
However, at present data are lacking to suggest a GABA-ergic mechanism of
anticonvulsant activity of the histaminergic neuronal system.
In summary, we have demonstrated an interaction between histamine H3-receptors in the
rat basal ganglia and the dopaminergic neuron system. 6-0HDA lesions of dopaminergic
neurons altered histamine H3-receptor antagonist [125I]iodophenpropit binding in the
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striatum and in striatal output nuclei i.e. the SNR, the EPN and the GP. The changed
histamine H3-receptor binding may be of importance in the pathology of motor disorders
like Parkinson's disease and Huntington's disease and, consequently, the histamine H3-
receptor may be a new potential target in these disorders.
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A quantitative and whole-body autoradiographic study of the
radio-iodinated histamine H3-receptor antagonist
iodophenpropit, after intravenous administration to rats
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Jacobus D.M. Herscheid2, Bengt S. Larsson3, and Hendrik Timmerman
Abstract
The histamine H3-receptor antagonist [l25I]iodophenpropit has been successfully introduced as a
radioligand to study H3-receptors in the central nervous system (CNS) in vitro. The present study was
conducted to obtain insight into the in vivo distribution of iodophenpropit. [125I]Iodophenpropit was
intravenously injected into rats and the distribution of the radioactivity at intervals of three minutes up to
four days after injection was studied by whole-body autoradiography. Using [131I]-labelled iodophenpropit,
the radioactivity present in different tissues after injection of the radioligand was quantified.
At three minutes after injection autoradiographic images showed a heterogeneous distribution of the
radioactivity. High amounts of radioactivity were found in several peripheral tissues in which HTreceptors
have previously been identified such as lung, heart, stomach, intestine, spleen and pituitary. Only a minor
fraction (of about 0.05 %) of the injected radioactivity was detected in the brain, mainly in the choroid
plexus. Pre-injection of unlabelled iodophenpropit, did not substantially affect the tissue distribution of
radioactivity in most tissues. After one hour considerable amounts of radioactivity were transferred to the
intestine, probably via biliary excretion, indicating the onset of elimination of the compound and/or its
radiolabelled metabolites via the faeces. Four days after injection the radioactivity was almost completely
eliminated from all tissues except for the thyroid gland in which an accumulation was seen.
In conclusion, iodophenpropit poorly penetrates into the brain. The compound can be regarded as a
potential ligand for in vivo pharmacological studies, being a preferentially peripherally acting H3-receptor
antagonist.
IRephartox B.V., Maarssen, The Netherlands. 2Radionuclide Center, Vrije Universiteit, Amsterdam.
3Division of TOXicology, Department of Pharmaceutical Biosciences, Uppsala Biomedical Center,
Uppsala University, Uppsala, Sweden.
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Introduction
The histamine H3-receptor was identified in 1983 as the autoreceptor of histaminergic
neurons in the CNS (Arrang et at., 1983). Besides modulation of neuronal histamine
release, activation of histamine H3-receptors has been shown to modulate the release of
various other neurotransmitters such as serotonin (Fink et at., 1990), noradrenaline
(Schlicker et at., 1989), acetylcholine (Clapham & Kilpatrick, 1992) and neuropeptides
(Matsubara et at., 1992). Receptor binding studies with radiolabelled H3-receptor
agonists (Pollard et at., 1993; Cumming et at., 1991) and antagonists (Jansen et at.,
1994; Ligneau et at., 1994; Yanai et at., 1994) showed that H3-receptors are
heterogeneously distributed in the CNS exhibiting receptor densities up to 300 fmoVmg of
protein (Jansen et at., 1994). Centrally acting H3-receptor ligands have been
demonstrated to modulate sleep and wakefulness, cognition, locomotion, and feeding
behaviour, and were shown to affect electrically induced convulsions (for review see:
Schwartz et at., 1991 and Onodera et at., 1994). Histamine H3-receptors have also been
functionally identified in many peripheral tissues like lung (Ichinose & Barnes, 1989;
Burgaud et at., 1992; Cardell & Edvinsson, 1994; Dimitriadou et at., 1994), heart (Luo
et at., 1991; Malinowska & Schlicker, 1993; Endou et at., 1994), stomach (Bado et
at., 1991; Coruzzi et at., 1991; Bado et at., 1994; Soldani et at., 1994), intestine
(Trzeciakowski, 1987; Hew et at., 1990; Menkveld & Timmerman, 1990; Leurs et at.,
1991), spleen (Dimitriadou et at., 1994), skin (Archer & Greaves, 1993; Ohkubo et
at., 1994) and perivascular tissue (Ishikawa & Sperelakis, 1987; Ea-Kim & Oudart,
1988). The wide distribution of histamine H3-receptors suggests the involvement of this
receptor in many (patho)physiological processes.
The H3-receptor agonist (R)cx-methylhistamine and the H3-antagonist thioperamide were
the first ligands used to study histamine H3-receptors in vitro and in vivo (Arrang et
at., 1987). More recently, other selective H3-receptor agonists and antagonists derived
from different chemical classes have been introduced (Leurs et at., 1995). In our
laboratory the H3-receptor antagonist clobenpropit has been developed, being one of the
most potent histamine H3-receptor antagonists in vitro known so far (Van der Goot et
at., 1992). Clobenpropit is a brain penetrating compound, although in rats its central
effects occur at relatively high doses (5 - 15 mg/kg, s.c. or p.o.; Barnes et at., 1993).
[l25I]Iodophenpropit, a close derivative of clobenpropit, has previously been introduced
as a radioligand (Menge et at., 1992; Jansen et at., 1992). This radiolabelled antagonist
was shown to be a suitable tool for H3-receptor studies in vitro (Jansen et at., 1994;
Leurs et at., 1996). At present, no data have been provided on the in vivo pharmacology
of iodophenpropit. Iodophenpropit and related compounds (for example its fluorinated
derivatives) could have a potential application for in vivo imaging techniques like single
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photon emission computed tomography (SPECT) and positron emission tomography
(PET).
In order to get information on the in vivo kinetics of iodophenpropit, [1 251]- and [13il]_
labelled iodophenpropit were injected into rats. The distribution of radioactivity after
injection of [1 251]-iodophenpropit was studied using whole-body autoradiography.
[13il]-lodophenpropit was used to quantify the radioactivity present in rat tissues at
different intervals after administration.
Materials and methods
Chemicals
[1251]-lodophenpropit (specific activity of 2000 Ci mmol-1) and [13il]-iodophenpropit
(specific activity of 15000 Ci mmol- i ) were synthesized according to the method
described by Menge et al. (Menge et al., 1992). HPLC-Analysis showed that the [1 251]-
and [13il]-iodinated products were chemically pure and had a radiochemical purity >99%.
Unlabelled iodophenpropit dihydrobromide was from laboratory stock. All other
chemicals used were of analytical grade.
Whole-body autoradiographic studies
Male and female rats (160-200g, Central animal facility, Uppsala Biomedical Center)
were injected intravenously with [i251]iodophenpropit (9.25 MBq (250IlCi)/kg),
dissolved in 60 mM sodium citrate solution (injection volume: 160 to 200 Ill). After the
injection, rats were placed back in their home cages and received food and water ad
libitum. The rats were killed by carbondioxide anaesthesia at intervals of 3 and 15 min,
1, 2, and 4 hours, and 1 and 4 days after injection. Whole-body autoradiography was
performed according to Ullberg (Ullberg, 1954; Ullberg et ai., 1982). The rats were
embedded in aqueous carboxymethyl cellulose and immediately frozen in hexane, cooled
with dry-ice (-70°C). Sagittal cryostat sections (20 Ilm) were cut using a cryomicrotome
(PMV 450 MP, Stockholm, Sweden) and were attached onto tape (No. 810, MMM Co.,
USA). The sections were freeze dried at -20°C (atmospheric pressure) for one day, and
they were subsequently exposed to X-ray film (Structurix D7, Agfa-Gaevert, Germany,
stored at -20°C). The films were developed after 4-6 weeks of exposure. Some sections
were stained with hematoxylin-eosin for detailed anatomic examination.
Preparation oftissue samples for quantitative measurement ofradioactivity
Male Wistar rats (180-200 g, Harlan C.P.B., Zeist, Netherlands) were injected with 4.63
MBq (125IlCi)/kg [13il]-iodophenpropit (dissolved in 60mM sodium citrate) into the
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lateral tail vein (injection volume of 180 to 200 fll). At different intervals after the injection
i.e. 15 and 30 min, 1 and 24 hours (four rats per interval), the animals were anaesthetized
with ether and blood samples were taken by heart punction. Next, the rats were killed by
cervical dislocation and the following tissues were collected: thyroid gland, brain,
cerebellum, heart, lung, intestine, liver, kidneys, adrenals, pancreas, spleen, testis,
prostate, skeletal muscle (hind paw), urine (24h interval) and faeces (24h interval). Rats
kept for 24 hours were housed in metabolic cages, receiving food and water ad libitum.
Tissue samples were weighed and the radioactivity present in the samples was measured
by an LKB gamma counter. In a separate experiment rats were injected with unlabelled
iodophenpropit (3 mg/kg, Lv., dissolved in saline, injection volume 180 to 200 fll, n=4)
or saline (control group, n=4), at 5 minutes preceding injection with [131I]-iodophen-
propit (4.63 MBq (l25flCi)/kg; procedure as described above). At 30 minutes after the
injection with [131I]-iodophenpropit the rats were anaesthetized with ether and were
processed as described above.
Results
General autoradiographic distribution pattern
The distribution of radioactivity at different intervals after a single injection of [1251]-
iodophenpropit is displayed in Figure 1 (female rats series are shown). At three minutes
after injections with [125I]-iodophenpropit the radioactivity was heterogeneously
distributed. High amounts of radioactivity were found in the kidneys, adrenals, lung, the
heart muscle, liver and the upper part of the gastrointestinal tract. Also the thyroid gland,
the salivary gland and the brown fat showed a high amount of radioactivity. Almost no
radioactivity was detected in the CNS (Figure 1). A similar distribution was seen at fifteen
minutes after injection. At two hours after the injection, a considerable amount of
radioactivity had been transferred to the lower part of the intestinal tract, visible in the
faeces, indicating elimination of the compound and/or its radiolabelled metabolites. At one
day after injection the radioactivity was markedly reduced in most tissues (Figure 1). A
relatively large amount of radioactivity was retained in the kidney medulla, the adrenal
cortex, the lower part of the intestine, the brown fat, the salivary gland and the thyroid. At
four days after administration of [125I]-iodophenpropit, the radioactivity was eliminated
almost exclusively from all tissues, except for the thyroid gland, in which a marked
accumulation of radioactivity was observed. No clear differences of the autoradiographic
images between male and female rats were found (data not shown).
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Timecourse ofthe radioactivity in separate tissues
The radioactivity found in the heart was largely confined to the heart muscle, and was
gradually declining after one hour following injection (Figure 1).
In the respiratory system one of the highest optical densities of radioactivity were
observed in the lung (Figure 1). The radioactivity in the lung gradually decreased from
two hours after injection of [125I]-iodophenpropit. In the trachea the radioactivity was
low.
High amounts of radioactivity were found in the digestive system. In the stomach the
radioactivity was predominantly found in the glandular part part from three minutes to one
hour after injection. From one hour to one day after injection of [125I]iodophenpropit
increasing amounts of radioactivity were transported into the intestine, indicating biliary
excretion of the radioligand and/or its metabolites, which also was indicated by the spotty
distribution pattern of the radioactivity in the liver at three and fifteen minutes. This
pattern is characteristic for the accumulation in the bile ducts. A clear reduction of the
radioactivity in the liver was observed from one hour after injection of [l25I]iodophen-
propit. High amounts of radioactivity were also found in the salivary gland and the
pancreas. The radioactivity in the digestive system was markedly reduced at one day after
the injection and was almost completely excreted at four days after injection with
[l25I]iodophenpropit. At one day after injection a relatively large amount of radioactivity
was retained in the salivary gland.
A high amount of radioactivity was present in the kidneys, especially in the cortex at three
and fifteen minutes after injection. At one hour, the radioactivity in the kidney cortex was
reduced. A relatively large amount of radioactivity was still present in the medullary part
at one day after injection. The radioactivity almost exclusively disappeared from the
kidneys at four days after injection.
Almost no radioactivity was detected in the eNS. Apparently iodophenpropit has a poor
ability to penetrate the blood brain barrier. The spots of radioactivity observed in the brain
represent binding to the choroid plexus (Figure 1).
In the endocrine organs a relatively large amount of radioactivity was observed in the
adrenal gland, the pituitary and in the thyroid gland. The radioactivity in the pituitary
gradually declined from the sixty minutes interval to be eliminated at four days after the
injections. In the adrenal gland, a relatively large amount of radioactivity was retained
after one day. At four days after injection the radioactivity was almost completely
eliminated. At one and four days after injections with [l25I]iodophenpropit the
radioactivity in the thyroid was increased.
Of the lymphatic tissues, high amount of radioactivity was observed in the spleen. The
radioactivity in the bone marrow was low, and almost no radioactivity was observed in
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15 min.
60 min.
Figure 1. Autoradiograms of rats at different intervals after intravenous injection of fI25/]_
iodophenpropit. Rats were killed at intervals of 3 min, 15 min, 1 h, 2 h, 4 h, 1day and 4 days after
injection 9.25 MBq (250jlCi}/kg; see: 'materials and methods' for further details). Shown are
representative autoradiograms derived from sagittal cryostat sections (20 jlm) of female rats.
Abbreviations: adr. gland, adrenal gland; ch. plexus, choroid plexus; sal. gland, salivary gland; thyroid,
thyroid gland.
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1 day
4 days
Figure 1. (Continued).
thyroid
\
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the thymus.
A relatively large amount of radioactivity was observed in the brown fat (see Figure 1).
The radioactivity was relatively slowly eliminated from this tissue at one day after
injection but almost disappeared at the four days after injection. A moderate amount of
radioactivity was found in the skeletal muscles and bones.
Quantification ofthe radioactivity in different tissues
In a separate study the radioactivity was quantified in various male rat tissues at different
intervals after injection of [l31I]-iodophenpropit, as shown in Table 1. The results of
these experiments are in general agreement with the results of the whole-body
Table 1. Radioactivity in rat tissues after intravenous injection of[131lj-iodophenpropit.
0/0 injected dose/g at different intervals after injection
tissue 15 min 30 min 60 min 24 h
blood 0.18 ± 0.03 0.15 ±om 0.15 ± 0.02 0.10 ± O.03a
thyroid gland 1.22 ± 0.17 2.10 ± 0.69 1.59 ± 0.48 7.27 ± 1.85d
brain 0.03 ± 0.00 0.03 ± 0.00 0.04 ± O.OOa om ± O.OOd
cerebellum 0.05 ± 0.01 0.06 ± O.OOa 0.06 ± 0.02 0.03 ±O.Old
heart 1.69 ± 0.23 2.11 ± 0.60 1.61 ± 0.32 0.27 ±O.lOd
lung 5.19 ± 0.55 5.92 ± 1.10 4.72 ± 1.14 0.88 ±0.21 d
intestine 1.69 ± 0.46 1.88 ± 0.71 1.92 ± 0.23 0.33 ±O.03d
liver 2.33 ± 0.27 2.33 ± 0.52 1.53 ±0.15a 0.20 ±0.04d
kidneys 6.73 ± 0.34 6.36 ± 1.51 3.35 ±0.28a,b 0.92 ± O.13d
adrenals 3.82 ± 1.09 3.87 ± 0.91 3.40 ± 0.32 2.18 ± 0.27b,c
pancreas 1.42 ± 0.12 1.65 ± 0.35 1.41 ± 0.25 1.03 ± 0.13
spleen 3.04 ± 0.37 2.79 ± 0.86 2.21 ± 0.30a 0.50 ±O.17d
testes 0.02 ± 0.00 0.04 ± om 0.04 ± oma 0.05 ±oma
prostate 0.22 ± om 0.34 ± 0.09 0.29 ± 0.07 0.16 ± 0.03a,b
muscle 0.27 ± 0.05 0.26 ± 0.05 0.23 ± 0.06 0.10 ± 0.02a,b
faeces 6.39 ± 0.40
urine 2.04 ± 0.23
Rats were injected with [131Il-iodophenpropit (4.63 MBq (125lJ.Ci)/kg, Lv.) and tissues were collected at
different intervals after the injection as described in 'materials and methods'. Values are given as the mean
± SD of four rats and were compared using a two tailed, unpaired Student's t-tests with a Bonferroni
correction for multiple comparison. aSignificantly different from 15 minute interval (P < 0.05),
bsignificantly different from 30 minute interval (P < 0.05), Csignificantly different from 60 minute
interval (P < 0.05), dsignificantly different from 15, 30 and 60 minute interval (P < 0.05).
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autoradiographic studies. At fifteen minutes to one hour after injection the highest
amounts of radioactivity were found in the lung, liver, kidneys, adrenals and the spleen
(Table 1). A very low amount of radioactivity (between 0.04% - 0.05% of the total
amount injected) was observed in brain tissue. From fifteen minutes to the one hour after
injection no significant changes of the radioactivity in most tissues were observed. At one
day after injection the radioactivity was significantly decreased in most tissues (Table 1).
However, in the pancreas, the adrenals and the testes only a small reduction of the
radioactivity was measured. In the thyroid gland a marked increase (about six-fold) of the
radioactivity was found at one day after the injection of [131I]-iodophenpropit (0.7% of
the radioactivity injected).
Table 2. The effect of injection of unlabelled iodophenpropit on the tissue distribution of the
radioactivity after intravenous injection of[l3lIJ-iodophenpropit.
% injected dose/g, 30 minutes after injection
tissue
blood
thyroid gland
brain
cerebellum
heart
lung
intestine
liver
kidneys
adrenals
pancreas
spleen
testes
prostate
muscle
saline
0.40 ± 0.04
2.38 ± 1.15
0.05 ± 0.01
0.08 ± 0.03
2.26 ± 0.71
5.97 ± 1.75
3.39 ± 1.39
3.08 ± 0.74
6.72 ± 0.48
5.59 ± 1.97
1.83 ± 0.61
3.38 ± 0.44
0.05 ± 0.01
0.43 ± 0.14
0.39 ± 0.15
iodophenpropit
0.27 ± 0.05*
3.30 ± 1.18
0.05 ± 0.00
0.08 ± 0.00
1.76 ± 0.25
4.14 ± 0.32
2.59 ± 0.29
3.75 ± 0.35
7.96± 1.61
5.37 ± 2.82
1.89 ± 0.30
2.03 ± 0.41*
0.05 ± 0.00
0.46 ± 0.10
0.42 ± 0.15
Rats were injected with [13lI]-iodophenpropit (4.63 MBq(1251J,Ci)/kg, Lv.) and tissues were collected at
30 minutes after the injection as described in 'materials and methods'. Values are given as the mean ± SD
of four rats. Saline or unlabelled iodophenpropit (3mg/kg, i.v.) were injected 5 minutes prior to injection
of [131I]-iodophenpropit. Statistical significance between the saline and the iodophenpropit injected group
was considered using a two tailed, unpaired Student's t-test; *p < 0.05.
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Pre-injection ofiodophenpropit
Injection of unlabelled iodophenpropit (3 mg/kg, iv.) prior to injection of [1 311]-
iodophenpropit did not significantly affect the distribution of the radioactivity in most
tissues, as determined at thirty minutes after injection with [l311]-iodophenpropit (Table
2). The effect of pre-injection of iodophenpropit on the distribution was smaller than 23%
in these tissues. Injection of unlabelled iodophenpropit significantly reduced the
radioactivity in the blood (-32 ± 12% of the saline injected group, n=4) and in the spleen
(-40 ± 12%, n=4). A relatively large but not significant reduction and increase was found
in the lung (-31 ±5%, n=4) and in the thyroid (+39 ±49%, n=4), respectively.
Discussion
[1 251]-lodophenpropit was previously introduced as a radioligand for histamine H3-
receptor binding studies (Jansen et aI., 1992; Menge et at., 1992). The radiolabelled
H3-receptor antagonist has been demonstrated to bind with high affinity and in a saturable
and reversible manner to histamine H3-receptors in the rat CNS (Jansen et at., 1994).
With its pA2-value of 9.6, iodophenpropit is one of the most potent histamine H3-receptor
antagonists currently known. The present study was conducted to get insight in the in
vivo potential of iodophenpropit as a radioligand. lodophenpropit and related compounds
(for example its fluorinated derivatives) could be potential tools to study the (patho)
physiological role of histamine H3-receptors e.g. using in vivo imaging techniques like
SPECT and PET. The distribution of radioactivity was investigated after a single injection
of radiolabelled iodophenpropit in rats, using whole-body autoradiography and
quantitative determination.
After injection of rats with [1251]_ or [1311]-labelled iodophenpropit, the radioactivity was
heterogeneously distributed and was observed in almost all tissues. Radioactivity was
present in various peripheral tissues in which histamine H3-receptors have been
functionally identified, such as lung (Ichinose & Barnes, 1989; Burgaud et at., 1992;
Cardell & Edvinsson, 1994; Dimitriadou et at., 1994), spleen (Dimitriadou et at.,
1994), heart (Luo et at., 1991; Malinowska & Schlicker, 1993; Endou et at., 1994),
stomach (Bado et at., 1991; Coruzzi et at., 1991; Bado et at., 1994; Soldani et aI.,
1994), intestine (Trzeciakowski, 1987; Hew et at., 1990; Menkveld & Timmerman,
1990) and pituitary (Pollard et aI., 1993; West et at., 1994). In many of these tissues the
effects of histamine H3-receptor activation are mediated by the presynaptic inhibition of
neurotransmitter release. The densities of H3-receptors in peripheral tissues are rather low
(Arrang et at., 1987; Korte et at., 1990). Therefore, it is likely that the binding of
[1251]-iodophenpropit to histamine H3-receptors in these tissues is not clearly observed in
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the autoradiograms, being overruled by binding of [l25I]-iodophenpropit and/or of its
radiolabelled metabolites to non H3-receptor components. Consequently, it may be
difficult to visualize histamine H3-receptors in peripheral tissues in vivo using
radiolabelled iodophenpropit. Pre-injection of unlabelled iodophenpropit did not
substantially affect the distribution of the radioactivity in most tissues. However, a clear
reduction was found in the spleen (-40%; P < 0.05) and in the lung (-31 %; P> 0.05)
after injection of unlabelled iodophenpropit. The reduced radioactivity in these tissues was
not observed after pre-injection of the H3-agonist (R)a-methylhistamine and the H3-
antagonist thioperamide, however (unpublished results). Therefore, the altered
distribution of the radioactivity in these tissues after pre-injection of unlabelled
iodophenpropit may not be related to the displacement of [l25I]iodophenpropit from H3-
receptors.
Only a small amount of radioactivity (i.e. about 0.05% of the injected dose) was detected
in brain, the tissue where the highest densities of H3-receptors are found, indicating that
iodophenpropit has a poor ability to penetrate the blood brain barrier. From the
autoradiographic studies it was apparent that the radioactivity found in brain tissue largely
represented binding to the choroid plexus. Altogether, these results indicate that
iodophenpropit may not be a suitable candidate for the in vivo imaging of central
histamine H3-receptors.
In the present study preliminary information is obtained with respect to the in vivo
distribution of iodophenpropit. It may be speculated that the radioactivity distribution
pattern detected after the short interval of three minutes was largely the unmodified
radiolabelled compound. At one hour after injection a considerable amount of radioactivity
was transferred to the lower part of the digestive system implying the onset of elimination
of the compound and/or its radiolabelled metabolites. Also, at intervals from one hour the
radioactivity in the kidney shifted from the cortex to the medullary part. At four days after
injection the radioactivity was largely eliminated from the rat, showing that the
radiolabelled iodophenpropit and/or its radioactive metabolites had almost quantitatively
been eliminated. The accumulation of radioactivity in the thyroid gland indicates an
involvement of deiodination in the metabolic pathway of iodophenpropit.
In conclusion, as a consequence of the poor ability of iodophenpropit to penetrate into the
brain, radioiodinated iodophenpropit is not a good candidate for brain imaging of
histamine H3-receptors in vivo. In general, iodophenpropit can be regarded as a potential
ligand for in vivo pharmacological studies, being a preferentially peripherally acting H3-
receptor antagonist.
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The histamine H3-receptor agonist immepip and the
H3-receptor antagonist clobenpropit modulate rat hypothalamic
histamine release in vivo. Effects of intrahypothalamic and
peripheral application
Frank P. Jansen, Takatoshi Mochizuki!, Yumiko Yamamoto2,
Hendrik Timmennan, and Atsushi Yamatodani2
Abstract
We investigated the effect of the new potent and selective histamine H3-receptor agonist immepip
(VUF4708) and the histamine Hrreceptor antagonist clobenpropit (VUF9153) on in vivo neuronal
histamine release from the anterior hypothalamic area (AHy) of urethane anesthetized rats, using
microdialysis. The AHy was perfused with artificial cerebrospinal fluid. Fractions were collected every 20
minutes and were assayed for histamine by an HPLC-fluorometric method.
Intrahypothalamic perfusion with the H3-agonist immepip potently and concentration dependently reduced
histamine release from the AHy. Histamine release was decreased to 75% and 35% (P < 0.05) of its basal
level after perfusion with 1 and 10 nM immepip respectively. At concentrations of 0.1 and 1 JlM
immepip histamine release was below its detection limit (10 fmollsample). Peripheral injection of
immepip (5 mglkg) caused a sustained decreased of histamine release to 50% of the basal value (P <
0.05). The Hrantagonist clobenpropit potently increased histamine release after intrahypothalamic
perfusion. The maximal increase of histamine release was two-fold, observed at a concentration of 10 nM
clobenpropit. Histamine release was also increased upon peripheral injection of clobenpropit (5 - 15
mglkg) to about 150% of the basal value. A more marked increase of histamine release to 250% of the
basal value was observed after injection of the H3-receptor antagonist thioperamide (5 mglkg).
In conclusion, intrahypothalamic perfusion with the H3-agonist immepip and the Hrantagonist
clobenpropit potently and oppositely modulated in vivo histamine release from the AHy. These findings
support previous in vitro studies measuring histamine release from brain slices and synaptosomes. The
decreased histamine release after peripheral injection of immepip indicates that this novel agonist readily
crosses the blood brain barrier, making it a potential candidate for in vivo Hrreceptor studies.
Hypothalamic histamine release was differentially increased upon peripheral injection of clobenpropit and
of thioperamide. The possible explanation for this difference is discussed.
IDepartrnent of Pharmacology, Ehime University School of Medicine, Ehime, Japan. 2Department of
Medical Physics, School of Allied Health Sciences, Faculty of Medicine, Osaka University, Osaka, Japan.
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Introduction
Histamine is a well established neurotransmitter in invertebrate and vertebrate CNS
including mammals (Timmerman, 1990; Onodera et at., 1994; Schwartz et at., 1995).
Histaminergic neurons originate from the posterior hypothalamus and project in a rather
diffuse way to essentially all parts of the CNS (Schwartz et at., 1991; Wada et at.,
1991). In vitro techniques using brain slices and synaptosomes demonstrated that
neuronal histamine release is modulated by presynaptic histamine H3-autoreceptors
(Arrang et at., 1983; Van der Werf et at., 1987) and by various heteroreceptors i.e. 0.2-
adrenoceptors (Hill & Straw, 1988), M1-muscarinic receptors (Gulat-Marnay et at.,
1989), lC-opioid receptors (Gulat-Marnay et at., 1990), galanin receptors (Arrang et at.,
1991), I!-opioid receptors (Itoh et at., 1988) and nicotine receptors (Ono et at., 1992).
More recently, microdialysis methods were applied in order to study histamine release in
vivo (Itoh et at., 1991; Mochizuki et at., 1991). It was shown that the histaminergic
output from the rat hypothalamus displays a circadian rhythm (Mochizuki et at., 1992).
Neuronal histamine release in vivo was reduced by peripheral injection of 0.-
fluoromethylhistamine, an irreversible inhibitor of the histamine synthesizing enzyme
histidine decarboxylase (Mochizuki et at., 1991). Microdialysis studies also
demonstrated a role of H3-autoreceptors (Mochizuki et at., 1991; Itoh et at., 1992; Prast
et at., 1994), o.2-adrenoceptors (Prast et at., 1991; Laitinen et at., 1995), NMDA
receptors (Okakura et at., 1992), interleukin-1,8 (Niimi et at., 1994), I!-opioid
receptors (Chikai et at., 1994; Chikai & Saeki, 1995) and GABA receptors (Okakura-
Mochizuki et a/., 1996) in the modulation of in vivo neuronal histamine release.
In vitro and in vivo release studies substantially contributed to the present knowledge of
histaminergic neuron (patho)physiology and of the possible routes to influence neuronal
histamine related effects, such as arousal, locomotor activity, learning and memory,
appetite, autonomic regulation and pituitary hormone secretion (for review see: Schwartz
et at., 1991; Onodera et at., 1994). To modify the activity of the histaminergic system,
the development of brain penetrating H3-receptor ligands is of major interest. The H3-
agonist immepip (Vollinga et at., 1994) and the H3-antagonist clobenpropit (Van der
Goot et at., 1992) have been described as novel potent and selective probes to study H3-
receptors in vitro (Figure 1). Both compounds belong to a chemical class different from
the H3-ligands which have predominantly been used for in vivo studies, Le. the H3-
agonist (R)o.-methylhistamine and the H3-antagonist thioperamide (Arrang et a/., 1987).
In the present study we investigated the effect of intrahypothalamic and of systemic
administration of immepip and of clobenpropit on in vivo neuronal histamine release
from the anterior hypothalamus of the rat using microdialysis, to get insight in the
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dynamics of hypothalamic histamine release and in the in vivo potential of both H3-
receptor ligands modulating neuronal histamine release.
immepip
pD2 =8.01)
clobenpropit
pA2 =9.9
2)
Figure 1. The chemical structures of the Hragonist immepip and the Hrantagonist clobenpropit.
1)Vollinga et al., 1994; 2)Van der Goot, et al., 1992; activities were determined by an in vitro test
system measuring histamine Hrreceptor mediated relaxation of the electrically contracted guinea-pig
jejunum.
Materials and methods
Microdialysis method
The microdialysis procedure used was previously described by Mochizuki and colleagues
(Mochizuki et al., 1991). In brief, male Wistar rats (200-250g) were anaesthetized with
urethane (1.2 glkg, i.p.) and placed in a stereotaxic frame. A hole was drilled into the
skull and subsequently, a microdialysis probe (CMA/12, Carnegie, Stockholm, Sweden)
was inserted into the anterior hypothalamic area (AHy, coordinates: AP: 1.5, L: 0.5, V:
9.2 mm relative to the bregma and dural surface; see Figure 2). The AHy was
continuously perfused with sterile artificial cerebrospinal fluid (artificial CSF; 2 mM
sodiumphosphate buffer, 140 mM NaCl, 3 mM KC1, 2.5 mM CaCI2' 1 mM MgCl2 and 5
mM glucose, pH7.4) at a constant flow of 1 1l1·min-l. A hundred minutes after
implantation of the microdialysis probe, samples were collected every twenty minutes.
Administration of immepip and clobenpropit was started after collecting the third basal
fraction. The histamine content of the samples was measured as previously described,
using an HPLC-fluorometric method (Yamatodani et al., 1985). Briefly, 20 III dialysate
samples were mixed with 2111 of 20% (v/v) perchloric acid and were injected into a 4 x 50
mm column packed with a cation exchanger, TSKgel SP2SW (particle size 5 11m,
Tosoh). Histamine was eluted with 0.25 M KH2P04 (flow: 0.6 ml/min) and derivatized
by the on-line automated Shore's o-phtalaldehyde method. The detection limit for
histamine was 10 frnoVsample. Neither immepip nor clobenpropit interfered with the
assay of histamine.
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Figure 2. Schematic representation of the microdialysis probe positioned in the anterior hypothalamic
area ofthe rat brain.
Drugs and chemicals
Immepip dihydrobromide (VUF4708; 4-(1H-imidazol-4-ylmethyl)piperidine
dihydrobromide, thioperamide dimaleate and clobenpropit dihydrobromide (VUF9153)
were from laboratory stock (Vrije Universiteit, Amsterdam, The Netherlands). All other
chemicals used were of analytical grade.
Administration ofdrugs
For intrahypothalamic application immepip and clobenpropit were dissolved in artificial
CSF and were infused through the microdialysis probe. When administered peripherally,
drugs were dissolved in sterile sodium chloride solution (0.9% w/v) and were injected
subcutaneously (volume: Iml/kg body weight).
Statistical analysis
Histamine content of the samples after administration of drugs were compared with the
histamine content of the basal fraction preceding administration of the drugs. To
determine the statistical significance of the drug effects, an unpaired two-tailed Student's
t-test with a Bonferroni correction for multiple comparison was used. Histamine content
of the samples was considered significantly different from the basal release when P-
values were smaller than 0.05.
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Results
Under the experimental conditions a constant release of histamine from the anterior
hypothalamic area (AHy) was observed, remaining stable from collection of the first
sample up to at least five hours (Mochizuki et al., 1991). The average histamine content
in the dialysates was 58 ±5 fmoV20 min (mean ± s.e.m.).
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Figure 3. The effect of intrahypothalamic perfusion with immepip on histamine release. Perfusion
with immepip was started after collection of the third basal fraction, as indicated by the horizontal bars
(Figure A). The values in Figure B correspond to the fourth fractions collected after perfusion with the
corresponding concentrations of immepip. Values are given as the mean ± S.E.M. of three to five
experiments. (*P < 0.05, compared to the third basal fraction, ND: not detected, histamine release below
detection limit (10 fmollsample).
Effect oflocal and peripheral application ofimmepip on hypothalamic histamine release
Histamine release from the AHy was potently and concentration dependently inhibited by
intrahypothalamic perfusion with the histamine H3-receptor agonist immepip (Figure 3).
At a concentration of 1 nM immepip histamine release decreased to 75% of the basal value
(Figure 3A). Histamine release was significantly reduced to 35% of its basal value (P <
0.05) after perfusion with 10 nM immepip. At concentrations higher than 10 nM immepip
the histamine release was below its detection limit (10 fmol/sample, Figure 3B).
Peripheral injection of immepip at a dose of 1 mglkg (s.c.) induced a small and transient
decrease of histamine release to 70% of the basal value, 60 minutes after injection (P <
0.05; Figure 4). At a dose of 5 mglkg (s.c.) immepip caused a sustained decrease of the
histamine release to 50% of the basal value lasting for more than three hours.
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Figure 4. The effect of sc. injection of immepip on hypothalamic histamine release. Immepip was
injected after collection of the third fraction as indicated by the arrow. Values are given as the mean ±
S.E.M. offour to five experiments. (*p < 0.05 compared to the third basal fraction). Symbols used: (0),
1 mg/kg; (. ), 5 mg/kg immepip. Injection ofsaline did not affect basal histamine levels (not shown).
Effect of local and peripheral application of clobenpropit on hypothalamic histamine
release
Clobenpropit, administered through the dialysis probe, potently increased histamine
release. At a clobenpropit concentration of 10 nM histamine release was significantly
increased approximately two-fold (Figure SA). Higher concentrations of clobenpropit
caused no further increase of histamine release (Figure 5B). Histamine release was
moderately increased upon peripheral injection of clobenpropit (5 - 15 mglkg, s.c.), to
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Figure 5. The effect of intrahypothalamic perfusion with clobenpropit on histamine release. Perfusion
with clobenpropit was started after collection of the third basal fraction, as indicated by the horizontal
bars (Figure A). The values in Figure B correspond to the fourth fractions collected after perfusion with
the corresponding concentrations of clobenpropit. Values are given as the mean ± S.E.M. of five
experiments. (*P < 0.05, compared to the third basal fraction).
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Figure 6. The effect of sc. injection of clobenpropit and thioperamide on hypothalamic histamine
release. The drugs were injected after collection ofthe third fraction as indicated by the arrow. Values are
given as the mean ± S.E.M. of three to six experiments. (*p < 0.05, compared to the third basal
fraction). Symbols used: Symbols used: (0), 2 mg/kg; (0), 5 mg/kg; (_), 15 mg/kg clobenpropit; (A),
5 mg/kg thioperamide. Injection of saline did not affect basal histamine levels (not shown).
about 150% of its basal value (Figure 6). In contrast, the H3-receptor antagonist
thioperamide (5 mg/kg) rapidly and markedly increased histamine release to about 250%
of the basal value (Figure 6).
Discussion
The H3-receptor agonist immepip and the H3-antagonist clobenpropit were recently
described as novel ligands exhibiting a high affinity and selectivity for H3-receptors on
the guinea-pig intestine (Vollinga et al., 1994; Van der Goot et al., 1992) and in rat
brain (Jansen et al., 1994). Immepip and clobenpropit belong to the most potent H3-
receptor ligands in vitro. Yet, the in vivo potency of both compounds has been largely
unexplored. In the present study we have demonstrated that intrahypothalamic perfusion
with immepip and with clobenpropit potently and oppositely modulate in vivo histamine
release from the anterior hypothalamic area (AHy). These observations are in general
agreement with in vitro studies describing the effects of H3-agonists and H3-antagonists
on the depolarization induced histamine release from brain slices and synaptosomes.
(Arrang et al., 1983; Van der Werf et al., 1987). Previous reports showed that
histamine release from the AHy is almost quantitatively of neuronal origin, being sensitive
to tetrodotoxin, calcium dependent and increased by electrical stimulation and infusion of
potassium (Mochizuki et al., 1991; Hoh et al., 1992). In addition, the AHy is almost
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devoid of mast cells (Olsson, 1968). As the AHy is enriched with histaminergic nerve
endings, the effect of intrahypothalamic perfusion with immepip and clobenpropit is likely
to be caused by their action at H3-receptors located on these histaminergic nerve endings.
The increase of histamine release by the H3-antagonist clobenpropit may be explained by
a tonic autoinhibition of histamine release from histaminergic neurons by endogenous
histamine.
Intrahypothalamic perfusion with immepip induced a sustained decrease of neuronal
histamine release. Previously, the effect of local perfusion with the H3-receptor agonist
(R)a-methylhistamine on neuronal histamine release has been studied, using the push-
pull technique (Prast et at., 1994). In the mentioned study, histamine release from the
AHy was transiently decreased after perfusion with (R)a-methylhistamine. The effective
concentration of (R)a-methylhistamine (10 j..lmolll) to decrease histamine release largely
exceeded the concentration of immepip inhibiting histamine release in our study (10 oM).
It may be noted however, that in the study ofPrast et al. the concentration dependency of
(R)a-methylhistamine was not studied, and drugs were examined on a shorter time-scale,
using a different perfusion technique (i.e. push-pull cannula). Although we could not
compare the effect of intrahypothalamic perfusion with (R)a-methylhistamine in our
assay, due to interference of the compound with the determination of histamine, immepip
may be a more potent inhibitor of hypothalamic histamine release than (R)a-
methylhistamine, when administered directly into the tissue. Accordingly, in our
laboratory it was recently observed that immepip was about 20-fold more potent than
(R)a-methylhistamine to inhibit the electrically stimulated [3H]noradrenaline release from
rat cerebral cortex slices in vitro (Alves-Rodrigues, personal communication). Moreover,
in a recent microdialysis study it was found that the potassium stimulated acetylcholine
release from rat cerebral cortex was inhibited by local administration of H3-receptor
agonists, immepip showing a 3-fold higher potency than (R)a-methylhistamine (Blandina
et at., 1996).
Peripheral injection of immepip (5mg/kg) induced a sustained decrease of histamine
release to about 50% of its basal level. In line with this observation, peripheral injection
of the same dose of (R)a-methylhistamine (5 mglkg) has been previously shown to cause
a sustained decrease of histamine release from the AHy (Itoh et at., 1992). Thus,
immepip has a comparable potency to (R)a-methylhistamine, when the drugs are
administered peripherally. The prolonged effect of immepip on hypothalamic histamine
release indicates that immepip is potentially a new pharmacological tool to study H3-
receptors in vivo, being able to cross the blood brain barrier. The decreased histamine
release observed after peripheral injection of immepip is in accordance with its effect seen
after intrahypothalamic perfusion.
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At present, (R)a-methylhistamine is the most commonly used H3-agonist for in vivo
H3-receptor studies. It is noteworthy though, that several studies reported non-H3-
receptor mediated effects of (R)a-methylhistamine in the peripheral tissues. In vivo
studies on the rat cardiovascular system and the guinea-pig respiratory system revealed a
histamine HI-receptor agonistic (Hey et al., 1992; Malinowska & Schlicker, 1993;
Hegde et al., 1994) and an a2-adrenoceptor agonistic (Malinowska & Schlicker, 1993)
activity of (R)a-methylhistamine, observed at doses required to obtain H3-receptor
mediated effects in the CNS. Also for an other brain penetrating H3-agonist imetit, non-
H3-receptor mediated effects have been found in the rat cardiovascular system, probably
resulting from a 5HT3-receptor agonistic activity ofthe compound (Coruzzi et al., 1995;
Leurs et al., 1995). With respect to in vivo H3-receptor studies immepip may therefore
be an improved tool, lacking cardiovascular side effects observed with (R)a-
methylhistamine and with imetit (Coruzzi et at., 1995).
Histamine release was increased about two-fold after intrahypothalamic perfusion with
clobenpropit. This result is comparable to local perfusion with thioperamide (Yamamoto,
personal communication; Prast et al., 1994). Subcutaneous injection of clobenpropit
increased histamine release to about 150% of the basal value. Controversially, a marked
increase of histamine release to 250% of the basal value was observed after subcutaneous
injection of thioperamide (5mg/kg). It has previously been demonstrated that clobenpropit
is able to penetrate into the brain. In ex vivo receptor binding studies the ability of
clobenpropit to penetrate into the brain was about two-fold weaker than observed for
thioperamide however (Barnes et al., 1993; Mochizuki et at., 1996). At a dose of 10
mg/kg (s.c.) clobenpropit completely abolished the increase in water consumption
induced by (R)a-methylhistamine (Barnes et al., 1993). Considering these data, it seems
reasonable to assume that the doses of both clobenpropit and of thioperamide used in the
present microdialysis study were high enough to reach a complete H3-receptor occupancy
in rat CNS.
It is not possible to give a straightforward explanation for the different effect of
subcutaneous injection of clobenpropit and of thioperamide on histamine release. We
would like however to make the following remarks. At first, there may be a
pharmacokinetic/pharmacodynamic explanation for the different effect between the two
compounds. Recently, it has has been shown that thioperamide is heterogeneously
distributed in different brain areas of the rat after peripheral injection (Sakurai et al.,
1994). One hour after injection of a high dose ofthioperamide (10 mg/kg, i.v.) relatively
high tissue concentrations were found in the hypothalamus, striatum and thalamus and a
relatively low concentration in the cerebral cortex. Moreover, the elimination of
thioperamide was brain region dependent. Although no information on the distribution of
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clobenpropit in different brain areas is available so far, a possible difference between the
pharmacokinetics of thioperamide and of clobenpropit might explain the different effect of
both compounds on neuronal histamine release in the hypothalamus after peripheral
injection. Secondly, we suggest that the effect of peripheral injection of H3-ligands on
hypothalamic histamine release may not simply be explained by the binding of these
compounds to hypothalamic H3-autoreceptors. It has been shown that H3-ligands are able
to modulate the release of other neurotransmitters such as noradrenaline (Schlicker et ai.,
1989), acetylcholine (Clapham & Kilpatrick, 1992; Mochizuki et at., 1994) and
serotonin (Fink et at., 1990; Alves-Rodrigues et ai., 1995), by activation of H3-
receptors. Modulation of the release of neurotransmitters via H3 heteroreceptors may in
return have an effect on histamine release being potentially influenced by
neurotransmitters like noradrenaline (Hill & Straw, 1988) opioid peptides (Gulat-Marnay
et at., 1990), acetylcholine (Gulat-Mamay et at., 1989), dopamine (Prast et ai., 1993),
glutamate (Okakura et at., 1992), GABA (Okakura-Mochizuki et ai., 1996) and galanin
(Arrang et at., 1991). Therefore, the effects on histamine release of H3-ligands injected
peripherally, may be an overall result of the binding of these drugs to both H3-
autoreceptors and H3-heteroreceptors throughout the CNS. Illustratively, it has recently
been reported that the effect of the selective az-adrenoceptor antagonist atipamezole on
hypothalamic histamine was dependent on its route of administration (Laitinen et ai.,
1995). In this study it was found that the effects of local perfusion with a2-adrenoceptor
ligands in vivo generally agreed with the effects observed on noradrenaline release from
brain slices in vitro (Laitinen et at., 1995). However, local perfusion with atipamezole
increased hypothalamic histamine release whereas systemic administration of the drug
decreased histamine release. Therefore, it may be argued that the observations in the
present study and in the study cited, cast some doubt on the usefulness of local
intracerebral drug perfusion and of in vitro neurotransmitter release models to predict the
effect of peripheral application of drugs on in vivo neurotransmitter release.
In conclusion, we have demonstrated that intrahypothalamic perfusion with the new H3-
agonist immepip and the H3-antagonist clobenpropit potently and oppositely modulate in
vivo histamine release from the AHy. These findings support previous results from in
vitro techniques measuring histamine release from brain slices and synaptosomes.
Histamine release was potently inhibited by subcutaneous injection of immepip. Hence,
this H3-agonist is potentially a new pharmacological tool to study H3-receptors in vivo,
being able cross the blood brain barrier. The different increase of histamine release
observed upon peripheral injection of clobenpropit compared to thioperamide may be
related to the complex mechanism by which systemically administered drugs influence
neurotransmitter release in a specific brain area.
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Summary and discussion
The H3-receptor was first described by Arrang and colleagues in 1983, following up the
identification of the histaminergic neuron system in the brain. H3-Autoreceptors mediate
the feedback inhibition of synthesis and release of neuronal histamine. Additionally, H3-
receptors are involved in modulation of the release of various other neurotransmitters in
the CNS and PNS, via pre- and postsynaptic mechanisms. The role of H3-receptors in the
modulation of neurotransmitter release is briefly reviewed in Chapter 1 of this thesis.
The availability of selective ligands, both in vitro ~d in vivo, is of great importance to
study the pharmacology of the H3-receptor and to elucidate its physiological and
pathophysiological role. Meanwhile various selective compounds are available. Progress
on the synthesis of novel H3-ligands allowed the development of different radioligands as
well. Initially tritiated agonists were applied in H3-receptor binding studies. Although
radiolabelled agonists are valuable H3-receptor binding tools, their complex binding
profile urged the introduction of radiolabelled H3-antagonists.
From 1992 up till now five different radiolabelled antagonists have been reported in
literature. The first radiolabelled H3-antagonist, [l25I]iodophenpropit, has been developed
in our laboratory. In chapter 2 to 7 of this thesis, the validation of [l25I]iodophenpropit as
an H3-receptor radioligand and its consequent application to study characteristics,
distribution and possible function of H3-receptors in rodent brain is described. As an
introduction to these chapters, an overview of the different H3-receptor radioligands
presented in literature so far is given in Chapter 1.
In Chapter 2 and 3, binding of [l25I]iodophenpropit to rat brain is described. The
radioligand saturably and reversibly binds to rat cerebral cortex membranes, with an
affinity closely related to its antagonistic potency. These observations, together with the
analysis of competition binding curves of various histaminergic ligands and the
autoradiographic examination of [l25I]iodophenpropit binding sites, confirmed the
selective labelling by [l25I]iodophenpropit of sites representing the 'functional H3-
receptor' .
The binding of [l25I]iodophenpropit to rat cerebral cortex membranes was biphasically
displaced by H3-agonists. Based on the sensitivity of agonist competition binding curves
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neurotransmitter of the basal ganglia. The striatum is enriched with dopaminergic
terminals originating from the substantia nigra pars compacta (nigrostriatal system) and to
less extent from the ventral tegmental area (mesolimbic system). In Chapter 6, we
examined the link between rat H3-receptors and neurotransmission related to the
dopaminergic system.
Transversal brain sections of 6-hydroxydopamine (6-0HDA) treated rats were incubated
with [125I]iodophenpropit and the autoradiographic distribution of [l25I]iodophenpropit
binding sites was examined. Storage phosphor autoradiography was again used to
quantify the brain autoradiograms. Unilateral denervation of dopaminergic neurons altered
[l25I]iodophenpropit binding in four different areas of the basal ganglia. In the striatum,
6-0HDA treatment produced a moderate increase of [l25I]iodophenpropit binding, similar
to observations reported in literature using the radiolabelled agonist [3H](R)a.-
methylhistamine (studies by Ryu et ai., 1994, 1996). Hence, striatal H3-receptors may
not be located on dopaminergic terminals, but rather on GABA-ergic neurons,
representing the major part of the striatal efferents. These striatal efferents project to three
different areas of the basal ganglia, Le. the globus pallidus (GP), the entopeduncular
nucleus (EPN) and the substantia nigra pars reticulata (SNR). Consequently, the striatal
efferents are referred to as the striatopallidal, the striatoentopeduncular and the
striatonigral pathway, respectively. Lesions with 6-0HDA reduced [125I]iodophenpropit
binding in the GP, whereas [l25I]iodophenpropit binding was increased in the EPN and
in the SNR. These bi-directional effects of 6-0HDA treatment on [125I]iodophenpropit
binding can be explained neurochemically and functionally. Striatopallidal neurons are
inhibited by striatal dopamine whereas striatoentopeduncular and striatonigral neurons are
stimulated by striatal dopamine. Hence, the reduced [125I]iodophenpropit binding in the
GP and the increased [125I]iodophenpropit binding in the EPN and the SNR may be
compensatory mechanisms to a reduced inhibition of striatopallidal neurons and to a
reduced stimulation of striatoentopeduncular and striatonigral neurons, respectively, due
to striatal dopamine depletion.
Altogether, the findings described in Chapter 6 suggest that H3-receptors in the basal
ganglia playa role in neurotransmission related to the dopaminergic system.
In Chapter 7, we examined the distribution of radioactivity at different intervals after
intravenous injection of radiolabelled iodophenpropit into rats. Whole-body
autoradiography was used to visualize the distribution of the radioactivity. This study was
conducted in order to get insight into the potential use of iodophenpropit and of its
derivatives for in vivo imaging studies (e.g. PET and SPECT) in the CNS. At three
minutes after injection of radio-iodinated iodophenpropit, the radioactivity was
heterogeneously distributed and was found in many peripheral tissues in which H3-
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receptors are present. The brain penetration of iodophenpropit was low (about 0.05% of
the injected dose) and the radioactivity observed in the brain was largely confined to the
choroid plexus. At one hour after injection considerable amounts of radioactivity were
found in the intestine indicating the onset of elimination of radiolabelled iodophenpropit
and/or of its radiolabelled metabolites. The radioactivity was almost completely eliminated
from all tissues at four days after injection, except for the thyroid gland.
Due to its low brain penetration iodophenpropit may not be a good candidate for brain
imaging studies of H3-receptors in vivo. Iodophenpropit can be regarded as a
preferentially peripherally acting H3-receptor antagonist.
In Chapter 8, we studied the effect of the novel H3-receptor agonist immepip and of the
H3-antagonist clobenpropit, a close derivative of iodophenpropit, on neuronal histamine
release from the anterior hypothalamus in vivo. Intrahypothalamic perfusion with
immepip potently and concentration dependently inhibited histamine release. A decreased
histamine release was also found after peripheral injection of immepip (5 mg/kg),
indicating that the agonist penetrates into the brain. Immepip can be regarded as a
promising tool for in vivo H3-receptor studies in the CNS.
Intrahypothalamic perfusion with clobenpropit concentration dependently increased
histamine release. This result indicates that neuronal histamine release is tonically
inhibited in vivo by histamine via H3-autoreceptors. Clobenpropit (5-15mglkg) also
increased histamine release after peripheral injection. The increase induced by
clobenpropit was less pronounced than the increase found after peripheral injection of the
H3-antagonist thioperamide. Obviously, the effect of peripheral drug application on
neurotransmitter release in one specific brain area is the overall result of drug effects on
neurotransmission in the entire CNS. This rationale may explain the different effects of
peripheral injection of clobenpropit and of thioperamide on hypothalamic histamine
release.
General conclusion
This thesis demonstrates that [l25I]iodophenpropit selectively labels H3-receptors in
rodent CNS in vitro. [l25I]Iodophenpropit proves to be a valuable tool to obtain
knowledge on characteristics, distribution and function of H3-receptors in the CNS of rats
and mice.
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Samenvatting en discussie
De H3-receptor is voor het eerst beschreven door Arrang in 1983, volgend op de
identificatie van histamine als neurotransmitter in de hersenen. De H3-autoreceptor
medieert de 'feed-back remrning' van de synthese en afgifte van neuronaal histamine.
Tevens is de H3-receptor betrokken bij de modulatie van de afgifte van verschillende
andere transmitters in het centraal zenuwstelsel (CZS) en in het perifere zenuwstelsel, via
post- en presynaptische mechanismen. In Hoofdstuk 1 van dit proefschrift wordt een
overzicht gegeven van de rol van H3-receptoren bij regulatie van de neurotransmitter-
afgifte.
De beschikbaarheid van selectieve liganden, zowel in vitro als in vivo, is van groot
belang bij de bestudering van de farmacologie van H3-receptoren en bij de opheldering
van de fysiologische en pathofysiologische rol van de H3-receptor. Inmiddels zijn diverse
selectieve stoffen voorhanden. De vooruitgang op het gebied van de synthese van nieuwe
H3-liganden maakte ook de ontwikkeling mogelijk van radioliganden. Aanvankelijk
werden alleen H3-agonisten toegepast in H3-receptor bindingsstudies. Radioactieve H3-
agonisten bleken waardevol als radioliganden. Echter, het complexe bindingsprofiel van
de agonisten maakte de ontwikkeling van radiogelabelde H3-antagonisten wenselijk.
Vanaf 1992 tot op heden zijn in de literatuur vijf verschillende H3-antagonisten als
radioligand beschreven. De eerste radioactief gelabelde H3-antagonist is [l25I]iodophen-
propit, ontwikkeld binnen ons laboratorium. De validatie van [l25I]iodophenpropit als
radioligand voor de Hrreceptor en de toepassing bij het bestuderen van de
karakteristieken, verdeling en mogelijke functie van H3-receptoren in ratten en muizen
staat beschreven in Hoofdstuk 2 tim 7 van dit proefschrift. Ter inleiding tot deze
hoofdstukken wordt in Hoofdstuk 1 een overzicht gegeven van de verschillende
radioliganden voor de H3-receptor.
In Hoofdstuk 2 en 3 wordt de binding van [l25I]iodophenpropit aan rattehersenen
beschreven. [125I]Iodophenpropit bindt op verzadigbare en reversibele wijze aan
membraanpreparaten van de cerebrale cortex van de rat. De daarbij gemeten bindings-
affiniteit stemt goed overeen met de antagonistische activiteit van het radioligand. De
genoemde bevindingen, samen met de analyse van competitiebindingscurven van diverse
histaminerge liganden en met de waargenomen autoradiografische verdeling van
[l25I]iodophenpropit binding, bevestigt een selectieve interactie met bindingsplaatsen die
overeenkomen met de 'functionele H3-receptor' .
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De binding van [l25I]iodophenpropit aan cerebrale cortexmembranen van de rat werd op
bifasische wijze verdrongen door H3-agonisten. Op grond van de gevoeligheid van de
agonist competitiebindingscurven voor guanine-nucleotiden, wordt geconcludeerd dat de
bifasische verdringing het gevolg is van de betrokkenheid van G-eiwitten bij binding van
de agonist met de receptor, en niet het gevolg van receptorheterogeniteit. Hiermee leveren
de studies met [l25I]iodophenpropit aanvullend bewijs voor de betrokkenheid van G-
eiwitten bij de H3-receptorgemedieerde signaaltransmissie. Bifasische competitie-
bindingscurven werden ook gevonden voor de H3-antagonisten burimamide en dimaprit.
Mogelijk zijn deze bevindingen het gevolg van heterogeniteit van de bindingsplaatsen van
[l25I]iodophenpropit, aangezien competitiebindingscurven van H3-antagonisten niet
werden be'invloed door guanine-nucleotiden. Voor burimamide zijn bifasische
competitiebindingscurven ook gevonden in studies waarbij gebruik werd gemaakt van
H3-agonisten als radioligand. De bifasische competitiebindingscurven zijn niet gevonden
met de meer recentelijk beschreven radioactief gelabelde H3-antagonisten. Vooralsnog
wordt het bestaan van H3-receptorsubtypen niet niet duidelijk onderbouwd door
functionele studies (zie ook Hoofdstuk 1 en de discussie van Hoofdstuk 5).
In Hoofdstuk 4 wordt de binding van [l25I]iodophenpropit aan membranen van de
hersenen van de muis bestudeerd. Muizen zijn routinematig gebruikt bij de bestudering
van functionele H3-receptor modellen. Er was echter weinig bekend over de
bindingskarakteristieken van H3-liganden ten aanzien van H3-receptoren in het CZS van
de muis, gemeten met behulp van receptorbindingsstudies. In vivo studies (uitgevoerd in
het laboratorium van Prof. Watanabe, Sendai, Japan) toonden aan dat de H3-antagonist
clobenpropit, chemisch verwant aan iodophenpropit, een potentie heeft als anticonvul-
sivum in muizen, die beduidend hoger ligt dan potenties gemeten in CZS-modellen in
ratten. De bovengenoemde gegevens waren aanleiding om de [125I]iodophenpropit
bindingsplaatsen in de hersenen van de muis nader te bestuderen. Uit deze studies is
gebleken dat de affiniteiten van de meeste H3-receptor liganden (clobenpropit inbegrepen)
voor de [l25I]iodophenpropit bindingsplaatsen in de muizehersenen vergelijkbaar zijn met
de affiniteiten gemeten in de cerebrale cortex van de rat. Deze bevindingen geven dus geen
verklaring voor de in vivo potentieverschillen van clobenpropit tussen ratten en muizen.
Competitiebindingscurven van H3-antagonisten waren monofasisch. Daarmee werden
geen aanwijzingen gevonden voor H3-receptorheterogeniteit. Competitiebindingscurven
van H3-agonisten werden be'invloed door guanine-nucleotiden, in overeenstemming met
de interactie van de H3-receptoren met G-eiwitten. De verdeling van H3-receptoren in de
hersenen van de muis was vergelijkbaar met de verdeling beschreven in de hersenen van
rat en cavia. Echter, bij de muis werd een relatief hoge H3-receptordichtheid gemeten in
de globus pallidus. De nonspecifieke [l25I]iodophenpropit binding in muizehersenen
- 165-
Chapter 9
(-25%) was substantieel lager dan de nonspecifieke [125I]iodophenpropit binding
gemeten in de cerebrale cortex van de rat (-50%).
In hoofdstuk 5 werden de karakteristieken en distributie van [l25I]iodophenpropit
bindingsplaatsen in het CZS van de rat bestudeerd met behulp van receptorauto-
radiografie. Bij de kwantificatie van de binding van [l25I]iodophenpropit aan verschil-
lende hersengebieden werd gebuik gemaakt van 'storage phosphor autoradiography', een
nieuwe methode waarbij de radioactief gelabelde hersencoupes worden blootgesteld aan
'storage phosphor screens', in plaats van blootstelling aan conventionele films.
'Vingerafdrukken' van de radioactief gelabelde hersencoupes werden opgeslagen in de
'storage phosphor screens'. Door het aflezen van de 'storage phosphor screens' met
behulp van een 'storage phosphorimager' werden digitale weergaven van de
autoradiogrammen verkregen. 'Storage phosphor autoradiography' heeft diverse
voordelen ten opzichte van conventionele methoden die worden toegepast bij
computerondersteunde analyse van grafische data. Een voorbeeld daarvan is de hoge mate
van lineariteit over een groot gebied van radioactieve intensiteiten (beschreven in
Hoofdstuk 5).
We stelden vast dat de [125I]iodophenpropit bindingsplaatsen heterogeen zijn verdeeld in
de hersenen van de rat. De hoogste dichtheden werden gevonden in de cerebrale cortex,
het striatum en de substantia nigra. Een middelmatig lage dichtheid werd gevonden in de
hypothalamus, de hippocampus en de thalamus. De [125I]iodophenpropitbinding was laag
in de hersenstam en in het cerebellum.
De dichtheden van de [125I]iodophenpropitbindingsplaatsen gemeten in membraan-
preparaten van de cerebrale rattecortex zijn substantieel hoger dan de dichtheden van
[3H](R)a-methylhistaminebindingsplaatsen in hetzelfde preparaat (zie discussie van
Hoofdstuk 3). Mogelijk binden radioactief gelabelde agonisten met name aan H3-
receptoren in de G-eiwit gekoppelde toestand. Ais gevolg hiervan labelen de agonisten
slechts een subpopulatie van de aanwezige H3-receptoren. Met deze veronderstelling kan
worden verklaard dat relatief lage H3-receptordichtheden worden gemeten wanneer H3-
agonisten worden gebruikt als radioligand, in vergelijking met radioactief gelabelde H3-
antagonisten. Ondanks de farmacodynamische verschillen tussen H3-agonisten en H3-
antagonisten, was het distributiepatroon van de [125I]iodophenpropitbindingsplaatsen in
de rattehersenen in algemene overeenstemming met het distributiepatroon van [3H](R)a-
methylhistarninebindingsplaatsen gemeten in membranen van specifieke hersengebieden
van de rat (Pollard et al., 1993). In de substantia nigra werd daarentegen met
[l25I]iodophenpropit een hogere labeling gemeten dan met [3H](R)d'-methylhistamine.
Deze constatering is mogelijk gerelateerd aan een afwijkende G-eiwitkoppeling van H3-
receptoren in de substantia nigra.
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am de [125I]iodophenpropit bindingsplaatsen in de rattehersenen nader te karakteriseren,
werden in verschillende hersengebieden competitiebindingscurves gemaakt van een
chemisch heterogene groep H3-antagonisten, en van de beide stereoisomeren van a-
methylhistamine. 'Storage phosphor autoradiography' werd gebruikt bij de kwantificatie
van de bindingscurven. De verschillende H3-liganden maakten geen onderscheid tussen
de [125I]iodophenpropitbindingsplaatsen. De binding van [l25I]iodophenpropit in de
onderzochte hersengebieden werd niet tot hetzelfde niveau verdrongen door (R)a-
methylhistamine als door de H3-antagonist thioperamide. In de meeste gebieden was de
binding verdrongen door (R)a-methylhistamine 10 tot 20% lager dan de binding
verdrongen door thioperamide. Grotere verschillen (tot 40%) werden gemeten in gebieden
met een lagere H3-receptordichtheid (zoals de thalamus, de hippocampus en de
hypothalamus). Verschillen tussen binding verdrongen door agonisten en door
antagonisten zijn ook gevonden voor andere radioactief gelabelde antagonisten. Dit
fenomeen heeft belangrijke implicaties voor de definitie van de nonspecifieke binding in
deze hersengebieden.
De verdeling van de H3-receptorbindingsplaatsen is niet gelijk aan de verdeling van het
histaminerge systeem. Daarom is het aannemelijk dat een groot deel van de cerebrale H3-
receptoren niet is gelegen op histaminerge neuronen. Dit geldt mogelijk in het bijzonder
voor de basale ganglia, alwaar hoge H3-receptordichtheden samengaan met een relatief
geringe histaminerge innervatie. Dopamine is een belangrijke neurotransmitter in de basale
ganglia. In het striatum bevinden zich veel dopaminerge zenuwuiteinden afkomstig van de
substantia nigra pars compacta (nigrostriataal systeem) en, in mindere mate, dopaminerge
zenuwuiteinden afkomstig van het ventrale tegmentum (mesolimbisch systeem). In
Hoofdstuk 6 is het verband onderzocht tussen H3-receptoren in de basale ganglia van de
rat en neurotransmissie gerelateerd aan het dopaminerge systeem.
Transversale hersencoupes van unilateraal met 6-hydroxydopamine (6-0HDA)
voorbehandelde ratten werden gelncubeerd met [l25I]iodophenpropit waarna de verdeling
van de [125I]iodophenpropitbindingsplaatsen werd bestudeerd met behulp van
autoradiografie. Denervatie van dopaminerge neuronen leidde tot een veranderde
[l25I]iodophenpropit binding in vier verschillende gebieden deeluitrnakend van de basale
ganglia. In het striatum van werd een geringe toename van de [l25I]iodophenpropit-
binding gevonden, vergelijkbaar met bevindingen beschreven in studies waarbij
[3H](R)a-methylhistamine werd gebruikt als radioligand (Ryu et at., 1994, 1996).
Waarschijnlijk zijn H3-receptoren in het striatum niet gelegen op dopaminerge
zenuwuiteinden, maar voor een belangrijk deel op GABA-erge neuronen, welke het
grootste deel van de striatale efferente zenuwbanen vertegenwoordigen. De striatale
efferenten projecteren naar drie verschillende gebieden die deel uitmaken van de basale
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ganglia te weten de globus pallidus (GP), de nucleus entopeduncularis (EPN) en de
substantia nigra, pars reticulata (SNR). De striatale efferenten worden respectievelijk
aangeduid als de 'striatopallidale, de striatoentopedunculaire en de striatonigrale
projecties. Behandeling van ratten met 6-0HDA leidde tot een afname van de
[l25I]iodophenpropitbinding in de GP, en tot een toename van de [125I]iodophenpropit-
binding in de EPN en in de SNR. Deze bi-directionele effecten kunnen worden verklaard
aan de hand van neurochemische en functionele gegevens. Striatopallidale neuronen
worden geremd door striataal dopamine. Daarentegen worden striatoentopedunculaire en
striatonigrale neuronen gestimuleerd door striataal dopamine. De afname van de
[l25I]iodophenpropitbinding in de GP, en de toename van de [l25I]iodophenpropit-
binding in de EPN en in de SNR, zijn mogelijk het gevolg van compensatiemechanismen
voor respectievelijk de verminderde remming van striatopallidale neuronen en de
verminderde stimulatie van striatoentopedunculaire en striatonigrale neuronen, als gevolg
van de depletie van dopamine in het striatum.
Samenvattend tonen de resultaten beschreven in Hoofdstuk 6 aan dat er een verband
bestaat tussen H3-receptoren in de basale ganglia van de rat en de dopaminerge neuro-
transmissie.
In Hoofdstuk 7 werd de verdeling van radioactiviteit onderzocht op verschillende
tijdsintervallen na intraveneuze injectie van radioactief gelabeld iodophenpropit in ratten.
De verdeling van de radioactiviteit werd gevisualiseerd met behulp van 'whole-body
autoradiography'. Doel van de studies was inzicht te verkrijgen in de mogelijkheid om
iodophenpropit en derivaten te gebruiken bij in vivo studies (PET of SPECT) naar de
H3-receptor in het CZS. Drie minuten na injectie van radiogelabeld iodophenpropit werd
een heterogene verdeling van de radioactiviteit waargenomen. De radioactiviteit werd
gemeten in verschillende perifere weefsels waarvan de aanwezigheid van H3-receptoren is
vastgesteld. De hersenpenetratie van [l25I]iodophenpropit was laag (ongeveer 0.05% van
de gei'njecteerde dosis) en de radioactiviteit was met name waarneembaar in de plexus
choroldeus. Een uur na injectie was een aanzienlijke hoeveelheid van de radioactiviteit
zichtbaar in de darm duidend op de eliminatie van radioactief gelabeld iodophenpropit
en/of van zijn radioactieve metabolieten. Vier dagen na de injectie was de radioactiviteit
vrijwel geheel geelimineerd, met uitzondering van de schildklier.
Gezien de geringe hersenpenetratie van iodophenpropit is het niet waarschijnlijk dat de
stof kan worden toegepast bij visualisatie van de H3-receptor in vivo, na perifere
toediening. Iodophenpropit kan worden beschouwd als een perifeer actieve Hrreceptor
antagonist.
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In Hoofdstuk 8 werd het effect onderzocht van de nieuwe H3-receptor agonist immepip
en van de H3-antagonist clobenpropit (chemisch verwand aan iodophenpropit) op de
neuronale histamineafgifte uit de anteriore hypothalamus in vivo. Perfusie van de
hypothalamus met immepip leidde tot een concentratieafhankelijke remming van de
histamineafgifte. Afname van de histamineafgifte werd ook gemeten na perifere injectie
van immepip (5 mg/kg). Immepip is dus in staat om de bloed-hersenbarriere te
doordringen. De stof kan worden beschouwd als een veelbelovende 'tool' om de H3-
receptor in het CZS in vivo te bestuderen.
Perfusie van de hypothalamus met clobenpropit leidde tot een concentratieafhankelijke
toename van de histamineafgifte. Deze bevinding impliceert dat de histamineafgifte in
vivo onder tonische invloed staat van histamine via de activering van H3-autoreceptoren.
De histamineafgifte werd ook verhoogd na perifere toediening van clobenpropit (5-15
mg/kg). De toename van de histamineafgifte was minder groot dan de toename van de
histarnineafgifte na perifere injectie van de Hrantagonist thioperamide. Het effect van
perifere toediening van een farmacon op de neurotransmitterafgifte in een specifiek
hersengebied is de resultante van effecten van het farmacon op de neurotransmissie in het
gehele CZS, hetgeen de mogelijke verklaring is voor het verschillend effect van perifere
injectie van clobenpropit en van thioperarnide op de histamineafgifte in de hypothalamus.
Algemene conclusie
In dit proefschrift wordt aangetoond dat [l25I]iodophenpropit selectief bindt aan H3-
receptoren in het CZS van ratten en muizen in vitro. [125I]Iodophenpropit is een
waardevolle 'tool' om kennis te verkrijgen omtrent de karakteristieken, de verdeling en de
functie van H3-receptoren in het CZS van ratten en muizen.
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Nawoord
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ik noemen. Rob, aIle discussies, nuttige tips en jouw beoordeling van mijn manuscripten
zijn verweven in dit boekje. Alex: see you up in the north next summer! Ellen Mooijman,
bedankt voor aIle adviezen betreft de engelse taal. En natuurlijk Bram, bedankt voor de
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de synthetische 'H3-autoreceptor feedback'. Jos Eersels, bedankt voor het steeds weer
opnieuw synthetiseren van [125I]iodophenpropit! Tjaard en meneer Coops, jullie kritische
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waar ik de afgelopen jaren (zowel binnen als buiten de VU) mee heb gemusiceerd:
bedankt voor aIle (z)waanzinnige ervaringen! Muziek was een zeer fijne en onmisbare
afwisseling om me 'pharmacologically sound' te kunnen voelen.
Hans-Peter, jij verdient een speciale plaats in dit geheel. Als klasgenoot, studiegenoot,
collega, en goede vriend hebben wij jarenlang hetzelfde pad gevolgd. Ook jouw handige
praktische tips waren een belangrijke bijdrage aan dit boekje.
Paul, jou wil ik alvast bedanken voor je rol als paranimfomaan...
Pa en rna, bedankt voor de vrijheid die jullie mij geven om mijn eigen pad te kiezen.
Tot slot, Gerreke, jij was en bent voor mij meer dan een collega.
Ik zie uit naar dat wat komen gaat!
- 176-
